Kroger, Burkhard (Limburgerhof, DE)
Schroder, Hartwig (Nussloch, DE)
Zelder, Oskar (Speyer, DE)
Haberhauer, Gregor (Limburgerhof, DE)
1. An isolated nucleic acid molecule selected from the group consisting of a) an isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2543, or a complement thereof; b) an isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2544, or a complement thereof; c) an isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2544, or a complement thereof; d) an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 50% identical to the entire nucleotide sequence of SEQ ID NO:2543, or a complement thereof; and e) an isolated nucleic acid molecule comprising a fragment of at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2543, or a complement thereof.
2. An isolated nucleic acid molecule comprising the nucleic acid molecule of claim 1 and a nucleotide sequence encoding a heterologous polypeptide.
3. A vector comprising the nucleic acid molecule of claim 1.
4. The vector of claim 3, which is an expression vector.
5. A host cell transfected with the expression vector of claim 4.
6. The host cell of claim 5, wherein said cell is a microorganism.
7. The host cell of claim 6, wherein said cell belongs to the genus Corynebacterium or Brevibacterium.
8. A method of producing a polypeptide comprising culturing the host cell of claim 5 in an appropriate culture medium to, thereby, produce the polypeptide.
9. A method for producing a fine chemical, comprising culturing the cell of claim 5 such that the fine chemical is produced.
10. The method of claim 9, wherein said method further comprises the step of recovering the fine chemical from said culture.
11. The method of claim 9, wherein said cell belongs to the genus Corynebacterium or Brevibacterium.
12. The method of claim 9, wherein said cell is selected from the group consisting of Corynebacterium glutamicum, Corynebacterium herculis, Corynebacterium, lilium, Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Corynebacterium acetophilum, Corynebacterium ammoniagenes, Corynebacterium fujiokense, Corynebacterium nitrilophilus, Brevibacterium ammoniagenes, Brevibacterium butanicum, Brevibacterium divaricatum, Brevibacterium flavum, Brevibacterium healii, Brevibacterium ketoglutamicum, Brevibacterium ketosoreductum, Brevibacterium lactofermentum, Brevibacterium linens, Brevibacterium paraffinolyticum, and those strains set forth in Table 3.
13. The method of claim 9, wherein expression of the nucleic acid molecule from said vector results in modulation of production of said fine chemical.
14. The method of claim 9, wherein said fine chemical is selected from the group consisting of organic acids, proteinogenic and nonproteinogenic amino acids, purine and pyrimidine bases, nucleosides, nucleotides, lipids, saturated and unsaturated fatty acids, diols, carbohydrates, aromatic compounds, vitamins, cofactors, polyketides, and enzymes.
15. The method of claim 9, wherein said fine chemical is an amino acid selected from the group consisting of lysine, glutamate, glutamine, alanine, aspartate, glycine, serine, threonine, methionine, cysteine, valine, leucine, isoleucine, arginine, proline, histidine, tyrosine, phenylalanine, and tryptophan.
16. An isolated polypeptide selected from the group consisting of a) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2544; b) an isolated polypeptide comprising a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2544; c) an isolated polypeptide which is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2543; d) an isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 50% identical to the entire nucleotide sequence of SEQ ID NO:2543; e) an isolated polypeptide comprising an amino acid sequence which is at least 50% identical to the entire amino acid sequence of SEQ ID NO:2544; and f) an isolated polypeptide comprising a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2544, wherein said polypeptide fragment maintains a biological activity of the polypeptide comprising the amino sequence.
17. The isolated polypeptide of claim 16, further comprising heterologous amino acid sequences.
18. A method for diagnosing the presence or activity of Corynebacterium diphtheriae in a subject, comprising detecting the presence of at least one of the nucleic acid molecules of claim 1, thereby diagnosing the presence or activity of Corynebacterium diphtheriae in the subject.
19. A method for diagnosing the presence or activity of Corynebacterium diphtheriae in a subject, comprising detecting the presence of at least one of the polypeptide molecules of claim 16, thereby diagnosing the presence or activity of Corynebacterium diphtheriae in the subject.
20. A host cell comprising a nucleic acid molecule selected from the group consisting of a) the nucleic acid molecule of SEQ ID NO:2543, wherein the nucleic acid molecule is disrupted by at least one technique selected from the group consisting of a point mutation, a truncation, an inversion, a deletion, an addition, a substitution and homologous recombination; b) the nucleic acid molecule of SEQ ID NO:2543, wherein the nucleic acid molecule comprises one or more nucleic acid modifications as compared to the sequence of SEQ ID NO:2543, wherein the modification is selected from the group consisting of a point mutation, a truncation, an inversion, a deletion, an addition and a substitution; and c) the nucleic acid molecule of SEQ ID NO:2543, wherein the regulatory region of the nucleic acid molecule is modified relative to the wild-type regulatory region of the molecule by at least one technique selected from the group consisting of a point mutation, a truncation, an inversion, a deletion, an addition, a substitution and homologous recombination.
RELATED APPLICATIONS
This application is a divisional of U.S. application Ser. No. 11/092,052, filed Mar. 28, 2005, which is a continuation of U.S. application Ser. No. 09/605,703, filed Jun. 27, 2000, now U.S. Pat. No. 6,962,989, issued Nov. 8, 2005, which, in turn, claims priority to prior filed U.S. Provisional Patent Application Ser. No. 60/142,764, filed Jul. 8, 1999, and U.S. Provisional Patent Application Ser. No. 60/152,318, filed Sep. 3, 1999. The entire contents of both of the aforementioned applications are hereby expressly incorporated herein by reference.
BACKGROUND OF THE INVENTION
Certain products and by-products of naturally-occurring metabolic processes in cells have utility in a wide array of industries, including the food, feed, cosmetics, and pharmaceutical industries. These molecules, collectively termed ‘fine chemicals’, include organic acids, both proteinogenic and non-proteinogenic amino acids, nucleotides and nucleosides, lipids and fatty acids, diols, carbohydrates, aromatic compounds, vitamins and cofactors, and enzymes. Their production is most conveniently performed through the large-scale culture of bacteria developed to produce and secrete large quantities of one or more desired molecules. One particularly useful organism for this purpose is Corynebacterium glutamicum , a gram positive, nonpathogenic bacterium. Through strain selection, a number of mutant strains have been developed which produce an array of desirable compounds. However, selection of strains improved for the production of a particular molecule is a time-consuming and difficult process.
Incorporation of Material Submitted on Compact Discs
This application incorporates herein by reference the material contained on the compact discs submitted herewith as part of this application. Specifically, the file “seqlistcorrected” (8.19 MB) contained on each of Copy 1, Copy 2 and the CRF copy of the Sequence Listing is hereby incorporated herein by reference. This file was created on Jul. 31, 2006. In addition, the files “Appendix A” (1.33 MB) and “Appendix B” (480 KB) contained on each of the compact disks entitled “Appendices Copy 1” and “Appendices Copy 2” are hereby incorporated herein by reference. Each of these files were created on Jul. 31, 2006.
SUMMARY OF THE INVENTION
The invention provides novel bacterial nucleic acid molecules which have a variety of uses. These uses include the identification of microorganisms which can be used to produce fine chemicals, the modulation of fine chemical production in C. glutamicum or related bacteria, the typing or identification of C. glutamicum or related bacteria, as reference points for mapping the C. glutamicum genome, and as markers for transformation. These novel nucleic acid molecules encode proteins, referred to herein as marker and fine chemical production (MCP) proteins.
C. glutamicum is a gram positive, aerobic bacterium which is commonly used in industry for the large-scale production of a variety of fine chemicals, and also for the degradation of hydrocarbons (such as in petroleum spills) and for the oxidation of terpenoids. The MCP nucleic acid molecules of the invention, therefore, can be used to identify microorganisms which can be used to produce fine chemicals, e.g., by fermentation processes. Modulation of the expression of the MCP nucleic acids of the invention, or modification of the sequence of the MCP nucleic acid molecules of the invention, can be used to modulate the production of one or more fine chemicals from a microorganism (e.g., to improve the yield or production of one or more fine chemicals from a Corynebacterium or Brevibacterium species).
The MCP nucleic acids of the invention may also be used to identify an organism as being Corynebacterium glutamicum or a close relative thereof, or to identify the presence of C. glutamicum or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of C. glutamicum genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a C. glutamicum gene which is unique to this organism, one can ascertain whether this organism is present. Although Corynebacterium glutamicum itself is nonpathogenic, it is related to species pathogenic in humans, such as Corynebacterium diphtheriae (the causative agent of diphtheria); the detection of such organisms is of significant clinical relevance.
The MCP nucleic acid molecules of the invention may also serve as reference points for mapping of the C. glutamicum genome, or of genomes of related organisms. Similarly, these molecules, or variants or portions thereof, may serve as markers for genetically engineered Corynebacterium or Brevibacterium species.
The MCP proteins encoded by the novel nucleic acid molecules of the invention may be involved, for example, in the direct or indirect production of one or more fine chemicals from C. glutamicum . The MCP proteins of the invention may also participate in the degradation of hydrocarbons or the oxidation of terpenoids. These proteins may also be utilized for the identification of Corynebacterium glutamicum or organisms related to C. glutamicum ; the presence of an MCP protein specific to C. glutamicum and related species in a mixture of proteins may indicate the presence of one of these bacteria in the sample. Further, these MCP proteins may have homologues in plants or animals which are involved in a disease state or condition; these proteins thus may serve as useful pharmaceutical targets for drug screening and the development of therapeutic compounds.
Given the availability of cloning vectors for use in Corynebacterium glutamicum , such as those disclosed in Sinskey et al., U.S. Pat. No. 4,649,119, and techniques for genetic manipulation of C. glutamicum and the related Brevibacterium species (e.g., lactofermentum) (Yoshihama et al, J. Bacteriol. 162: 591-597 (1985); Katsumata et al., J. Bacteriol. 159: 306-311 (1984); and Santamaria et al., J. Gen. Microbiol. 130: 2237-2246 (1984)), the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to modulate the production of one or more fine chemicals. This modulation may be due to a direct effect of manipulation of a gene of the invention, or it may be due to an indirect effect of such manipulation. For example, by modifying the activity of a protein involved in the biosynthesis or degradation of a fine chemical (i.e., through mutagenesis of the corresponding gene), one may directly modulate the ability of the cell to synthesize or to degrade this compound, thereby modulating the yield and/or efficiency of production of the fine chemical. Similarly, by modulating the activity of a protein which regulates a fine chemical metabolic pathway, one may directly influence whether the production of the desired compound is up- or down-regulated, either of which will modulate the yield or efficiency of production of the fine chemical from the cell.
Indirect modulation of fine chemical production may also result by modifying the activity of a protein of the invention (i.e., by mutagenesis of the corresponding gene) such that the overall ability of the cell to grow and divide or to remain viable and productive is increased. The production of fine chemicals from C. glutamicum is generally accomplished by the large-scale fermentative culture of these microorganisms, conditions which are frequently suboptimal for growth and cell division. By engineering a protein of the invention (e.g., a stress response protein, a cell wall protein, or proteins involved in the metabolism of compounds necessary for cell growth and division to occur, such as nucleotides and amino acids) such that it is better able to survive, grow, and multiply in such conditions, it may be possible to increase the number and productivity of such engineered C. glutamicum cells in large-scale culture, which in turn should result in increased yields and/or efficiency of production of one or more desired fine chemicals. Further, the metabolic pathways of any cell are necessarily interrelated and coregulated. By altering the activity or regulation of any one metabolic pathway in C. glutamicum (i.e., by altering the activity of one of the proteins of the invention which participates in such a pathway), it is possible to concomitantly alter the activity or regulation of other metabolic pathways in this microorganism, which may be directly involved in the synthesis or degradation of a fine chemical.
The invention provides novel nucleic acid molecules which encode proteins, referred to herein as MCP proteins, which are capable of, for example, modulating the production or efficiency of production of one or more fine chemicals from C. glutamicum , or of serving as identifying markers for C. glutamicum or related organisms. Nucleic acid molecules encoding an MCP protein are referred to herein as MCP nucleic acid molecules. In a preferred embodiment, the MCP protein is capable of modulating the production or efficiency of production of one or more fine chemicals from C. glutamicum , or of serving as identifying markers for C. glutamicum or related organisms. Examples of such proteins include those encoded by the genes set forth in Table 1.
Accordingly, one aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs, DNAs, or RNAs) comprising a nucleotide sequence encoding an MCP protein or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection or amplification of MCP-encoding nucleic acid (e.g., DNA or mRNA). In particularly preferred embodiments, the isolated nucleic acid molecule comprises one of the nucleotide sequences set forth in Appendix A or the coding region or a complement thereof of one of these nucleotide sequences. In other particularly preferred embodiments, the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80% or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence set forth in Appendix A, or a portion thereof. In other preferred embodiments, the isolated nucleic acid molecule encodes one of the amino acid sequences set forth in Appendix B. The preferred MCP proteins of the present invention also preferably possess at least one of the MCP activities described herein.
In another embodiment, the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B, e.g., sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains an MCP activity. Preferably, the protein or portion thereof encoded by the nucleic acid molecule maintains the ability to modulate the production or efficiency of production of one or more fine chemicals from C. glutamicum , or of serving as an identifying marker for C. glutamicum or related organisms. In one embodiment, the protein encoded by the nucleic acid molecule is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90% and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an amino acid sequence of Appendix B (e.g., an entire amino acid sequence selected from those sequences set forth in Appendix B). In another preferred embodiment, the protein is a full length C. glutamicum protein which is substantially homologous to an entire amino acid sequence of Appendix B (encoded by an open reading frame shown in Appendix A).
In another preferred embodiment, the isolated nucleic acid molecule is derived from C. glutamicum and encodes a protein (e.g., an MCP fusion protein) which includes a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of Appendix B and is able to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target for drug development, or to serve as an identifying marker for C. glutamicum or related organisms, and which also includes heterologous nucleic acid sequences encoding a heterologous polypeptide or regulatory regions.
In another embodiment, the isolated nucleic acid molecule is at least 15 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising a nucleotide sequence of Appendix A. Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring C. glutamicum MCP protein, or a biologically active portion thereof.
Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention, and host cells into which such vectors have been introduced. In one embodiment, such a host cell is used to produce an MCP protein by culturing the host cell in a suitable medium. The MCP protein can then be isolated from the medium or the host cell.
Yet another aspect of the invention pertains to a genetically altered microorganism in which an MCP gene has been introduced or altered. In one embodiment, the genome of the microorganism has been altered by introduction of a nucleic acid molecule of the invention encoding wild-type or mutated MCP sequence as a transgene. In another embodiment, an endogenous MCP gene within the genome of the microorganism has been altered, e.g., functionally disrupted, by homologous recombination with an altered MCP gene. In another embodiment, an endogenous or introduced MCP gene in a microorganism has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional MCP protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of an MCP gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the MCP gene is modulated. In a preferred embodiment, the microorganism belongs to the genus Corynebacterium or Brevibacterium , with Corynebacterium glutamicum being particularly preferred. In a preferred embodiment, the microorganism is also utilized for the production of a desired compound, such as an amino acid, with lysine being particularly preferred.
In another aspect, the invention provides a method of identifying the presence or activity of Cornyebacterium diphtheriae in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth in Appendix A or Appendix B) in a subject, thereby detecting the presence or activity of Corynebacterium diphtheriae in the subject.
Still another aspect of the invention pertains to an isolated MCP protein or a portion, e.g., a biologically active portion, thereof. In a preferred embodiment, the isolated MCP protein or portion thereof is capable of modulating the production or efficiency of production of one or more fine chemicals from C. glutamicum , or of serving as an identifying marker for C. glutamicum or related organisms. In another preferred embodiment, the isolated MCP protein or portion thereof is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to, for example, modulate the production or efficiency of production of one or more fine chemicals from C. glutamicum , or to serve as identifying markers for C. glutamicum or related organisms.
The invention also provides an isolated preparation of an MCP protein. In preferred embodiments, the MCP protein comprises an amino acid sequence of Appendix B. In another preferred embodiment, the invention pertains to an isolated full length protein which is substantially homologous to an entire amino acid sequence of Appendix B (encoded by an open reading frame set forth in Appendix A). In yet another embodiment, the protein is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%, and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an entire amino acid sequence of Appendix B. In other embodiments, the isolated MCP protein comprises an amino acid sequence which is at least about 50% or more homologous to one of the amino acid sequences of Appendix B and is able to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target for drug development, or to serve as an identifying marker for C. glutamicum or related organisms.
Alternatively, the isolated MCP protein can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80%, or 90%, and even more preferably at least about 95%, 96%, 97%, 98,%, or 99% or more homologous, to a nucleotide sequence of Appendix B. It is also preferred that the preferred forms of MCP proteins also have one or more of the MCP bioactivities described herein.
The MCP polypeptide, or a biologically active portion thereof, can be operatively linked to a non-MCP polypeptide to form a fusion protein. In preferred embodiments, this fusion protein has an activity which differs from that of the MCP protein alone. In other preferred embodiments, this fusion protein is capable of modulating the yield, production and/or efficiency of production of one or more fine chemicals from C. glutamicum , or of serving as an identifying marker for C. glutamicum or related organisms. In particularly preferred embodiments, integration of this fusion protein into a host cell modulates production of a desired compound from the cell.
In another aspect, the invention provides methods for screening molecules which modulate the activity of an MCP protein, either by interacting with the protein itself or a substrate or binding partner of the MCP protein, or by modulating the transcription or translation of an MCP nucleic acid molecule of the invention.
Another aspect of the invention pertains to a method for producing a fine chemical. This method involves the culturing of a cell containing a vector directing the expression of an MCP nucleic acid molecule of the invention, such that a fine chemical is produced. In a preferred embodiment, this method further includes the step of obtaining a cell containing such a vector, in which a cell is transfected with a vector directing the expression of an MCP nucleic acid. In another preferred embodiment, this method further includes the step of recovering the fine chemical from the culture. In a particularly preferred embodiment, the cell is from the genus Corynebacterium or Brevibacterium , or is selected from those strains set forth in Table 3.
Another aspect of the invention pertains to methods for modulating production of a molecule from a microorganism. Such methods include contacting the cell with an agent which modulates MCP protein activity or MCP nucleic acid expression such that a cell associated activity is altered relative to this same activity in the absence of the agent. In a preferred embodiment, the cell is modulated for one or more C. glutamicum MCP protein activities, such that the yield, production, and/or efficiency of production of a desired fine chemical by this microorganism is improved. The agent which modulates MCP protein activity can be an agent which stimulates MCP protein activity or MCP nucleic acid expression. Examples of agents which stimulate MCP protein activity or MCP nucleic acid expression include small molecules, active MCP proteins, and nucleic acids encoding MCP proteins that have been introduced into the cell. Examples of agents which inhibit MCP activity or expression include small molecules and antisense MCP nucleic acid molecules.
Another aspect of the invention pertains to methods for modulating yields, production, and/or efficiency of production of a desired compound from a cell, involving the introduction of a wild-type or mutant MCP gene into a cell, either maintained on a separate plasmid or integrated into the genome of the host cell. If integrated into the genome, such integration can be random, or it can take place by homologous recombination such that the native gene is replaced by the introduced copy, causing the production of the desired compound from the cell to be modulated. In a preferred embodiment, said yields are increased. In another preferred embodiment, said chemical is a fine chemical. In a particularly preferred embodiment, said fine chemical is an amino acid. In especially preferred embodiments, said amino acid is L-lysine.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides MCP nucleic acid and protein molecules. These MCP nucleic acid molecules may be utilized in the identification of Corynebacterium glutamicum or related organisms, in the mapping of the C. glutamicum genome (or a genome of a closely related organism), or in the identification of microorganisms which may be used to produce fine chemicals, e.g., by fermentation processes. The proteins encoded by these nucleic acids may be utilized in the direct or indirect modulation of the production or efficiency of production of one or more fine chemicals from C. glutamicum , as identifying markers for C. glutamicum or related organisms, in the oxidation of terpenoids or the degradation of hydrocarbons, or as targets for the development of therapeutic pharmaceutical compounds. Aspects of the invention are further explicated below.
I. Fine Chemicals
The term ‘fine chemical’ is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries. Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described e.g. in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm et al., eds. VCH: Weinheim, and references contained therein), lipids, both saturated and unsaturated fatty acids (e.g., arachidonic acid), diols (e.g., propane diol, and butane diol), carbohydrates (e.g., hyaluronic acid and trehalose), aromatic compounds (e.g., aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, “Vitamins”, p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A. S., Niki, E. & Packer, L. (1995) “Nutrition, Lipids, Health, and Disease” Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research—Asia, held Sep. 1-3, 1994 at Penang, Malaysia, AOCS Press, (1995)), enzymes, polyketides (Cane et al. (1998) Science 282: 63-68), and all other chemicals described in Gutcho (1983) Chemicals by Fermentation, Noyes Data Corporation, ISBN: 0818805086 and references therein. The metabolism and uses of certain of these fine chemicals are further explicated below.
A. Amino Acid Metabolism and Uses
Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms. The term “amino acid” is art-recognized. The proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) are not normally found in proteins (see Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97 VCH: Weinheim (1985)). Amino acids may be in the D- or L-optical configuration, though L-amino acids are generally the only type found in naturally-occurring proteins. Biosynthetic and degradative pathways of each of the 20 proteinogenic amino acids have been well characterized in both prokaryotic and eukaryotic cells (see, for example, Stryer, L. Biochemistry, 3 rd edition, pages 578-590 (1988)). The ‘essential’ amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), so named because they are generally a nutritional requirement due to the complexity of their biosyntheses, are readily converted by simple biosynthetic pathways to the remaining 11 ‘nonessential’ amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur.
Aside from their function in protein biosynthesis, these amino acids are interesting chemicals in their own right, and many have been found to have various applications in the food, feed, chemical, cosmetics, agriculture, and pharmaceutical industries. Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine. Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L-methionine and tryptophan are all utilized in the pharmaceutical industry. Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/L-methionine are common feed additives. (Leuchtenberger, W. (1996) Amino aids—technical production and use, p. 466-502 in Rehm et al. (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim). Additionally, these amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N-acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others described in Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH: Weinheim, 1985.
The biosynthesis of these natural amino acids in organisms capable of producing them, such as bacteria, has been well characterized (for review of bacterial amino acid biosynthesis and regulation thereof, see Umbarger, H. E. (1978) Ann. Rev. Biochem. 47: 533-606). Glutamate is synthesized by the reductive amination of α-ketoglutarate, an intermediate in the citric acid cycle. Glutamine, proline, and arginine are each subsequently produced from glutamate. The biosynthesis of serine is a three-step process beginning with 3-phosphoglycerate (an intermediate in glycolysis), and resulting in this amino acid after oxidation, transamination, and hydrolysis steps. Both cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transferal of the side-chain β-carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase. Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. Tryptophan is also produced from these two initial molecules, but its synthesis is an 11-step pathway. Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase. Alanine, valine, and leucine are all biosynthetic products of pyruvate, the final product of glycolysis. Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle. Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate. Isoleucine is formed from threonine. A complex 9-step pathway results in the production of histidine from 5-phosphoribosyl-1-pyrophosphate, an activated sugar.
Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. Biochemistry 3 rd ed. Ch. 21 “Amino Acid Degradation and the Urea Cycle” p. 495-516 (1988)). Although the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them. Thus it is not surprising that amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid biosynthetic pathways, see Stryer, L. Biochemistry, 3 rd ed. Ch. 24: “Biosynthesis of Amino Acids and Heme” p. 575-600 (1988)). Thus, the output of any particular amino acid is limited by the amount of that amino acid present in the cell.
B. Vitamin, Cofactor, and Nutraceutical Metabolism and Uses
Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, “Vitamins” vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term “vitamin” is art-recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. The group of vitamins may encompass cofactors and nutraceutical compounds. The language “cofactor” includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic. The term “nutraceutical” includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).
The biosynthesis of these molecules in organisms capable of producing them, such as bacteria, has been largely characterized (Ullman's Encyclopedia of Industrial Chemistry, “Vitamins” vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley & Sons Ong, A. S., Niki, E. & Packer, L. (1995) “Nutrition, Lipids, Health, and Disease” Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research—Asia, held Sep. 1-3, 1994 at Penang, Malaysia, AOCS Press: Champaign, IL X, 374 S).
Thiamin (vitamin B 1 ) is produced by the chemical coupling of pyrimidine and thiazole moieties. Riboflavin (vitamin B 2 ) is synthesized from guanosine-5′-triphosphate (GTP) and ribose-5′-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). The family of compounds collectively termed ‘vitamin B 6 ’ (e.g., pyridoxine, pyridoxamine, pyridoxa-5′-phosphate, and the commercially used pyridoxin hydrochloride) are all derivatives of the common structural unit, 5-hydroxy-6-methylpyridine. Pantothenate (pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-β-alanine ) can be produced either by chemical synthesis or by fermentation. The final steps in pantothenate biosynthesis consist of the ATP-driven condensation of β-alanine and pantoic acid. The enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to β-alanine and for the condensation to panthotenic acid are known. The metabolically active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps. Pantothenate, pyridoxal-5′-phosphate, cysteine and ATP are the precursors of Coenzyme A. These enzymes not only catalyze the formation of panthothante, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)-panthenol (provitamin B 5 ), pantetheine (and its derivatives) and coenzyme A.
Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been identified. Many of the corresponding proteins have been found to also be involved in Fe-cluster synthesis and are members of the nifS class of proteins. Lipoic acid is derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the α-ketoglutarate dehydrogenase complex. The folates are a group of substances which are all derivatives of folic acid, which is turn is derived from L-glutamic acid, p-amino-benzoic acid and 6-methylpterin. The biosynthesis of folic acid and its derivatives, starting from the metabolism intermediates guanosine-5′-triphosphate (GTP), L-glutamic acid and p-amino-benzoic acid has been studied in detail in certain microorganisms.
Corrinoids (such as the cobalamines and particularly vitamin B 12 ) and porphyrines belong to a group of chemicals characterized by a tetrapyrole ring system. The biosynthesis of vitamin B 12 is sufficiently complex that it has not yet been completely characterized, but many of the enzymes and substrates involved are now known. Nicotinic acid (nicotinate), and nicotinamide are pyridine derivatives which are also termed ‘niacin’. Niacin is the precursor of the important coenzymes NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) and their reduced forms.
The large-scale production of these compounds has largely relied on cell-free chemical syntheses, though some of these chemicals have also been produced by large-scale culture of microorganisms, such as riboflavin, Vitamin B 6 , pantothenate, and biotin. Only Vitamin B 12 is produced solely by fermentation, due to the complexity of its synthesis. In vitro methodologies require significant inputs of materials and time, often at great cost.
C. Purine, Pyrimidine, Nucleoside and Nucleotide Metabolism and Uses
Purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections. The language “purine” or “pyrimidine” includes the nitrogenous bases which are constituents of nucleic acids, co-enzymes, and nucleotides. The term “nucleotide” includes the basic structural units of nucleic acid molecules, which are comprised of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar is D-deoxyribose), and phosphoric acid. The language “nucleoside” includes molecules which serve as precursors to nucleotides, but which are lacking the phosphoric acid moiety that nucleotides possess. By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are nucleotides which may serve as energy stores (e.g., ADP, ATP) or as coenzymes (i.e., FAD and NAD).
Several publications have described the use of these chemicals for these medical indications, by influencing purine and/or pyrimidine metabolism (e.g. Christopherson, R. I. and Lyons, S. D. (1990) “Potent inhibitors of de novo pyrimidine and purine biosynthesis as chemotherapeutic agents.” Med. Res. Reviews 10: 505-548). Studies of enzymes involved in purine and pyrimidine metabolism have been focused on the development of new drugs which can be used, for example, as immunosuppressants or anti-proliferants (Smith, J. L., (1995) “Enzymes in nucleotide synthesis.” Curr. Opin. Struct. Biol. 5: 752-757; (1995) Biochem Soc. Transact. 23: 877-902). However, purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates in the biosynthesis of several fine chemicals (e.g., thiamine, S-adenosyl-methionine, folates, or riboflavin), as energy carriers for the cell (e.g., ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (e.g., IMP or GMP) or for several medicinal applications (see, for example, Kuninaka, A. (1996) Nucleotides and Related Compounds in Biotechnology vol. 6, Rehm et al., eds. VCH: Weinheim, p. 561-612). Also, enzymes involved in purine, pyrimidine, nucleoside, or nucleotide metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed.
The metabolism of these compounds in bacteria has been characterized (for reviews see, for example, Zalkin, H. and Dixon, J. E. (1992) “de novo purine nucleotide biosynthesis”, in: Progress in Nucleic Acid Research and Molecular Biology, vol. 42, Academic Press: p. 259-287; and Michal, G. (1999) “Nucleotides and Nucleosides”, Chapter 8 in: Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, Wiley: New York). Purine metabolism has been the subject of intensive research, and is essential to the normal functioning of the cell. Impaired purine metabolism in higher animals can cause severe disease, such as gout. Purine nucleotides are synthesized from ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5′-phosphate (IMP), resulting in the production of guanosine-5′-monophosphate (GMP) or adenosine-5′-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell. Pyrimidine biosynthesis proceeds by the formation of uridine-5′-monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5′-triphosphate (CTP). The deoxy-forms of all of these nucleotides are produced in a one step reduction reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to participate in DNA synthesis.
D. Trehalose Metabolism and Uses
Trehalose consists of two glucose molecules, bound in α, α-1,1 linkage. It is commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages. However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto et al., (1998) U.S. Pat. No. 5,759,610; Singer, M. A. and Lindquist, S. (1998) Trends Biotech. 16: 460-467; Paiva, C. L. A. and Panek, A. D. (1996) Biotech. Ann. Rev. 2: 293-314; and Shiosaka, M. (1997) J. Japan 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art.
II. Elements and Methods of the Invention
The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as MCP nucleic acid molecules. These MCP nucleic acid molecules are useful not only for the identification of C. glutamicum or related bacterial species, but also as markers for the mapping of the C. glutamicum genome and in the identification of bacteria useful for the production of fine chemicals by, e.g., fermentative processes. The present invention is also based, at least in part, on the MCP protein molecules encoded by these MCP nucleic acid molecules. These MCP proteins are capable of modulating the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , of serving as identifying markers for C. glutamicum or related organisms, of degrading hydrocarbons, and of serving as targets for the development of therapeutic pharmaceutical compounds. In one embodiment, the MCP molecules of the invention directly or indirectly participate in one or more fine chemical metabolic pathways in C. glutamicum . In a preferred embodiment, the activity of the MCP molecules of the invention to indirectly or directly participate in such metabolic pathways has an impact on the production of a desired fine chemical by this microorganism. In a particularly preferred embodiment, the MCP molecules of the invention are modulated in activity, such that the C. glutamicum metabolic pathways in which the MCP proteins of the invention participate are modulated in efficiency or output, which either directly or indirectly modulates the production or efficiency of production of a desired fine chemical by C. glutamicum.
The language, “MCP protein” or “MCP polypeptide” includes proteins which are able to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target protein for drug screening or design, or to serve as identifying markers for C. glutamicum or related organisms. Examples of MCP proteins include those encoded by the MCP genes set forth in Table 1 and Appendix A. The terms “MCP gene” or “MCP nucleic acid sequence” include nucleic acid sequences encoding an MCP protein, which consist of a coding region and also corresponding untranslated 5′ and 3′ sequence regions. Examples of MCP genes include those set forth in Table 1. The terms “production” or “productivity” are art-recognized and include the concentration of the fermentation product (for example, the desired fine chemical) formed within a given time and a given fermentation volume (e.g., kg product per hour per liter). The term “efficiency of production” includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a fine chemical). The term “yield” or “product/carbon yield” is art-recognized and includes the efficiency of the conversion of the carbon source into the product (i.e., fine chemical). This is generally written as, for example, kg product per kg carbon source. By increasing the yield or production of the compound, the quantity of recovered molecules, or of useful recovered molecules of that compound in a given amount of culture over a given amount of time is increased. The terms “biosynthesis” or a “biosynthetic pathway” are art-recognized and include the synthesis of a compound, preferably an organic compound, by a cell from intermediate compounds in what may be a multistep and highly regulated process. The terms “degradation” or a “degradation pathway” are art-recognized and include the breakdown of a compound, preferably an organic compound, by a cell to degradation products (generally speaking, smaller or less complex molecules) in what may be a multistep and highly regulated process. The language “metabolism” is art-recognized and includes the totality of the biochemical reactions that take place in an organism. The metabolism of a particular compound, then, (e.g., the metabolism of an amino acid such as glycine) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this compound.
In another embodiment, the MCP molecules of the invention are capable of modulating the production of a desired molecule, such as a fine chemical, in a microorganism such as C. glutamicum , either directly or indirectly. Using recombinant genetic techniques, one or more of the MCP proteins of the invention may be manipulated such that its function is modulated. Such modulation of function may result in the modulation of the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum.
For example, by modifying the activity of a protein involved in the biosynthesis or degradation of a fine chemical (i.e., through mutagenesis of the corresponding gene), one may directly modulate the ability of the cell to synthesize or to degrade this compound, thereby modulating the yield and/or efficiency of production of the fine chemical. Similarly, by modulating the activity of a protein which regulates a fine chemical metabolic pathway, one may directly influence whether the production of the desired compound is up- or down-regulated, either of which will modulate the yield or efficiency of production of the fine chemical from the cell.
Indirect modulation of fine chemical production may also result by modifying the activity of a protein of the invention (i.e., by mutagenesis of the corresponding gene) such that the overall ability of the cell to grow and divide or to remain viable and productive is increased. The production of fine chemicals from C. glutamicum is generally accomplished by the large-scale fermentative culture of these microorganisms, conditions which are frequently suboptimal for growth and cell division. By engineering a protein of the invention (e.g., a stress response protein, a cell wall protein, or proteins involved in the metabolism of compounds necessary for cell growth and division to occur, such as nucleotides and amino acids) such that it is better able to survive, grow, and multiply in such conditions, it may be possible to increase the number and productivity of such engineered C. glutamicum cells in large-scale culture, which in turn should result in increased yields and/or efficiency of production of one or more desired fine chemicals. Further, the metabolic pathways of any cell are necessarily interrelated and coregulated. By altering the activity or regulation of any one metabolic pathway in C. glutamicum (i.e., by altering the activity of one of the proteins of the invention which participates in such a pathway), it is possible to concomitantly alter the activity or regulation of other metabolic pathways in this microorganism, which may be directly involved in the synthesis or degradation of a fine chemical.
The isolated nucleic acid sequences of the invention are contained within the genome of a Corynebacterium glutamicum strain available through the American Type Culture Collection, given designation ATCC 13032. The nucleotide sequences of the isolated C. glutamicum MCP nucleic acid molecules and the predicted amino acid sequences of the C. glutamicum MCP proteins are shown in Appendices A and B, respectively. Computational analyses were performed which classified and/or identified many of these nucleotide sequences as sequences having homology to E. coli or Bacillus subtilis genes.
The present invention also pertains to proteins which have an amino acid sequence which is substantially homologous to an amino acid sequence of Appendix B. As used herein, a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the selected amino acid sequence, e.g., the entire selected amino acid sequence. A protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, or 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to the selected amino acid sequence.
The MCP protein or a biologically active portion or fragment thereof of the invention is able to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target for drug development, or to serve as an identifying marker for C. glutamicum or related organisms.
Various aspects of the invention are described in further detail in the following subsections:
A. Isolated Nucleic Acid Molecules
One aspect of the invention pertains to isolated nucleic acid molecules that encode MCP polypeptides or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes or primers for the identification or amplification of MCP-encoding nucleic acid (e.g., MCP DNA). These nucleic acid molecules may be used to identify C. glutamicum or related organisms, to map the genome of C. glutamicum or closely related bacteria, or to identify microorganisms useful for the production of fine chemicals, e.g., by fermentative processes. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. This term also encompasses untranslated sequence located at both the 3′ and 5′ ends of the coding region of the gene: at least about 100 nucleotides of sequence upstream from the 5′ end of the coding region and at least about 20 nucleotides of sequence downstream from the 3′ end of the coding region of the gene. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated MCP nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (e.g, a C. glutamicum cell). Moreover, an “isolated” nucleic acid molecule, such as a DNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.
A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having a nucleotide sequence of Appendix A, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a C. glutamicum MCP DNA can be isolated from a C. glutamicum library using all or portion of one of the sequences of Appendix A as a hybridization probe and standard hybridization techniques (e.g., as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989). Moreover, a nucleic acid molecule encompassing all or a portion of one of the sequences of Appendix A can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this sequence (e.g., a nucleic acid molecule encompassing all or a portion of one of the sequences of Appendix A can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this same sequence of Appendix A). For example, mRNA can be isolated from normal endothelial cells (e.g., by the guanidinium-thiocyanate extraction procedure of Chirgwin et al. (1979) Biochemistry 18: 5294-5299) and DNA can be prepared using reverse transcriptase (e.g., Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, Md.; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, Fla.) and random polynucleotide primers or oligonucleotide primers based upon one of the nucleotide sequences shown in Appendix A. Synthetic oligonucleotide primers for polymerase chain reaction amplification can be designed based upon one of the nucleotide sequences shown in Appendix A. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to an MCP nucleotide sequence can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises one of the nucleotide sequences shown in Appendix A. The sequences of Appendix A correspond to the Corynebacterium glutamicum MCP DNAs of the invention. This cDNA comprises sequences encoding MCP proteins (i.e., the “coding region”, indicated in each sequence in Appendix A), as well as 5′ untranslated sequences and 3′ untranslated sequences, also indicated in Appendix A. Alternatively, the nucleic acid molecule can comprise only the coding region of any of the sequences in Appendix A.
For the purposes of this application, it will be understood that each of the sequences set forth in Appendix A has an identifying RXA or RXN number having the designation “RXA” or “RXN” followed by 5 digits (i.e., RXA00003 or RXN00022). Each of these sequences comprises up to three parts: a 5′ upstream region, a coding region, and a downstream region. Each of these three regions is identified by the same RXA or RXN designation to eliminate confusion. The recitation “one of the sequences in Appendix A”, then, refers to any of the sequences in Appendix A, which may be distinguished by their differing RXA or RXN designations. The coding region of each of these sequences is translated into a corresponding amino acid sequence, which is set forth in Appendix B. The sequences of Appendix B are identified by the same RXA or RXN designations as Appendix A, such that they can be readily correlated. For example, the amino acid sequence in Appendix B designated RXA00003 is a translation of the coding region of the nucleotide sequence of nucleic acid molecule RXA00003 in Appendix A, and the amino acid sequence in Appendix B designated RXN00022 is a translation of the coding region of the nucleotide sequence of nucleic acid molecule RXN00022 in Appendix A. Each of the RXA and RXN nucleotide and amino acid sequences of the invention has also been assigned a SEQ ID NO, as indicated in Table 1.
Several of the genes of the invention are “F-designated genes”. An F-designated gene includes those genes set forth in Table 1 which have an ‘F’ in front of the RXA designation. For example, SEQ ID NO:3, designated, as indicated on Table 1, as “F RXA01638”, is an F-designated gene, as are SEQ ID NOs: 5, 9, and 11 (designated on Table 1 as “F RXA01639”, “F RXA01590”, and “F RXA01542”, respectively).
In one embodiment, the nucleic acid molecules of the present invention are not intended to include those compiled in Table 2.
In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of one of the nucleotide sequences shown in Appendix A, or a portion thereof. A nucleic acid molecule which is complementary to one of the nucleotide sequences shown in Appendix A is one which is sufficiently complementary to one of the nucleotide sequences shown in Appendix A such that it can hybridize to one of the nucleotide sequences shown in Appendix A, thereby forming a stable duplex.
In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence shown in Appendix A, or a portion thereof. Ranges and identity values intermediate to the above-recited ranges, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to one of the nucleotide sequences shown in Appendix A, or a portion thereof.
Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of one of the sequences in Appendix A, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of an MCP protein. The nucleotide sequences determined from the cloning of the MCP genes from C. glutamicum allows for the generation of probes and primers designed for use in identifying and/or cloning MCP homologues in other cell types and organisms, as well as MCP homologues from other Corynebacteria or related species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense strand of one of the sequences set forth in Appendix A, an anti-sense sequence of one of the sequences set forth in Appendix A, or naturally occurring mutants thereof. Primers based on a nucleotide sequence of Appendix A can be used in PCR reactions to clone MCP homologues. Probes based on the MCP nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells which misexpress an MCP protein, such as by measuring a level of an MCP-encoding nucleic acid in a sample of cells, e.g., detecting MCP mRNA levels or determining whether a genomic MCP gene has been mutated or deleted.
In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target for drug development, or to serve as an identifying marker for C. glutamicum or related organisms. As used herein, the language “sufficiently homologous” refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain as an amino acid residue in one of the sequences of Appendix B) amino acid residues to an amino acid sequence of Appendix B such that the protein or portion thereof is able to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target for drug development, or to serve as an identifying marker for C. glutamicum or related organisms. Examples of such activities are also described herein. Thus, “the function of an MCP protein” contributes to the overall regulation of one or more fine chemical metabolic pathways, or to the degradation of a hydrocarbon, or to the oxidation of a terpenoid.
In another embodiment, the protein is at least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of Appendix B.
Portions of proteins encoded by the MCP nucleic acid molecules of the invention are preferably biologically active portions of one of the MCP proteins. As used herein, the term “biologically active portion of an MCP protein” is intended to include a portion, e.g., a domain/motif, of an MCP protein that modulates the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , that degrades hydrocarbons, that oxidizes terpenoids, that may serve as a target for drug development, or that may serve as an identifying marker for C. glutamicum or related organisms. To determine whether an MCP protein or a biologically active portion thereof can modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , can degrade hydrocarbons, or can oxidize terpenoids, an assay of activity may be performed. Such assay methods are well known to those of ordinary skill in the art, as detailed in Example 8 of the Exemplification.
Additional nucleic acid fragments encoding biologically active portions of an MCP protein can be prepared by isolating a portion of one of the sequences in Appendix B, expressing the encoded portion of the MCP protein or peptide (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of the MCP protein or peptide.
The invention further encompasses nucleic acid molecules that differ from one of the nucleotide sequences shown in Appendix A (and portions thereof) due to degeneracy of the genetic code and thus encode the same MCP protein as that encoded by the nucleotide sequences shown in Appendix A. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in Appendix B. In a still further embodiment, the nucleic acid molecule of the invention encodes a full length C. glutamicum protein which is substantially homologous to an amino acid sequence of Appendix B (encoded by an open reading frame shown in Appendix A).
It will be understood by one of ordinary skill in the art that in one embodiment the sequences of the invention are not meant to include the sequences of the prior art, such as those Genbank sequences set forth in Tables 2 or 4 which were available prior to the present invention. In one embodiment, the invention includes nucleotide and amino acid sequences having a percent identity to a nucleotide or amino acid sequence of the invention which is greater than that of a sequence of the prior art (e.g., a Genbank sequence (or the protein encoded by such a sequence) set forth in Tables 2 or 4). For example, the invention includes a nucleotide sequence which is greater than and/or at least 39% identical to the nucleotide sequence designated RXA00008 (SEQ ID NO: 1549), a nucleotide sequence which is greater than and/or at least 42% identical to the nucleotide sequence designated RXA00059 (SEQ ID NO:1571), and a nucleotide sequence which is greater than and/or at least 39% identical to the nucleotide sequence designated RXA00096 (SEQ ID NO:93). One of ordinary skill in the art would be able to calculate the lower threshold of percent identity for any given sequence of the invention by examining the GAP-calculated percent identity scores set forth in Table 4 for each of the three top hits for the given sequence, and by subtracting the highest GAP-calculated percent identity from 100 percent. One of ordinary skill in the art will also appreciate that nucleic acid and amino acid sequences having percent identities greater than the lower threshold so calculated (e.g., at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more identical) are also encompassed by the invention.
In addition to the C. glutamicum MCP nucleotide sequences shown in Appendix A, it will be appreciated by those of ordinary skill in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of MCP proteins may exist within a population (e.g., the C. glutamicum population). Such genetic polymorphism in the MCP gene may exist among individuals within a population due to natural variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding an MCP protein, preferably a C. glutamicum MCP protein. Such natural variations can typically result in 1-5% variance in the nucleotide sequence of the MCP gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in MCP that are the result of natural variation and that do not alter the functional activity of MCP proteins are intended to be within the scope of the invention.
Nucleic acid molecules corresponding to natural variants and non- C. glutamicum homologues of the C. glutamicum MCP DNA of the invention can be isolated based on their homology to the C. glutamicum MCP nucleic acid disclosed herein using the C. glutamicum DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising a nucleotide sequence of Appendix A. In other embodiments, the nucleic acid is at least 30, 50, 100, 250 or more nucleotides in length. As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those of ordinary skill in the art and can be found in Current Protocols in Molecular Biology , John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 50-65° C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a sequence of Appendix A corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein). In one embodiment, the nucleic acid encodes a natural C. glutamicum MCP protein.
In addition to naturally-occurring variants of the MCP sequence that may exist in the population, one of ordinary skill in the art will further appreciate that changes can be introduced by mutation into a nucleotide sequence of Appendix A, thereby leading to changes in the amino acid sequence of the encoded MCP protein, without altering the functional ability of the MCP protein. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in a sequence of Appendix A. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence of one of the MCP proteins (Appendix B) without altering the activity of said MCP protein, whereas an “essential” amino acid residue is required for MCP protein activity. Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved in the domain having MCP activity) may not be essential for activity and thus are likely to be amenable to alteration without altering MCP activity.
Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding MCP proteins that contain changes in amino acid residues that are not essential for MCP activity. Such MCP proteins differ in amino acid sequence from a sequence contained in Appendix B yet retain at least one of the MCP activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 50% homologous to an amino acid sequence of Appendix B and is able to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target for drug development, or to serve as an identifying marker for C. glutamicum or related organisms. Preferably, the protein encoded by the nucleic acid molecule is at least about 50-60% homologous to one of the sequences in Appendix B, more preferably at least about 60-70% homologous to one of the sequences in Appendix B, even more preferably at least about 70-80%, 80-90%, 90-95% homologous to one of the sequences in Appendix B, and most preferably at least about 96%, 97%, 98%, or 99% homologous to one of the sequences in Appendix B.
To determine the percent homology of two amino acid sequences (e.g., one of the sequences of Appendix B and a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence (e.g., one of the sequences of Appendix B) is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (e.g., a mutant form of the sequence selected from Appendix B), then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid “identity”). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology=# of identical positions/total # of positions×100).
An isolated nucleic acid molecule encoding an MCP protein homologous to a protein sequence of Appendix B can be created by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of Appendix A such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into one of the sequences of Appendix A by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an MCP protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an MCP coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for an MCP activity described herein to identify mutants that retain MCP activity. Following mutagenesis of one of the sequences of Appendix A, the encoded protein can be expressed recombinantly and the activity of the protein can be determined using, for example, assays described herein (see Example 8 of the Exemplification).
In addition to the nucleic acid molecules encoding MCP proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An “antisense” nucleic acid comprises a nucleotide sequence which is complementary to a “sense” nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire MCP coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding an MCP protein. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the entire coding region of SEQ ID NO. 1 (RXN01638) comprises nucleotides 1 to 900). In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence encoding MCP. The term “noncoding region” refers to 5′ and 3′ sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).
Given the coding strand sequences encoding MCP disclosed herein (e.g., the sequences set forth in Appendix A), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of MCP mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of MCP mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of MCP mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed by chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
The antisense nucleic acid molecules of the invention are typically administered to a cell or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an MCP protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. The antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen. The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong prokaryotic, viral, or eukaryotic promoter are preferred.
In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual O-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids. Res. 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2′—O— methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).
In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave MCP mRNA transcripts to thereby inhibit translation of MCP mRNA. A ribozyme having specificity for an MCP-encoding nucleic acid can be designed based upon the nucleotide sequence of an MCP DNA disclosed herein (i.e., SEQ ID NO. 1 (RXN01368) in Appendix A). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an MCP-encoding mRNA. See, e.g., Cech et al. U.S. Pat. No. 4,987,071 and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, MCP mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J. W. (1993) Science 261:1411-1418.
Alternatively, MCP gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of an MCP nucleotide sequence (e.g., an MCP promoter and/or enhancers) to form triple helical structures that prevent transcription of an MCP gene in target cells. See generally, Helene, C. (1991) Anticancer Drug Des. 6(6):569-84; Helene, C. et al. (1992) Ann. N.Y. Acad. Sci. 660:27-36; and Maher, L. J. (1992) Bioassays 14(12):807-15.
B. Recombinant Expression Vectors and Host Cells
Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an MCP protein (or a portion thereof). As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term “regulatory sequence” is intended to include promoters, repressor binding sites, activator binding sites, enhancer regions and other expression control elements (e.g., terminators, other elements of mRNA secondary structure, or polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells. Preferred regulatory sequences are, for example, promoters such as cos-, tac-, trp-, tet-, trp-tet-, lpp-, lac-, lpp-lac-, lacI q -, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, arny, SPO2, λ-P R - or λ P L , which are used preferably in bacteria. Additional regulatory sequences are, for example, promoters from yeasts and fungi, such as ADC 1, MFα, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH, promoters from plants such as CaMV/35S, SSU, OCS, lib4, usp, STLS1, B33, nos or ubiquitin- or phaseolin-promoters. It is also possible to use artificial promoters. It will be appreciated by those of ordinary skill in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., MCP proteins, mutant forms of MCP proteins, fusion proteins, etc.).
The recombinant expression vectors of the invention can be designed for expression of MCP proteins in prokaryotic or eukaryotic cells. For example, MCP genes can be expressed in bacterial cells such as C. glutamicum , insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, M. A. et al. (1992) “Foreign gene expression in yeast: a review”, Yeast 8: 423-488; van den Hondel, C. A. M. J. J. et al. (1991) “Heterologous gene expression in filamentous fungi” in: More Gene Manipulations in Fungi, J. W. Bennet & L. L. Lasure, eds., p. 396-428: Academic Press: San Diego; and van den Hondel, C. A. M. J. J. & Punt, P. J. (1991) “Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, Peberdy, J. F. et al., eds., p. 1-28, Cambridge University Press: Cambridge), algae and multicellular plant cells (see Schmidt, R. and Willmitzer, L. (1988) High efficiency Agrobacterium tumefactiens —mediated transformation of Arabidopsis thaliana leaf and cotyledon explants” Plant Cell Rep.: 583-586), or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
Expression of proteins in prokaryotes is most often carried out with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.
Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D. B. and Johnson, K. S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. In one embodiment, the coding sequence of the MCP protein is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-X protein. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant MCP protein unfused to GST can be recovered by cleavage of the fusion protein with thrombin.
Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315), pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHS1, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN-III113-B1, λgt11, pBdCl, and pET 11d (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89; and Pouwels et al., eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21 (DE3) or HMS 174(DE3) from a resident λ prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter. For transformation of other varieties of bacteria, appropriate vectors may be selected. For example, the plasmids pIJ101, pIJ364, pIJ702 and pIJ361 are known to be useful in transforming Streptomyces , while plasmids pUB 110, pC 194, or pBD214 are suited for transformation of Bacillus species. Several plasmids of use in the transfer of genetic information into Corynebacterium include pHM 1519, pBL1, pSA77, or pAJ667 (Pouwels et al., eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018).
One strategy to maximize recombinant protein expression is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as C. glutamicum (Wada et al. (1992) Nucleic Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
In another embodiment, the MCP protein expression vector is a yeast expression vector. Examples of vectors for expression in yeast S. cerevisiae include pYepSec1 (Baldari, et al., (1987) Embo J. 6:229-234), 2μ, pAG-1, Yep6, Yep13, pEMBLYe23, pMFa (Kuijan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al., (1987) Gene 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.). Vectors and methods for the construction of vectors appropriate for use in other fungi, such as the filamentous fungi, include those detailed in: van den Hondel, C. A. M. J. J. & Punt, P. J. (1991) “Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, J. F. Peberdy, et al., eds., p. 1-28, Cambridge University Press: Cambridge, and Pouwels et al., eds. (1985) Cloning Vectors. Elsevier: New York (IBSN 0 444 904018).
Alternatively, the MCP proteins of the invention can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) Mol. Cell. Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).
In another embodiment, the MCP proteins of the invention may be expressed in unicellular plant cells (such as algae) or in plant cells from higher plants (e.g., the spermatophytes, such as crop plants). Examples of plant expression vectors include those detailed in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) “New plant binary vectors with selectable markers located proximal to the left border”, Plant Mol. Biol. 20: 1195-1197; and Bevan, M. W. (1984) “Binary Agrobacterium vectors for plant transformation”, Nucl. Acid Res. 12: 8711-8721, and include pLGV23, pGHlac+, pBIN19, pAK2004, and pDH51 (Pouwels et al., eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018).
In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) PNAS 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the α-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).
The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to MCP mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al. (1986) “Antisense RNA as a molecular tool for genetic analysis”, Reviews—Trends in Genetics , Vol. 1(1).
Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
A host cell can be any prokaryotic or eukaryotic cell. For example, an MCP protein can be expressed in bacterial cells such as C. glutamicum , insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those of ordinary skill in the art. Microorganisms related to Corynebacterium glutamicum which may be conveniently used as host cells for the nucleic acid and protein molecules of the invention are set forth in Table 3.
Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation”, “transfection”, “conjugation” and “transduction” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.g., a plasmid, phage, phasmid, phagemid, transposon or other DNA) into a host cell, including using natural competence, chemical mediated transfer, calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. ( Molecular Cloning: A Laboratory Manual. 2nd, ed, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.
For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an MCP protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by, for example, drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
To create a homologous recombinant microorganism, a vector is prepared which contains at least a portion of an MCP gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g, functionally disrupt, the MCP gene. Preferably, this MCP gene is a Corynebacterium glutamicum MCP gene, but it can be a homologue from a related bacterium or even from a mammalian, yeast, or insect source. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous MCP gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous MCP gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous MCP protein). In the homologous recombination vector, the altered portion of the MCP gene is flanked at its 5′ and 3′ ends by additional nucleic acid of the MCP gene to allow for homologous recombination to occur between the exogenous MCP gene carried by the vector and an endogenous MCP gene in a microorganism. The additional flanking MCP nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, less than one kilobase of flanking DNA (both at the 5′ and 3′ ends) is included in the vector (see e.g., Thomas, K. R., and Capecchi, M. R. (1987) Cell 51: 503 for a description of homologous recombination vectors). The vector is introduced into a microorganism (e.g., by electroporation) and cells in which the introduced MCP gene has homologously recombined with the endogenous MCP gene are selected, using art-known techniques.
In another embodiment, recombinant microorganisms can be produced which contain selected systems which allow for regulated expression of the introduced gene. For example, inclusion of an MCP gene on a vector placing it under control of the lac operon permits expression of the MCP gene in the presence of IPTG. Such regulatory systems are well known in the art.
In another embodiment, an endogenous MCP gene in a host cell is disrupted (e.g., by homologous recombination or other genetic means known in the art) such that expression of its protein product does not occur. In another embodiment, an endogenous or introduced MCP gene in a host cell has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional MCP protein. In still another embodiment, one or more of the regulatory regions (e.g, a promoter, repressor, or inducer) of an MCP gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the MCP gene is modulated. One of ordinary skill in the art will appreciate that host cells containing more than one of the described MCP gene and protein modifications may be readily produced using the methods of the invention, and are meant to be included in the present invention.
A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) an MCP protein. Accordingly, the invention further provides methods for producing MCP proteins using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding an MCP protein has been introduced, or into which genome has been introduced a gene encoding a wild-type or altered MCP protein) in a suitable medium until MCP protein is produced. In another embodiment, the method further comprises isolating MCP proteins from the medium or the host cell.
C. Isolated MCP Proteins
Another aspect of the invention pertains to isolated MCP proteins, and biologically active portions thereof. An “isolated” or “purified” protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of MCP protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language “substantially free of cellular material” includes preparations of MCP protein having less than about 30% (by dry weight) of non-MCP protein (also referred to herein as a “contaminating protein”), more preferably less than about 20% of non-MCP protein, still more preferably less than about 10% of non-MCP protein, and most preferably less than about 5% non-MCP protein. When the MCP protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language “substantially free of chemical precursors or other chemicals” includes preparations of MCP protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of MCP protein having less than about 30% (by dry weight) of chemical precursors or non-MCP chemicals, more preferably less than about 20% chemical precursors or non-MCP chemicals, still more preferably less than about 10% chemical precursors or non-MCP chemicals, and most preferably less than about 5% chemical precursors or non-MCP chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same organism from which the MCP protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a C. glutamicum MCP protein in a microorganism such as C. glutamicum.
An isolated MCP protein or a portion thereof of the invention is able to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target for drug development, or to serve as an identifying marker for C. glutamicum or related organisms. In preferred embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target for drug development, or to serve as an identifying marker for C. glutamicum or related organisms. The portion of the protein is preferably a biologically active portion as described herein. In another preferred embodiment, an MCP protein of the invention has an amino acid sequence shown in Appendix B. In yet another preferred embodiment, the MCP protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of Appendix A. In still another preferred embodiment, the MCP protein has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to one of the nucleic acid sequences of Appendix A, or a portion thereof. Ranges and identity values intermediate to the above-recited values, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. The preferred MCP proteins of the present invention also preferably possess at least one of the MCP activities described herein. For example, a preferred MCP protein of the present invention includes an amino acid sequence encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to a nucleotide sequence of Appendix A, and which is able to modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum , to degrade hydrocarbons, to oxidize terpenoids, to serve as a target for drug development, or to serve as an identifying marker for C. glutamicum or related organisms.
In other embodiments, the MCP protein is substantially homologous to an amino acid sequence of Appendix B and retains the functional activity of the protein of one of the sequences of Appendix B yet differs in amino acid sequence due to natural variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the MCP protein is a protein which comprises an amino acid sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of Appendix B and which has at least one of the MCP activities described herein. Ranges and identity values intermediate to the above-recited values, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In another embodiment, the invention pertains to a full length C. glutamicum protein which is substantially homologous to an entire amino acid sequence of Appendix B.
Biologically active portions of an MCP protein include peptides comprising amino acid sequences derived from the amino acid sequence of an MCP protein, e.g., an amino acid sequence shown in Appendix B or the amino acid sequence of a protein homologous to an MCP protein, which include fewer amino acids than a full length MCP protein or the full length protein which is homologous to an MCP protein, and exhibit at least one activity of an MCP protein. Typically, biologically active portions (peptides, e.g., peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif with at least one activity of an MCP protein. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein. Preferably, the biologically active portions of an MCP protein include one or more selected domains/motifs or portions thereof having biological activity.
MCP proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the MCP protein is expressed in the host cell. The MCP protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, an MCP protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native MCP protein can be isolated from cells (e.g., endothelial cells, bacterial cells, fungal cells or other cells), for example using an anti-MCP antibody, which can be produced by standard techniques utilizing an MCP protein or fragment thereof of this invention.
The invention also provides MCP chimeric or fusion proteins. As used herein, an MCP “chimeric protein” or “fusion protein” comprises an MCP polypeptide operatively linked to a non-MCP polypeptide. An “MCP polypeptide” refers to a polypeptide having an amino acid sequence corresponding to an MCP protein, whereas a “non-MCP polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the MCP protein, e.g., a protein which is different from the MCP protein and which is derived from the same or a different organism. Within the fusion protein, the term “operatively linked” is intended to indicate that the MCP polypeptide and the non-MCP polypeptide are fused in-frame to each other. The non-MCP polypeptide can be fused to the N-terminus or C-terminus of the MCP polypeptide. For example, in one embodiment the fusion protein is a GST-MCP fusion protein in which the MCP sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant MCP proteins. In another embodiment, the fusion protein is an MCP protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells, bacterial host cells, fungal host cells), expression and/or secretion of an MCP protein can be increased through use of a heterologous signal sequence.
Preferably, an MCP chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology , eds. Ausubel et al. John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An MCP-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the MCP protein.
Homologues of the MCP protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the MCP protein. As used herein, the term “homologue” refers to a variant form of the MCP protein which acts as an agonist or antagonist of the activity of the MCP protein. An agonist of the MCP protein can retain substantially the same, or a subset, of the biological activities of the MCP protein. An antagonist of the MCP protein can inhibit one or more of the activities of the naturally occurring form of the MCP protein, by, for example, competitively binding to a downstream or upstream member of a biochemical pathway which includes the MCP protein.
In an alternative embodiment, homologues of the MCP protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the MCP protein for MCP protein agonist or antagonist activity. In one embodiment, a variegated library of MCP variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of MCP variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential MCP sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of MCP sequences therein. There are a variety of methods which can be used to produce libraries of potential MCP homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential MCP sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S. A. (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477.
In addition, libraries of fragments of the MCP protein coding can be used to generate a variegated population of MCP fragments for screening and subsequent selection of homologues of an MCP protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an MCP coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the MCP protein.
Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of MCP homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recrusive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify MCP homologues (Arkin and Yourvan (1992) PNAS 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).
In another embodiment, cell based assays can be exploited to analyze a variegated MCP library, using methods well known in the art.
D. Uses and Methods of the Invention
The nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, vectors, and host cells described herein can be used in one or more of the following methods: identification of C. glutamicum and related organisms; mapping of genomes of organisms related to C. glutamicum ; identification and localization of C. glutamicum sequences of interest; evolutionary studies; determination of MCP protein regions required for function; modulation of an MCP protein activity; modulation of the activity of one or more metabolic pathways; and modulation of cellular production of a desired compound, such as a fine chemical.
The MCP nucleic acid molecules of the invention have a variety of uses. First, they may be used to identify an organism as being Corynebacterium glutamicum or a close relative thereof. Also, they may be used to identify the presence of C. glutamicum or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of C. glutamicum genes, and probes based thereon; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a C. glutamicum gene which is unique to this organism, one can ascertain whether this organism is present. Although Corynebacterium glutamicum itself is nonpathogenic, it is related to pathogenic species, such as Corynebacterium diphtheriae. Corynebacterium diphtheriae is the causative agent of diphtheria, a rapidly developing, acute, febrile infection which involves both local and systemic pathology. In this disease, a local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells; the bacilli secrete toxin which is disseminated through this lesion to distal susceptible tissues of the body. Degenerative changes brought about by the inhibition of protein synthesis in these tissues, which include heart, muscle, peripheral nerves, adrenals, kidneys, liver and spleen, result in the systemic pathology of the disease. Diphtheria continues to have high incidence in many parts of the world, including Africa, Asia, Eastern Europe and the independent states of the former Soviet Union. An ongoing epidemic of diphtheria in the latter two regions has resulted in at least 5,000 deaths since 1990.
In one embodiment, the invention provides a method of identifying the presence or activity of Corynebacterium diphtheriae in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth in Appendix A or Appendix B) in a subject, thereby detecting the presence or activity of Corynebacterium diphtheriae in the subject. C. glutamicum and C. diphtheriae are related bacteria, and many of the nucleic acid and protein molecules in C. glutamicum are homologous to C. diphtheriae nucleic acid and protein molecules, and can therefore be used to detect C. diphtheriae in a subject.
To detect the presence of C. glutamicum in a sample, techniques well known in the art may be employed. Specifically, the cells in the sample may optionally first be cultured in a suitable liquid or on a suitable solid culture medium to increase the number of cells in the sample. These cells are lysed, and the total DNA content extracted and optionally purified to remove debris and protein material which may interfere with subsequent analysis. The polymerase chain reaction or a similar technique known in the art is performed (for general reference on methodologies commonly used for the amplification of nucleic acid sequences, see Mullis et al., U.S. Pat. No. 4,683,195, Mullis et al., U.S. Pat. No. 4,965,188, and Innis, M. A., and Gelfand, D. H., (1989) PCR Protocols, A guide to Methods and Applications, Academic Press, p. 3-12, and (1988) Biotechnology 6:1197, and International Patent Application No. WO89/01050) in which primers specific to an MCP nucleic acid molecule of the invention are incubated with the nucleic acid sample such that, if present in the sample, that particular MCP nucleic acid sequence will be amplified. The particular MCP nucleic acid to be amplified is selected based on its uniqueness to the C. glutamicum genome, or to the genomes of C. glutamicum and only a few closely related bacteria. The presence of the desired amplified product is thus indicative of the presence of C. glutamicum , or an organism closely related to C. glutamicum.
Further, the nucleic acid and protein molecules of the invention may serve as markers for specific regions of the genome. It is possible, using techniques well known in the art, to ascertain the physical location on the C. glutamicum genome of the MCP nucleic acid molecules of the invention, which in turn provides markers on the genome which can be used to aid in the placement of other nucleic acid molecules and genes on the genome map. Also, the nucleic acid molecules of the invention may be sufficiently homologous to the sequences of related bacterial species that these nucleic acid molecules may similarly permit the construction of a genomic map in such bacteria (e.g., Brevibacterium lactofermentum ).
The nucleic acid molecules of the invention have utility not only in the mapping of the genome, but also for functional studies of C. glutamicum proteins. For example, to identify the region of the genome to which a particular C. glutamicum DNA-binding protein binds, the C. glutamicum genome could be digested, and the fragments incubated with the DNA-binding protein. Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable labels; binding of such a nucleic acid molecule to the genome fragment enables the localization of the fragment to the genome map of C. glutamicum , and, when performed multiple times with different enzymes, facilitates a rapid determination of the nucleic acid sequence to which the protein binds.
The MCP nucleic acid molecules of the invention are also useful for evolutionary and protein structural studies. The metabolic processes in which the molecules of the invention participate are utilized by a wide variety of prokaryotic and eukaryotic cells; by comparing the sequences of the nucleic acid molecules of the present invention to those encoding similar enzymes from other organisms, the evolutionary relatedness of the organisms can be assessed. Similarly, such a comparison permits an assessment of which regions of the sequence are conserved and which are not, which may aid in determining those regions of the protein which are essential for the functioning of the enzyme. This type of determination is of value for protein engineering studies and may give an indication of what the protein can tolerate in terms of mutagenesis without losing function.
The MCP protein molecules of the invention may also be utilized as markers for the classification of an unknown bacterium as C. glutamicum , or for the identification of C. glutamicum or closely related bacteria in a sample. For example, using techniques well known in the art, cells in a sample may optionally be amplified (e.g., by culturing in an appropriate medium) to increase the sample size, and then may be lysed to release proteins contained therein. This sample may optionally be purified to remove debris and nucleic acid molecules which may interfere with subsequent analysis. Antibodies specific for a selected MCP protein of the invention may be incubated with the protein sample in a typical Western assay format (see, e.g., Ausubel et al., (1988) Current Protocols in Molecular Biology, Wiley: New York) in which the antibody will bind to its target protein if this protein is present in the sample. An MCP protein is selected for this type of assay if it is unique or nearly unique to C. glutamicum or C. glutamicum and bacteria very closely related to C. glutamicum . Proteins in the sample are then separated by gel electrophoresis, and transferred to a suitable matrix, such as nitrocellulose. An appropriate secondary antibody having a detectable label (e.g., chemiluminescent or colorimetric) is incubated with this matrix, followed by stringent washing. The presence or absence of the label is indicative of the presence or absence of the target protein in the sample. If the protein is present, then this is indicative of the presence of C. glutamicum . A similar process enables the classification of an unknown bacterium as C. glutamicum ; if a panel of proteins specific to C. glutamicum are not detected in protein samples prepared from the unknown bacterium, then that bacterium is not likely to be C. glutamicum.
The invention provides methods for screening molecules which modulate the activity of an MCP protein, either by interacting with the protein itself or a substrate or binding partner of the MCP protein, or by modulating the transcription or translation of an MCP nucleic acid molecule of the invention. In such methods, a microorganism expressing one or more MCP proteins of the invention is contacted with one or more test compounds, and the effect of each test compound on the activity or level of expression of the MCP protein is assessed.
Genetic manipulation of the MCP nucleic acid molecules of the invention may result in the production of MCP proteins having functional differences from the wild-type MCP proteins. These proteins may be improved in efficiency or activity, may be present in greater numbers in the cell than is usual, or may be decreased in efficiency or activity.
Such changes in activity may directly modulate the yield, production, and/or efficiency of production of one or more fine chemicals from C. glutamicum . For example, by modifying the activity of a protein involved in the biosynthesis or degradation of a fine chemical (i.e., through mutagenesis of the corresponding gene), one may directly modulate the ability of the cell to synthesize or to degrade this compound, thereby modulating the yield and/or efficiency of production of the fine chemical. Similarly, by modulating the activity of a protein which regulates a fine chemical metabolic pathway, one may directly influence whether the production of the desired compound is up- or down-regulated, either of which will modulate the yield or efficiency of production of the fine chemical from the cell.
Indirect modulation of fine chemical production may also result by modifying the activity of a protein of the invention (i.e., by mutagenesis of the corresponding gene) such that the overall ability of the cell to grow and divide or to remain viable and productive is increased. The production of fine chemicals from C. glutamicum is generally accomplished by the large-scale fermentative culture of these microorganisms, conditions which are frequently suboptimal for growth and cell division. By engineering a protein of the invention (e.g., a stress response protein, a cell wall protein, or proteins involved in the metabolism of compounds necessary for cell growth and division to occur, such as nucleotides and amino acids) such that it is better able to survive, grow, and multiply in such conditions, it may be possible to increase the number and productivity of such engineered C. glutamicum cells in large-scale culture, which in turn should result in increased yields and/or efficiency of production of one or more desired fine chemicals. Further, the metabolic pathways of any cell are necessarily interrelated and coregulated. By altering the activity or regulation of any one metabolic pathway in C. glutamicum (i.e., by altering the activity of one of the proteins of the invention which participates in such a pathway), it is possible to concomitantly alter the activity or regulation of other metabolic pathways in this microorganism, which may be directly involved in the synthesis or degradation of a fine chemical.
The aforementioned mutagenesis strategies for MCP proteins to result in increased yields of a fine chemical from C. glutamicum are not meant to be limiting; variations on these strategies will be readily apparent to one of ordinary skill in the art. Using such strategies, and incorporating the mechanisms disclosed herein, the nucleic acid and protein molecules of the invention may be utilized to generate C. glutamicum or related strains of bacteria expressing mutated MCP nucleic acid and protein molecules such that the yield, production, and/or efficiency of production of a desired compound is improved. This desired compound may be any natural product of C. glutamicum , which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally occur in the metabolism of C. glutamicum , but which are produced by a C. glutamicum strain of the invention.
This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, published patent applications, Tables, Appendices, and the sequence listing cited throughout this application are hereby incorporated by reference.
EXEMPLIFICATION
Example 1
Preparation of Total Genomic DNA of Corynebacterium glutamicum ATCC 13032
A culture of Corynebacterium glutamicum (ATCC 13032) was grown overnight at 30° C. with vigorous shaking in BHI medium (Difco). The cells were harvested by centrifugation, the supernatant was discarded and the cells were resuspended in 5 ml buffer-I (5% of the original volume of the culture—all indicated volumes have been calculated for 100 ml of culture volume). Composition of buffer-I: 140.34 g/l sucrose, 2.46 g/l MgSO 4 ×7H 2 O, 10 ml/l KH 2 PO 4 solution (100 g/l, adjusted to pH 6.7 with KOH), 50 ml/l M12 concentrate (10 g/l (NH 4 ) 2 SO 4 , 1 g/l NaCl, 2 g/l MgSO 4 ×7H 2 O, 0.2 g/l CaCl 2 , 0.5 g/l yeast extract (Difco), 10 ml/l trace-elements-mix (200 mg/l FeSO 4 ×H 2 O, 10 mg/l ZnSO 4 ×7H 2 O, 3 mg/l MnCl 2 ×4H 2 O; 30 mg/l H 3 BO 3 20 mg/l CoCl 2 ×6H 2 O, 1 mg/l NiCl 2 ×6H 2 O, 3 mg/l Na 2 MoO 4 ×2H 2 O, 500 mg/l complexing agent (EDTA or critic acid), 100 ml/l vitamins-mix (0.2 mg/l biotin, 0.2 mg/l folic acid, 20 mg/, p-amino benzoic acid, 20 mg/l riboflavin, 40 mg/l α-panthothenate, 140 mg/l nicotinic acid, 40 mg/l pyridoxole hydrochloride, 200 mg/l myo-inositol). Lysozyme was added to the suspension to a final concentration of 2.5 mg/ml. After an approximately 4 h incubation at 37° C., the cell wall was degraded and the resulting protoplasts are harvested by centrifugation. The pellet was washed once with 5 ml buffer-I and once with 5 ml TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). The pellet was resuspended in 4 ml TE-buffer and 0.5 ml SDS solution (10%) and 0.5 ml NaCl solution (5 M) are added. After adding of proteinase K to a final concentration of 200 μg/ml, the suspension is incubated for ca. 18 h at 37° C. The DNA was purified by extraction with phenol, phenol-chloroform-isoamylalcohol and chloroform-isoamylalcohol using standard procedures. Then, the DNA was precipitated by adding 1/50 volume of 3 M sodium acetate and 2 volumes of ethanol, followed by a 30 min incubation at −20° C. and a 30 min centrifugation at 12,000 rpm in a high speed centrifuge using a SS34 rotor (Sorvall). The DNA was dissolved in 1 ml TE-buffer containing 20 μg/ml RNaseA and dialysed at 4° C. against 1000 ml TE-buffer for at least 3 hours. During this time, the buffer was exchanged 3 times. To aliquots of 0.4 ml of the dialysed DNA solution, 0.4 ml of 2 M LiCl and 0.8 ml of ethanol are added. After a 30 min incubation at −20° C., the DNA was collected by centrifugation (13,000 rpm, Biofuge Fresco, Heraeus, Hanau, Germany). The DNA pellet was dissolved in TE-buffer. DNA prepared by this procedure could be used for all purposes, including southern blotting or construction of genomic libraries.
Example 2
Construction of Genomic Libraries in Escherichia coli of Corynebacterium glutamicum ATCC13032
Using DNA prepared as described in Example 1, cosmid and plasmid libraries were constructed according to known and well established methods (see e.g., Sambrook, J. et al. (1989) “Molecular Cloning: A Laboratory Manual”, Cold Spring Harbor Laboratory Press, or Ausubel, F. M. et al. (1994) “Current Protocols in Molecular Biology”, John Wiley & Sons.)
Any plasmid or cosmid could be used. Of particular use were the plasmids pBR322 (Sutcliffe, J. G. (1979) Proc. Natl. Acad. Sci. USA, 75:3737-3741); pACYC177 (Change & Cohen (1978) J. Bacteriol 134:1141-1156), plasmids of the pBS series (pBSSK+, pBSSK−and others; Stratagene, LaJolla, USA), or cosmids as SuperCos1 (Stratagene, LaJolla, USA) or Lorist6 (Gibson, T. J., Rosenthal A. and Waterson, R. H. (1987) Gene 53:283-286. Gene libraries specifically for use in C. glutamicum may be constructed using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) J. Microbiol. Biotechnol. 4: 256-263).
Example 3
DNA Sequencing and Computational Functional Analysis
Genomic libraries as described in Example 2 were used for DNA sequencing according to standard methods, in particular by the chain termination method using ABI377 sequencing machines (see e.g., Fleischman, R. D. et al. (1995) “Whole-genome Random Sequencing and Assembly of Haemophilus Influenzae Rd., Science, 269:496-512). Sequencing primers with the following nucleotide sequences were used: 5′-GGAAACAGTATGACCATG-3′ or 5′-GTAAAACGACGGCCAGT-3′.
Example 4
In vivo Mutagenesis
In vivo mutagenesis of Corynebacterium glutamicum can be performed by passage of plasmid (or other vector) DNA through E. coli or other microorganisms (e.g. Bacillus spp. or yeasts such as Saccharomyces cerevisiae ) which are impaired in their capabilities to maintain the integrity of their genetic information. Typical mutator strains have mutations in the genes for the DNA repair system (e.g., mutHLS, mutD, mutT, etc.; for reference, see Rupp, W. D. (1996) DNA repair mechanisms, in: Escherichia coli and Salmonella , p. 2277-2294, ASM: Washington.) Such strains are well known to those of ordinary skill in the art. The use of such strains is illustrated, for example, in Greener, A. and Callahan, M. (1994) Strategies 7: 32-34.
Example 5
DNA Transfer Between Escherichia coli and Corynebacterium glutamicum
Several Corynebacterium and Brevibacterium species contain endogenous plasmids (as e.g., pHM1519 or pBL1) which replicate autonomously (for review see, e.g., Martin, J. F. et al. (1987) Biotechnology, 5:137-146). Shuttle vectors for Escherichia coli and Corynebacterium glutamicum can be readily constructed by using standard vectors for E. coli (Sambrook, J. et al. (1989), “Molecular Cloning: A Laboratory Manual”, Cold Spring Harbor Laboratory Press or Ausubel, F. M. et al. (1994) “Current Protocols in Molecular Biology”, John Wiley & Sons) to which a origin or replication for and a suitable marker from Corynebacterium glutamicum is added. Such origins of replication are preferably taken from endogenous plasmids isolated from Corynebacterium and Brevibacterium species. Of particular use as transformation markers for these species are genes for kanamycin resistance (such as those derived from the Tn5 or Tn903 transposons) or chloramphenicol (Winnacker, E. L. (1987) “From Genes to Clones-Introduction to Gene Technology, VCH, Weinheim). There are numerous examples in the literature of the construction of a wide variety of shuttle vectors which replicate in both E. coli and C. glutamicum , and which can be used for several purposes, including gene over-expression (for reference, see e.g., Yoshihama, M. et al. (1985) J. Bacteriol. 162:591-597, Martin J. F. et al. (1987) Biotechnology, 5:137-146 and Eikmanns, B. J et al. (1991) Gene, 102:93-98).
Using standard methods, it is possible to clone a gene of interest into one of the shuttle vectors described above and to introduce such a hybrid vectors into strains of Corynebacterium glutamicum . Transformation of C. glutamicum can be achieved by protoplast transformation (Kastsumata, R. et al. (1984) J. Bacteriol. 159306-311), electroporation (Liebl, E. et al. (1989) FEMS Microbiol. Letters, 53:399-303) and in cases where special vectors are used, also by conjugation (as described e.g. in Schafer, A et al. (1990) J. Bacteriol. 172:1663-1666). It is also possible to transfer the shuttle vectors for C. glutamicum to E. coli by preparing plasmid DNA from C. glutamicum (using standard methods well-known in the art) and transforming it into E. coli . This transformation step can be performed using standard methods, but it is advantageous to use an Mcr-deficient E. coli strain, such as NM522 (Gough & Murray (1983) J. Mol. Biol. 166:1-19).
Genes may be overexpressed in C. glutamicum strains using plasmids which comprise pCG1 (U.S. Pat. No. 4,617,267) or fragments thereof, and optionally the gene for kanamycin resistance from TN903 (Grindley, N. D. and Joyce, C. M. (1980) Proc. Natl. Acad. Sci. USA 77(12): 7176-7180). In addition, genes may be overexpressed in C. glutamicum strains using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) J. Microbiol. Biotechnol. 4: 256-263).
Aside from the use of replicative plasmids, gene overexpression can also be achieved by integration into the genome. Genomic integration in C. glutamicum or other Corynebacterium or Brevibacterium species may be accomplished by well-known methods, such as homologous recombination with genomic region(s), restriction endonuclease mediated integration (REMI) (see, e.g., DE Patent 19823834), or through the use of transposons. It is also possible to modulate the activity of a gene of interest by modifying the regulatory regions (e.g., a promoter, a repressor, and/or an enhancer) by sequence modification, insertion, or deletion using site-directed methods (such as homologous recombination) or methods based on random events (such as transposon mutagenesis or REMI). Nucleic acid sequences which function as transcriptional terminators may also be inserted 3′ to the coding region of one or more genes of the invention; such terminators are well-known in the art and are described, for example, in Winnacker, E. L. (1987) From Genes to Clones—Introduction to Gene Technology. VCH: Weinheim.
Example 6
Assessment of the Expression of the Mutant Protein
Observations of the activity of a mutated protein in a transformed host cell rely on the fact that the mutant protein is expressed in a similar fashion and in a similar quantity to that of the wild-type protein. A useful method to ascertain the level of transcription of the mutant gene (an indicator of the amount of mRNA available for translation to the gene product) is to perform a Northern blot (for reference see, for example, Ausubel et al. (1988) Current Protocols in Molecular Biology, Wiley: New York), in which a primer designed to bind to the gene of interest is labeled with a detectable tag (usually radioactive or chemiluminescent), such that when the total RNA of a culture of the organism is extracted, run on gel, transferred to a stable matrix and incubated with this probe, the binding and quantity of binding of the probe indicates the presence and also the quantity of mRNA for this gene. This information is evidence of the degree of transcription of the mutant gene. Total cellular RNA can be prepared from Corynebacterium glutamicum by several methods, all well-known in the art, such as that described in Bormann, E. R. et al. (1992) Mol. Microbiol. 6: 317-326.
To assess the presence or relative quantity of protein translated from this mRNA, standard techniques, such as a Western blot, may be employed (see, for example, Ausubel et al. (1988) Current Protocols in Molecular Biology, Wiley: New York). In this process, total cellular proteins are extracted, separated by gel electrophoresis, transferred to a matrix such as nitrocellulose, and incubated with a probe, such as an antibody, which specifically binds to the desired protein. This probe is generally tagged with a chemiluminescent or colorimetric label which may be readily detected. The presence and quantity of label observed indicates the presence and quantity of the desired mutant protein present in the cell.
Example 7
Growth of Genetically Modified Corynebacterium glutamicum —Media and Culture Conditions
Genetically modified Corynebacteria are cultured in synthetic or natural growth media. A number of different growth media for Corynebacteria are both well-known and readily available (Lieb et al. (1989) Appl. Microbiol. Biotechnol., 32:205-210; von der Osten et al. (1998) Biotechnology Letters, 11:11-16; Patent DE 4,120,867; Liebl (1992) “The Genus Corynebacterium , in: The Procaryotes, Volume II, Balows, A. et al., eds. Springer-Verlag). These media consist of one or more carbon sources, nitrogen sources, inorganic salts, vitamins and trace elements. Preferred carbon sources are sugars, such as mono-, di-, or polysaccharides. For example, glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose serve as very good carbon sources. It is also possible to supply sugar to the media via complex compounds such as molasses or other by-products from sugar refinement. It can also be advantageous to supply mixtures of different carbon sources. Other possible carbon sources are alcohols and organic acids, such as methanol, ethanol, acetic acid or lactic acid. Nitrogen sources are usually organic or inorganic nitrogen compounds, or materials which contain these compounds. Exemplary nitrogen sources include ammonia gas or ammonia salts, such as NH 4 Cl or (NH 4 ) 2 SO 4 , NH 4 OH, nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others.
Inorganic salt compounds which may be included in the media include the chloride-, phosphorous- or sulfate-salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron. Chelating compounds can be added to the medium to keep the metal ions in solution. Particularly useful chelating compounds include dihydroxyphenols, like catechol or protocatechuate, or organic acids, such as citric acid. It is typical for the media to also contain other growth factors, such as vitamins or growth promoters, examples of which include biotin, riboflavin, thiamin, folic acid, nicotinic acid, pantothenate and pyridoxin. Growth factors and salts frequently originate from complex media components such as yeast extract, molasses, corn steep liquor and others. The exact composition of the media compounds depends strongly on the immediate experiment and is individually decided for each specific case. Information about media optimization is available in the textbook “Applied Microbiol. Physiology, A Practical Approach (eds. P. M. Rhodes, P. F. Stanbury, IRL Press (1997) pp. 53-73, ISBN 0 19 963577 3). It is also possible to select growth media from commercial suppliers, like standard 1 (Merck) or BHI (grain heart infusion, DIFCO) or others.
All medium components are sterilized, either by heat (20 minutes at 1.5 bar and 121° C.) or by sterile filtration. The components can either be sterilized together or, if necessary, separately. All media components can be present at the beginning of growth, or they can optionally be added continuously or batchwise.
Culture conditions are defined separately for each experiment. The temperature should be in a range between 15° C. and 45° C. The temperature can be kept constant or can be altered during the experiment. The pH of the medium should be in the range of 5 to 8.5, preferably around 7.0, and can be maintained by the addition of buffers to the media. An exemplary buffer for this purpose is a potassium phosphate buffer. Synthetic buffers such as MOPS, HEPES, ACES and others can alternatively or simultaneously be used. It is also possible to maintain a constant culture pH through the addition of NaOH or NH 4 OH during growth. If complex medium components such as yeast extract are utilized, the necessity for additional buffers may be reduced, due to the fact that many complex compounds have high buffer capacities. If a fermentor is utilized for culturing the micro-organisms, the pH can also be controlled using gaseous ammonia.
The incubation time is usually in a range from several hours to several days. This time is selected in order to permit the maximal amount of product to accumulate in the broth. The disclosed growth experiments can be carried out in a variety of vessels, such as microtiter plates, glass tubes, glass flasks or glass or metal fermentors of different sizes. For screening a large number of clones, the microorganisms should be cultured in microtiter plates, glass tubes or shake flasks, either with or without baffles. Preferably 100 ml shake flasks are used, filled with 10% (by volume) of the required growth medium. The flasks should be shaken on a rotary shaker (amplitude 25 mm) using a speed-range of 100-300 rpm. Evaporation losses can be diminished by the maintenance of a humid atmosphere; alternatively, a mathematical correction for evaporation losses should be performed.
If genetically modified clones are tested, an unmodified control clone or a control clone containing the basic plasmid without any insert should also be tested. The medium is inoculated to an OD 600 of 0.5-1.5 using cells grown on agar plates, such as CM plates (10 g/l glucose, 2,5 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l agar, pH 6.8 with 2M NaOH) that had been incubated at 30° C. Inoculation of the media is accomplished by either introduction of a saline suspension of C. glutamicum cells from CM plates or addition of a liquid preculture of this bacterium.
Example 8
In vitro Analysis of the Function of Mutant Proteins
The determination of activities and kinetic parameters of enzymes is well established in the art. Experiments to determine the activity of any given altered enzyme must be tailored to the specific activity of the wild-type enzyme, which is well within the ability of one of ordinary skill in the art. Overviews about enzymes in general, as well as specific details concerning structure, kinetics, principles, methods, applications and examples for the determination of many enzyme activities may be found, for example, in the following references: Dixon, M., and Webb, E. C., (1979) Enzymes. Longmans: London; Fersht, (1985) Enzyme Structure and Mechanism. Freeman: New York; Walsh, (1979) Enzymatic Reaction Mechanisms. Freeman: San Francisco; Price, N. C., Stevens, L. (1982) Fundamentals of Enzymology. Oxford Univ. Press: Oxford; Boyer, P. D., ed. (1983) The Enzymes, 3 rd ed. Academic Press: New York; Bisswanger, H., (1994) Enzymkinetik, 2 nd ed. VCH: Weinheim (ISBN 3527300325); Bergmeyer, H. U., Bergmeyer, J., Graβ1, M., eds. (1983-1986) Methods of Enzymatic Analysis, 3 rd ed., vol. I-XII, Verlag Chemie: Weinheim; and Ullmann's Encyclopedia of Industrial Chemistry (1987) vol. A9, “Enzymes”. VCH: Weinheim, p. 352-363.
The activity of proteins which bind to DNA can be measured by several well-established methods, such as DNA band-shift assays (also called gel retardation assays). The effect of such proteins on the expression of other molecules can be measured using reporter gene assays (such as that described in Kolmar, H. et al. (1995) EMBO J. 14: 3895-3904 and references cited therein). Reporter gene test systems are well known and established for applications in both pro- and eukaryotic cells, using enzymes such as beta-galactosidase, green fluorescent protein, and several others.
The determination of activity of membrane-transport proteins can be performed according to techniques such as those described in Gennis, R. B. (1989) “Pores, Channels and Transporters”, in Biomembranes, Molecular Structure and Function, Springer: Heidelberg, p. 85-137; 199-234; and 270-322.
Example 9
Analysis of Impact of Mutant Protein on the Production of the Desired Product
The effect of the genetic modification in C. glutamicum on production of a desired compound (such as an amino acid) can be assessed by growing the modified microorganism under suitable conditions (such as those described above) and analyzing the medium and/or the cellular component for increased production of the desired product (i.e., an amino acid). Such analysis techniques are well known to one of ordinary skill in the art, and include spectroscopy, thin layer chromatography, staining methods of various kinds, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example, Ullman, Encyclopedia of Industrial Chemistry, vol. A2, p. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A. et al., (1987) “Applications of HPLC in Biochemistry” in: Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17; Rehm et al. (1993) Biotechnology, vol. 3, Chapter III: “Product recovery and purification”, page 469-714, VCH: Weinheim; Belter, P. A. et al. (1988) Bioseparations: downstream processing for biotechnology, John Wiley and Sons; Kennedy, J. F. and Cabral, J. M. S. (1992) Recovery processes for biological materials, John Wiley and Sons; Shaeiwitz, J. A. and Henry, J. D. (1988) Biochemical separations, in: Ulmann's Encyclopedia of Industrial Chemistry, vol. B3, Chapter 11, page 1-27, VCH: Weinheim; and Dechow, F. J. (1989) Separation and purification techniques in biotechnology, Noyes Publications.)
In addition to the measurement of the final product of fermentation, it is also possible to analyze other components of the metabolic pathways utilized for the production of the desired compound, such as intermediates and side-products, to determine the overall efficiency of production of the compound. Analysis methods include measurements of nutrient levels in the medium (e.g., sugars, hydrocarbons, nitrogen sources, phosphate, and other ions), measurements of biomass composition and growth, analysis of the production of common metabolites of biosynthetic pathways, and measurement of gasses produced during fermentation. Standard methods for these measurements are outlined in Applied Microbial Physiology, A Practical Approach, P. M. Rhodes and P. F. Stanbury, eds., IRL Press, p. 103-129; 131-163; and 165-192 (ISBN: 0199635773) and references cited therein.
Example 10
Purification of the Desired Product from C. glutamicum Culture
Recovery of the desired product from the C. glutamicum cells or supernatant of the above-described culture can be performed by various methods well known in the art. If the desired product is not secreted from the cells, the cells can be harvested from the culture by low-speed centrifugation, the cells can be lysed by standard techniques, such as mechanical force or sonication. The cellular debris is removed by centrifugation, and the supernatant fraction containing the soluble proteins is retained for further purification of the desired compound. If the product is secreted from the C. glutamicum cells, then the cells are removed from the culture by low-speed centrifugation, and the supernate fraction is retained for further purification.
The supernatant fraction from either purification method is subjected to chromatography with a suitable resin, in which the desired molecule is either retained on a chromatography resin while many of the impurities in the sample are not, or where the impurities are retained by the resin while the sample is not. Such chromatography steps may be repeated as necessary, using the same or different chromatography resins. One of ordinary skill in the art would be well-versed in the selection of appropriate chromatography resins and in their most efficacious application for a particular molecule to be purified. The purified product may be concentrated by filtration or ultrafiltration, and stored at a temperature at which the stability of the product is maximized.
There are a wide array of purification methods known to the art and the preceding method of purification is not meant to be limiting. Such purification techniques are described, for example, in Bailey, J. E. & Ollis, D. F. Biochemical Engineering Fundamentals, McGraw-Hill: New York (1986).
The identity and purity of the isolated compounds may be assessed by techniques standard in the art. These include high-performance liquid chromatography (HPLC), spectroscopic methods, staining methods, thin layer chromatography, NIRS, enzymatic assay, or microbiologically. Such analysis methods are reviewed in: Patek et al. (1994) Appl. Environ. Microbiol. 60: 133-140; Malakhova et al. (1996) Biotekhnologiya 11: 27-32; and Schmidt et al. (1998) Bioprocess Engineer. 19: 67-70. Ulmann's Encyclopedia of Industrial Chemistry, (1996) vol. A27, VCH: Weinheim, p. 89-90, p. 521-540, p. 540-547, p. 559-566, 575-581 and p. 581-587; Michal, G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley and Sons; Fallon, A. et al. (1987) Applications of HPLC in Biochemistry in: Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17.
Example 11
Analysis of the Gene Sequences of the Invention
The comparison of sequences and determination of percent homology between two sequences are art-known techniques, and can be accomplished using a mathematical algorithm, such as the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to MCP nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to MCP protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, one of ordinary skill in the art will know how to optimize the parameters of the program (e.g., XBLAST and NBLAST) for the specific sequence being analyzed.
Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Meyers and Miller ((1988) Comput. Appl. Biosci. 4: 11-17). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM 120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art, and include ADVANCE and ADAM. described in Torelli and Robotti (1994) Comput. Appl. Biosci. 10:3-5; and FASTA, described in Pearson and Lipman (1988) P.N.A.S. 85:2444-8.
The percent homology between two amino acid sequences can also be accomplished using the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4. The percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package, using standard parameters, such as a gap weight of 50 and a length weight of 3.
A comparative analysis of the gene sequences of the invention with those present in Genbank has been performed using techniques known in the art (see, e.g., Bexevanis and Ouellette, eds. (1998) Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins. John Wiley and Sons: New York). The gene sequences of the invention were compared to genes present in Genbank in a three-step process. In a first step, a BLASTN analysis (e.g., a local alignment analysis) was performed for each of the sequences of the invention against the nucleotide sequences present in Genbank, and the top 500 hits were retained for further analysis. A subsequent FASTA search (e.g., a combined local and global alignment analysis, in which limited regions of the sequences are aligned) was performed on these 500 hits. Each gene sequence of the invention was subsequently globally aligned to each of the top three FASTA hits, using the GAP program in the GCG software package (using standard parameters). In order to obtain correct results, the length of the sequences extracted from Genbank were adjusted to the length of the query sequences by methods well-known in the art. The results of this analysis are set forth in Table 4. The resulting data is identical to that which would have been obtained had a GAP (global) analysis alone been performed on each of the genes of the invention in comparison with each of the references in Genbank, but required significantly reduced computational time as compared to such a database-wide GAP (global) analysis. Sequences of the invention for which no alignments above the cutoff values were obtained are indicated on Table 4 by the absence of alignment information. It will further be understood by one of ordinary skill in the art that the GAP alignment homology percentages set forth in Table 4 under the heading “% homology (GAP)” are listed in the European numerical format, wherein a ‘,’ represents a decimal point. For example, a value of “40,345” in this column represents “40.345%”.
Example 12
Construction and Operation of DNA Microarrays
The sequences of the invention may additionally be used in the construction and application of DNA microarrays (the design, methodology, and uses of DNA arrays are well known in the art, and are described, for example, in Schena, M. et al. (1995) Science 270: 467-470; Wodicka, L. et al. (1997) Nature Biotechnology 15: 1359-1367; DeSaizieu, A. et al. (1998) Nature Biotechnology 16: 45-48; and DeRisi, J. L. et al. (1997) Science 278: 680-686).
DNA microarrays are solid or flexible supports consisting of nitrocellulose, nylon, glass, silicone, or other materials. Nucleic acid molecules may be attached to the surface in an ordered manner. After appropriate labeling, other nucleic acids or nucleic acid mixtures can be hybridized to the immobilized nucleic acid molecules, and the label may be used to monitor and measure the individual signal intensities of the hybridized molecules at defined regions. This methodology allows the simultaneous quantification of the relative or absolute amount of all or selected nucleic acids in the applied nucleic acid sample or mixture. DNA microarrays, therefore, permit an analysis of the expression of multiple (as many as 6800 or more) nucleic acids in parallel (see, e.g., Schena, M. (1996) BioEssays 18(5): 427-431).
The sequences of the invention may be used to design oligonucleotide primers which are able to amplify defined regions of one or more C. glutamicum genes by a nucleic acid amplification reaction such as the polymerase chain reaction. The choice and design of the 5′ or 3′ oligonucleotide primers or of appropriate linkers allows the covalent attachment of the resulting PCR products to the surface of a support medium described above (and also described, for example, Schena, M. et al. (1995) Science 270: 467-470).
Nucleic acid microarrays may also be constructed by in situ oligonucleotide synthesis as described by Wodicka, L. et al. (1997) Nature Biotechnology 15: 1359-1367. By photolithographic methods, precisely defined regions of the matrix are exposed to light. Protective groups which are photolabile are thereby activated and undergo nucleotide addition, whereas regions that are masked from light do not undergo any modification. Subsequent cycles of protection and light activation permit the synthesis of different oligonucleotides at defined positions. Small, defined regions of the genes of the invention may be synthesized on microarrays by solid phase oligonucleotide synthesis.
The nucleic acid molecules of the invention present in a sample or mixture of nucleotides may be hybridized to the microarrays. These nucleic acid molecules can be labeled according to standard methods. In brief, nucleic acid molecules (e.g., mRNA molecules or DNA molecules) are labeled by the incorporation of isotopically or fluorescently labeled nucleotides, e.g., during reverse transcription or DNA synthesis. Hybridization of labeled nucleic acids to microarrays is described (e.g., in Schena, M. et al. (1995) supra; Wodicka, L. et al. (1997), supra; and DeSaizieu A. et al. (1998), supra). The detection and quantification of the hybridized molecule are tailored to the specific incorporated label. Radioactive labels can be detected, for example, as described in Schena, M. et al. (1995) supra) and fluorescent labels may be detected, for example, by the method of Shalon et al. (1996) Genome Research 6: 639-645).
The application of the sequences of the invention to DNA microarray technology, as described above, permits comparative analyses of different strains of C. glutamicum or other Corynebacteria . For example, studies of inter-strain variations based on individual transcript profiles and the identification of genes that are important for specific and/or desired strain properties such as pathogenicity, productivity and stress tolerance are facilitated by nucleic acid array methodologies. Also, comparisons of the profile of expression of genes of the invention during the course of a fermentation reaction are possible using nucleic acid array technology.
Example 13
Analysis of the Dynamics of Cellular Protein Populations (Proteomics)
The genes, compositions, and methods of the invention may be applied to study the interactions and dynamics of populations of proteins, termed ‘proteomics’. Protein populations of interest include, but are not limited to, the total protein population of C. glutamicum (e.g., in comparison with the protein populations of other organisms), those proteins which are active under specific environmental or metabolic conditions (e.g., during fermentation, at high or low temperature, or at high or low pH), or those proteins which are active during specific phases of growth and development.
Protein populations can be analyzed by various well-known techniques, such as gel electrophoresis. Cellular proteins may be obtained, for example, by lysis or extraction, and may be separated from one another using a variety of electrophoretic techniques. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins largely on the basis of their molecular weight. Isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) separates proteins by their isoelectric point (which reflects not only the amino acid sequence but also posttranslational modifications of the protein). Another, more preferred method of protein analysis is the consecutive combination of both IEF-PAGE and SDS-PAGE, known as 2-D-gel electrophoresis (described, for example, in Hermann et al. (1998) Electrophoresis 19: 3217-3221; Fountoulakis et al. (1998) Electrophoresis 19: 1193-1202; Langen et al. (1997) Electrophoresis 18: 1184-1192; Antelmann et al. (1997) Electrophoresis 18: 1451-1463). Other separation techniques may also be utilized for protein separation, such as capillary gel electrophoresis; such techniques are well known in the art.
Proteins separated by these methodologies can be visualized by standard techniques, such as by staining or labeling. Suitable stains are known in the art, and include Coomassie Brilliant Blue, silver stain, or fluorescent dyes such as Sypro Ruby (Molecular Probes). The inclusion of radioactively labeled amino acids or other protein precursors (e.g., 35 S-methionine, 35 S-cysteine, 14 C-labelled amino acids, 15 N-amino acids, 15 NO 3 or 15 NH 4 + or 13 C-labelled amino acids) in the medium of C. glutamicum permits the labeling of proteins from these cells prior to their separation. Similarly, fluorescent labels may be employed. These labeled proteins can be extracted, isolated and separated according to the previously described techniques.
Proteins visualized by these techniques can be further analyzed by measuring the amount of dye or label used. The amount of a given protein can be determined quantitatively using, for example, optical methods and can be compared to the amount of other proteins in the same gel or in other gels. Comparisons of proteins on gels can be made, for example, by optical comparison, by spectroscopy, by image scanning and analysis of gels, or through the use of photographic films and screens. Such techniques are well-known in the art.
To determine the identity of any given protein, direct sequencing or other standard techniques may be employed. For example, N- and/or C-terminal amino acid sequencing (such as Edman degradation) may be used, as may mass spectrometry (in particular MALDI or ESI techniques (see, e.g., Langen et al. (1997) Electrophoresis 18: 1184-1192)). The protein sequences provided herein can be used for the identification of C. glutamicum proteins by these techniques.
The information obtained by these methods can be used to compare patterns of protein presence, activity, or modification between different samples from various biological conditions (e.g., different organisms, time points of fermentation, media conditions, or different biotopes, among others). Data obtained from such experiments alone, or in combination with other techniques, can be used for various applications, such as to compare the behavior of various organisms in a given (e.g., metabolic) situation, to increase the productivity of strains which produce fine chemicals or to increase the efficiency of the production of fine chemicals.
EQUIVALENTS
Those of ordinary skill in the art will recognize, or will be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
| ALIGNMENT RESULTS | ||||||||
| % | ||||||||
| length | homology | |||||||
| ID # | (NT) | Genbank Hit | Length | Accession | Name of Genbank Hit | Source of Genbank Hit | (GAP) | Date of Deposit |
| rxa00003 | 864 | GB_BA2: MPAE000013 | 10328 | AE000013 | Mycoplasma pneumoniae section 13 of 63 of the complete genome. | Mycoplasma pneumoniae | 37,409 | 18-Nov-96 |
| rxa00003 | 864 | GB_BA2: MPAE000013 | 10328 | AE000013 | Mycoplasma pneumoniae section 13 of 63 of the complete genome. | Mycoplasma pneumoniae | 37,409 | 18-Nov-96 |
| GB_BA2: MPAE000013 | 10328 | AE000013 | Mycoplasma pneumoniae section 13 of 63 of the complete genome. | Mycoplasma pneumoniae | 36,768 | 18-Nov-96 | ||
| rxa00008 | 615 | GB_HTG2: AC007356 | 185382 | AC007356 | Drosophila melanogaster chromosome 2 clone BACR24H09 (D595) RPCI-98 | Drosophila melanogaster | 39,203 | 2-Aug-99 |
| 24.H.9 map 49A-49B strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 13 unordered pieces. | ||||||||
| GB_HTG2: AC007356 | 185382 | AC007356 | Drosophila melanogaster chromosome 2 clone BACR24H09 (D595) RPCI-98 24.H.9 | Drosophila melanogaster | 39,203 | 2-Aug-99 | ||
| map 49A-49B strain y; cn bw sp, *** SEQUENCING IN PROGRESS***, | ||||||||
| 13 unordered pieces. | ||||||||
| GB_EST36: AV194293 | 380 | AV194293 | AV194293 Yuji Kohara unpublished cDNA: Strain N2 hermaphrodite embryo | Caenorhabditis elegans | 38,947 | 22-Jul-99 | ||
| Caenorhabditis elegans cDNA clone yk627f12 5′, mRNA sequence. | ||||||||
| rxa00015 | 432 | GB_GSS4: AQ684785 | 671 | AQ684785 | HS_5481_B2_H06_SP6E RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 41,388 | 28-Jun-99 |
| genomic clone Plate = 1057 Col = 12 Row = P, genomic survey sequence. | ||||||||
| GB_PR2: HS217O16 | 87552 | AL031771 | Human DNA sequence from clone 217O16 on chromosome 6q24 | Homo sapiens | 37,471 | 23-Nov-99 | ||
| Contains GSS, complete sequence. | ||||||||
| GB_EST15: AA528550 | 335 | AA528550 | nf01f01.s1 NCI_CGAP_Kid1 Homo sapiens cDNA clone IMAGE: | Homo sapiens | 40,789 | 19-Aug-97 | ||
| 912505, mRNA sequence. | ||||||||
| rxa00018 | 1422 | GB_VI: HS5MCP | 4320 | M25411 | Human cytomegalovirus major capsid protein (MCP) gene, complete cds. | human herpesvirus 5 | 38,231 | 30-OCT-1994 |
| GB_BA2: AE001270 | 12448 | AE001270 | Treponema pallidum section 86 of 87 of the complete genome. | Treponema pallidum | 37,130 | 16-Jul-98 | ||
| GB_IN1: LMFL2385 | 22004 | AL034389 | Leishmania major Friedlin cosmid L2385, complete sequence. | Leishmania major | 37,518 | 15-MAR-1999 | ||
| rxa00020 | 903 | GB_PR4: AC006960 | 179757 | AC006960 | Homo sapiens clone UWGC: djs58 from 7p14-15, complete sequence. | Homo sapiens | 36,618 | 05-MAR-1999 |
| GB_HTG3: AC008266 | 178972 | AC008266 | Homo sapiens clone DJ1145A24, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 35,419 | 21-Aug-99 | ||
| 3 unordered pieces. | ||||||||
| GB_HTG3: AC008266 | 178972 | AC008266 | Homo sapiens clone DJ1145A24, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 35,419 | 21-Aug-99 | ||
| 3 unordered pieces. | ||||||||
| rxa00021 | 1896 | GB_EST15: AA496164 | 429 | AA496164 | zu67e09.r1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE: 743080 5′, | Homo sapiens | 35,526 | 11-Aug-97 |
| mRNA sequence. | ||||||||
| GB_EST30: AI660039 | 443 | AI660039 | we65d06.x1 Soares_thymus_NHFTh Homo sapiens cDNA clone IMAGE: 2345963 | Homo sapiens | 42,574 | 10-MAY-1999 | ||
| 3′, mRNA sequence. | ||||||||
| GB_EST37: AI953059 | 522 | AI953059 | wq49g06.x1 NCI_CGAP_GC6 Homo sapiens cDNA clone IMAGE: 2474650 | Homo sapiens | 39,198 | 6-Sep-99 | ||
| 3′, mRNA sequence. | ||||||||
| rxa00022 | 1824 | GB_EST15: AA496164 | 429 | AA496164 | zu67e09.r1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE: 743080 5′, | Homo sapiens | 41,141 | 11-Aug-97 |
| mRNA sequence. | ||||||||
| GB_PR3: AF022141 | 43473 | AF022141 | Homo sapiens chromosome 21q22.2 cosmid Q13F10, complete sequence. | Homo sapiens | 37,262 | 21-Jan-98 | ||
| GB_EST18: AA678649 | 538 | AA678649 | ah07c05.s1 Gessler Wilms tumor Homo sapiens cDNA clone IMAGE: 1155944 3′ | Homo sapiens | 38,104 | 02-DEC-1997 | ||
| similar to gb: X16869 ELONGATION FACTOR 1-ALPHA 1 (HUMAN);, | ||||||||
| mRNA sequence. | ||||||||
| rxa00025 | 1560 | GB_PL2: AC009978 | 97554 | AC009978 | Genomic sequence for Arabidopsis thaliana BAC T23E18 from chromosome I, | Arabidopsis thaliana | 34,173 | 15-Nov-99 |
| complete sequence. | ||||||||
| GB_HTG2: AC005958 | 216706 | AC005958 | Homo sapiens , *** SEQUENCING IN PROGRESS ***, 40 unordered pieces. | Homo sapiens | 35,374 | 11-Nov-98 | ||
| GB_HTG2: AC005958 | 216706 | AC005958 | Homo sapiens , *** SEQUENCING IN PROGRESS ***, 40 unordered pieces. | Homo sapiens | 35,374 | 11-Nov-98 | ||
| rxa00027 | 489 | GB_PR3: HSDJ247C2 | 98358 | AL049713 | Human DNA sequence from clone 247C2 on chromosome 11p13, complete sequence. | Homo sapiens | 33,056 | 23-Nov-99 |
| GB_PR3: HSDJ247C2 | 98358 | AL049713 | Human DNA sequence from clone 247C2 on chromosome 11p13, complete sequence. | Homo sapiens | 37,988 | 23-Nov-99 | ||
| rxa00028 | ||||||||
| rxa00031 | 525 | GB_PL1: SPBC725 | 37949 | AL034352 | S. pombe chromosome II cosmid c725. | Schizosaccharomyces | 36,084 | 29-MAR-1999 |
| pombe | ||||||||
| GB_EST5: N22565 | 435 | N22565 | yw30f05.s1 Morton Fetal Cochlea Homo sapiens cDNA clone IMAGE: 253761 3′, | Homo sapiens | 41,570 | 20-DEC-1995 | ||
| mRNA sequence. | ||||||||
| GB_EST21: AA993042 | 464 | AA993042 | ot92f07.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE: | Homo sapiens | 41,499 | 27-Aug-98 | ||
| 1624261 3′, mRNA sequence. | ||||||||
| rxa00049 | 810 | GB_HTG2: HSJ749H19 | 253387 | AL117380 | Homo sapiens chromosome 20 clone RP4-749H19 map q13.11-13.33, | Homo sapiens | 37,132 | 03-DEC-1999 |
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG2: HSJ749H19 | 253387 | AL117380 | Homo sapiens chromosome 20 clone RP4-749H19 map q13.11-13.33, | Homo sapiens | 37,132 | 03-DEC-1999 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG4: AC010137 | 155817 | AC010137 | Homo sapiens clone NH0169D01, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 40,052 | 17-OCT-1999 | ||
| 4 unordered pieces. | ||||||||
| rxa00052 | 834 | GB_EST37: AI962012 | 382 | AI962012 | wt41e06.x1 NCI_CGAP_Pan1 Homo sapiens cDNA clone IMAGE: 2510050 | Homo sapiens | 40,486 | 20-Aug-99 |
| 3′ similar to SW: ALC2_HUMAN P01877 IG ALPHA-2 CHAIN C REGION.;, | ||||||||
| mRNA sequence. | ||||||||
| GB_GSS13: AQ454792 | 450 | AQ454792 | HS_5195_B2_H04_SP6E RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 40,991 | 21-Apr-99 | ||
| genomic clone Plate = 771 Col = 8 Row = P, genomic survey sequence. | ||||||||
| GB_GSS13: AQ454792 | 450 | AQ454792 | HS_5195_B2_H04_SP6E RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 40,278 | 21-Apr-99 | ||
| genomic clone Plate = 771 Col = 8 Row = P, genomic survey sequence. | ||||||||
| rxa00054 | 3036 | GB_GSS5: AQ773786 | 459 | AQ773786 | HS_2222_A1_E07_MR CIT Approved Human Genomic Sperm Library D | Homo sapiens | 40,087 | 29-Jul-99 |
| Homo sapiens genomic clone Plate = 2222 Col = 13 Row = I, | ||||||||
| genomic survey sequence. | ||||||||
| GB_GSS5: AQ773786 | 459 | AQ773786 | HS_2222_A1_E07_MR CIT Approved Human Genomic Sperm Library D | Homo sapiens | 40,087 | 29-Jul-99 | ||
| Homo sapiens genomic clone Plate = 2222 Col = 13 Row = I, | ||||||||
| genomic survey sequence. | ||||||||
| rxa00056 | 873 | GB_IN1: CEF56H9 | 28291 | Z74473 | Caenorhabditis elegans cosmid F56H9, complete sequence. | Caenorhabditis elegans | 35,301 | 23-Nov-98 |
| GB_IN1: CEF56H9 | 28291 | Z74473 | Caenorhabditis elegans cosmid F56H9, complete sequence. | Caenorhabditis elegans | 38,941 | 23-Nov-98 | ||
| rxa00058 | 687 | GB_HTG6: AC011647 | 141830 | AC011647 | Homo sapiens clone RP11-15D18, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 39,939 | 04-DEC-1999 |
| 29 unordered pieces. | ||||||||
| GB_HTG6: AC011647 | 141830 | AC011647 | Homo sapiens clone RP11-15D18, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 37,537 | 04-DEC-1999 | ||
| 29 unordered pieces. | ||||||||
| rxa00059 | 405 | GB_GSS6: AQ825754 | 463 | AQ825754 | HS_5441_A2_G02_SP6E RPCI-11 Human Male BAC Library | Homo sapiens | 34,444 | 27-Aug-99 |
| Homo sapiens genomic clone Plate = 1017 Col = 4 Row = M, | ||||||||
| genomic survey sequence. | ||||||||
| GB_PAT: I32939 | 30001 | I32939 | Sequence 1 from patent U.S. Pat. No. 5589385. | Unknown. | 42,049 | 6-Feb-97 | ||
| GB_PAT: AR031772 | 30001 | AR031772 | Sequence 1 from patent U.S. Pat. No. 5866410. | Unknown. | 42,049 | 29-Sep-99 | ||
| rxa00065 | 396 | GB_PAT: E16763 | 2517 | E16763 | gDNA encoding aspartate transferase (AAT). | Corynebacterium | 98,765 | 28-Jul-99 |
| glutamicum | ||||||||
| GB_EST32: AU050556 | 813 | AU050556 | AU050556 Paralichthys olivaceus library (Aoki T) Paralichthys olivaceus cDNA | Paralichthys olivaceus | 35,638 | 8-Jun-99 | ||
| clone WF7-19, mRNA sequence. | ||||||||
| GB_EST32: AU050215 | 733 | AU050215 | AU050215 Paralichthys olivaceus library (Aoki T) Paralichthys olivaceus cDNA | Paralichthys olivaceus | 35,638 | 8-Jun-99 | ||
| clone WB1-12, mRNA sequence. | ||||||||
| rxa00067 | 609 | GB_HTG3: AC008289 | 115120 | AC008289 | Drosophila melanogaster chromosome 2 clone BACR04E05(D1055) RPCI-98 04.E.5 | Drosophila melanogaster | 30,397 | 17-Aug-99 |
| map 57B-57B strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 100 unordered pieces. | ||||||||
| GB_IN2: AC004433 | 85862 | AC004433 | Drosophila melanogaster , chromosome 2R, region 57B1-57B6, P1 clone | Drosophila melanogaster | 35,501 | 01-DEC-1998 | ||
| DS03659, complete sequence. | ||||||||
| GB_HTG3: AC008289 | 115120 | AC008289 | Drosophila melanogaster chromosome 2 clone BACR04E05 (D1055) RPCI-98 04.E.5 | Drosophila melanogaster | 30,397 | 17-Aug-99 | ||
| map 57B-57B strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 100 unordered pieces. | ||||||||
| rxa00068 | 705 | GB_PL2: ATAC006201 | 87947 | AC006201 | Arabidopsis thaliana chromosome II BAC T27K22 genomic sequence, | Arabidopsis thaliana | 39,099 | 12-MAR-1999 |
| complete sequence. | ||||||||
| GB_HTG5: AC010146 | 271437 | AC010146 | Homo sapiens clone NH0355I13, WORKING DRAFT SEQUENCE, | Homo sapiens | 34,237 | 12-Nov-99 | ||
| 1 unordered pieces. | ||||||||
| GB_GSS3: B85079 | 307 | B85079 | RPCI11-29O9.TP RPCI-11 Homo sapiens genomic clone | Homo sapiens | 39,560 | 9-Apr-99 | ||
| RPCI-11-29O9, genomic survey sequence. | ||||||||
| rxa00077 | 1485 | GB_PR4: AC007157 | 152937 | AC007157 | Homo sapiens , clone hRPK.78_A_1, complete sequence. | Homo sapiens | 37,661 | 27-Apr-99 |
| GB_HTG1: CEY43C5 | 149571 | AL021449 | Caenorhabditis elegans chromosome IV clone Y43C5, *** SEQUENCING | Caenorhabditis elegans | 25,242 | 23-Jan-98 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: CEY43C5 | 149571 | AL021449 | Caenorhabditis elegans chromosome IV clone Y43C5, *** SEQUENCING | Caenorhabditis elegans | 38,258 | 23-Jan-98 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00079 | 345 | GB_IN1: CTAJ2763 | 1097 | AJ002763 | Chironomus tentans mRNA for P23 protein (23 kDa). | Chironomus tentans | 36,176 | 26-Jan-98 |
| GB_IN1: CTHRP23 | 752 | AJ003820 | Chironomus tentans mRNA for hnRNP protein, hrp23. | Chironomus tentans | 36,176 | 02-DEC-1998 | ||
| GB_EST17: AA650674 | 540 | AA650674 | 30788 Lambda-PRL2 Arabidopsis thaliana cDNA clone 277G7T7, mRNA sequence. | Arabidopsis thaliana | 36,965 | 31-OCT-1997 | ||
| rxa00080 | 1653 | GB_EST38: AW039986 | 564 | AW039986 | EST282477 tomato mixed elicitor, BTI Lycopersicon esculentum cDNA clone | Lycopersicon esculentum | 38,078 | 18-OCT-1999 |
| cLET19F23, mRNA sequence. | ||||||||
| GB_EST33: AI778332 | 378 | AI778332 | EST259211 tomato susceptible, Cornell Lycopersicon esculentum cDNA clone | Lycopersicon esculentum | 38,298 | 29-Jun-99 | ||
| cLES5A13, mRNA sequence. | ||||||||
| GB_EST38: AW039988 | 564 | AW039988 | EST282479 tomato mixed elicitor, BTI Lycopersicon esculentum cDNA clone | Lycopersicon esculentum | 38,078 | 18-OCT-1999 | ||
| cLET19F23, mRNA sequence. | ||||||||
| rxa00082 | 687 | GB_PR1: HSS171 | 333303 | AJ011930 | Homo sapiens chromosome 21q22.3, PAC clones 314N7, 225L15, | Homo sapiens | 36,111 | 10-Nov-98 |
| BAC clone 7B7, complete sequence bases 1. .333303. | ||||||||
| GB_PR1: HSS171 | 333303 | AJ011930 | Homo sapiens chromosome 21q22.3, PAC clones 314N7, 225L15, BAC | Homo sapiens | 35,432 | 10-Nov-98 | ||
| clone 7B7, complete sequence bases 1. .333303. | ||||||||
| GB_PR3: AC004000 | 128117 | AC004000 | Human PAC clone DJ404F18 from Xq23, complete sequence. | Homo sapiens | 38,750 | 15-Jan-98 | ||
| rxa00083 | 423 | GB_HTG1: CNS018OY | 168868 | AL109769 | Homo sapiens chromosome 14 clone R-501E21, *** SEQUENCING | Homo sapiens | 33,806 | 15-OCT-1999 |
| IN PROGRESS ***, in ordered pieces. | ||||||||
| GB_HTG1: CNS018OY | 168868 | AL109769 | Homo sapiens chromosome 14 clone R-501E21, *** SEQUENCING | Homo sapiens | 33,806 | 15-OCT-1999 | ||
| IN PROGRESS ***, in ordered pieces. | ||||||||
| GB_PR3: HS516C23 | 116685 | Z93021 | Human DNA sequence from clone 516C23 on chromosome 6q12 Contains CA | Homo sapiens | 36,562 | 23-Nov-99 | ||
| repeat (D6S402) and GSSs, complete sequence. | ||||||||
| rxa00087 | 651 | GB_BA1: PSEBPHABC | 6780 | M83673 | P. pseudoalcaligenes dioxygenase (bphABC) gene cluster, complete cds. | Pseudomonas | 39,564 | 26-Apr-93 |
| pseudoalcaligenes | ||||||||
| GB_BA1: PSEBPHA | 5700 | M86348 | Pseudomonas sp. LB400 biphenyl dioxygenase (bphA), biphenyl dioxygenase | Burkholderia sp. LB400 | 39,564 | 18-Jul-97 | ||
| (bphE), biphenyl dioxygenase (bphF) and biphenyl dioxygenase (bphG)s, | ||||||||
| complete cds, and dihydrodiol dehydrogenase (bphB), partial cds. | ||||||||
| GB_PAT: E04215 | 4721 | E04215 | Benzene dioxygenase gene. | Pseudomonas aeruginosa | 45,814 | 29-Sep-97 | ||
| rxa00093 | 2346 | GB_HTG2: AC007361 | 36465 | AC007361 | Homo sapiens clone NH0144P23, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 37,179 | 23-Apr-99 |
| 1 unordered pieces. | ||||||||
| GB_PR4: AC006043 | 189036 | AC006043 | Homo sapiens BAC clone NH0538D15 from 7q11.23-q21.1, complete sequence. | Homo sapiens | 37,060 | 20-Feb-99 | ||
| GB_HTG2: AC007361 | 36465 | AC007361 | Homo sapiens clone NH0144P23, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 37,179 | 23-Apr-99 | ||
| 1 unordered pieces. | ||||||||
| rxa00096 | 426 | GB_EST15: AA533064 | 534 | AA533064 | nj60d06.s1 NCI_CGAP_Pr9 Homo sapiens cDNA clone IMAGE: | Homo sapiens | 39,024 | 21-Aug-97 |
| 996875, mRNA sequence. | ||||||||
| GB_IN1: CELF01G12 | 34671 | U53342 | Caenorhabditis elegans cosmid F01G12. | Caenorhabditis elegans | 38,060 | 5-Apr-96 | ||
| GB_PR3: AC004511 | 45005 | AC004511 | Homo sapiens chromosome 5, P1 clone 792C12 (LBNL H22), complete sequence. | Homo sapiens | 39,163 | 31-MAR-1998 | ||
| rxa00097 | 1299 | GB_OM: CFU60590 | 6726 | U60590 | Canis familiaris TTX-resistant sodium channel mRNA, complete cds. | Canis familiaris | 39,528 | 8-Jan-98 |
| GB_GSS15: AQ664394 | 485 | AQ664394 | HS_5480_B1_B02_SP6E RPCI-11 Human Male BAC Library | Homo sapiens | 39,666 | 23-Jun-99 | ||
| Homo sapiens genomic clone Plate = 1056 Col = 3 Row = D, | ||||||||
| genomic survey sequence. | ||||||||
| GB_BA2: RSAF000233 | 5984 | AF000233 | Rhodobacter sphaeroides nitric oxide reductase operon: norC, norB, norQ, norD, | Rhodobacter sphaeroides | 37,500 | 6-Jun-97 | ||
| nnrT and nnrU genes, complete cds. | ||||||||
| rxa00101 | ||||||||
| rxa00108 | 643 | GB_PR4: AC007115 | 180821 | AC007115 | Homo sapiens chromosome 12 clone 917O5, complete sequence. | Homo sapiens | 35,165 | 17-Aug-99 |
| GB_PR3: AC004080 | 129354 | AC004080 | Homo sapiens PAC clone DJ0170O19 from 7p15-p21, complete sequence. | Homo sapiens | 38,560 | 29-Jan-98 | ||
| GB_HTG1: HSAJ9613 | 45302 | AJ009613 | Homo sapiens chromosome 17 clone cosmid 5L5 map p11,*** SEQUENCING | Homo sapiens | 39,274 | 11-Nov-98 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00110 | 672 | GB_PL1: MIATGENB | 166924 | Y08502 | A. thaliana mitochondrial genome, part B. | Mitochondrion Arabidopsis | 36,391 | 13-Nov-98 |
| thaliana | ||||||||
| GB_PL2: AC010718 | 87684 | AC010718 | Arabidopsis thaliana chromosome I BAC F28O16 genomic | Arabidopsis thaliana | 36,622 | 30-OCT-1999 | ||
| sequence, complete sequence. | ||||||||
| GB_PL2: AC007729 | 106639 | AC007729 | Arabidopsis thaliana chromosome II BAC T18C6 genomic sequence, | Arabidopsis thaliana | 35,053 | 5-Jun-99 | ||
| complete sequence. | ||||||||
| rxa00114 | 612 | GB_OM: BTMICSD1 | 362 | Z27071 | B. taurus (cos1E3) microsatellite DNA (362 bp). | Bos taurus | 37,117 | 10-Aug-95 |
| GB_OM: BTMICSD1 | 362 | Z27071 | B. taurus (cos1E3) microsatellite DNA (362 bp). | Bos taurus | 36,486 | 10-Aug-95 | ||
| rxa00117 | 714 | GB_PL2: AF080249 | 3194 | AF080249 | Arabidopsis thaliana kinesin-like heavy chain (KATD) mRNA, complete cds. | Arabidopsis thaliana | 37,846 | 14-Apr-99 |
| GB_PL2: IG002P16 | 110946 | AF007270 | Arabidopsis thaliana BAC IG002P16. | Arabidopsis thaliana | 37,110 | 12-Jun-97 | ||
| GB_PL2: AF080249 | 3194 | AF080249 | Arabidopsis thaliana kinesin-like heavy chain (KATD) mRNA, complete cds. | Arabidopsis thaliana | 36,506 | 14-Apr-99 | ||
| rxa00118 | 378 | GB_HTG2: AC008043 | 124844 | AC008043 | Drosophila melanogaster chromosome 3 clone BACR05A08 (D750) RPCI-98 | Drosophila melanogaster | 33,780 | 2-Aug-99 |
| 05.A.8 map 94A-94A strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 86 unordered pieces. | ||||||||
| GB_HTG2: AC008043 | 124844 | AC008043 | Drosophila melanogaster chromosome 3 clone BACR05A08 (D750) RPCI-98 | Drosophila melanogaster | 33,780 | 2-Aug-99 | ||
| 05.A.8 map 94A-94A strain y; cn bw sp, *** SEQUENCING IN PROGRESS***, | ||||||||
| 86 unordered pieces. | ||||||||
| GB_PR3: AC004827 | 129690 | AC004827 | Homo sapiens PAC clone DJ044L15 from Xq23, complete sequence. | Homo sapiens | 32,320 | 17-OCT-1998 | ||
| rxa00119 | 882 | GB_PR4: HSU34879 | 46610 | U34879 | Human 17-beta-hydroxysteroid dehydrogenase (EDH17B2) gene, complete cds. | Homo sapiens | 36,671 | 14-Jan-99 |
| GB_PR4: HSU34879 | 46610 | U34879 | Human 17-beta-hydroxysteroid dehydrogenase (EDH17B2) gene, complete cds. | Homo sapiens | 38,345 | 14-Jan-99 | ||
| GB_EST37: AW005997 | 702 | AW005997 | wz91c01.x1 NCI_CGAP_Brn25 Homo sapiens cDNA clone IMAGE: | Homo sapiens | 40,774 | 10-Sep-99 | ||
| 2566176 3′ similar to TR: O08609 O08609 TRANSCRIPTION | ||||||||
| FACTOR-LIKE PROTEIN 4.;, mRNA sequence. | ||||||||
| rxa00120 | 963 | GB_BA1: TRU80216 | 1936 | U80216 | Thermomicrobium roseum 70 kDa heat shock protein Hsp70 (DnaK) | Thermomicrobium roseum | 38,000 | 1-Feb-97 |
| gene, complete cds. | ||||||||
| GB_HTG1: HS791K14 | 155318 | AL035685 | Homo sapiens chromosome 20 clone RP4-791K14, *** SEQUENCING | Homo sapiens | 37,277 | 23-Nov-99 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: HS791K14 | 155318 | AL035685 | Homo sapiens chromosome 20 clone RP4-791K14, *** SEQUENCING | Homo sapiens | 37,277 | 23-Nov-99 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00121 | 834 | GB_HTG1: HSBA298O6 | 198847 | AL118525 | Homo sapiens chromosome 20 clone RP11-298O6, *** SEQUENCING | Homo sapiens | 36,199 | 24-Nov-99 |
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: HS791K14 | 155318 | AL035685 | Homo sapiens chromosome 20 clone RP4-791K14, *** SEQUENCING | Homo sapiens | 36,983 | 23-Nov-99 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: HS791K14 | 155318 | AL035685 | Homo sapiens chromosome 20 clone RP4-791K14,*** SEQUENCING | Homo sapiens | 36,983 | 23-Nov-99 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00122 | 1746 | GB_PL1: MZECPN60A | 6575 | L21007 | Corn nuclear-encoded mitochondrial chaperonin 60 (cpn60I) gene, complete cds. | Zea mays | 36,098 | 26-Jul-93 |
| GB_PL1: ZMCPNAGA | 2247 | Z12114 | Z. mays CPNA gene encoding mitochondrial chaperonin-60. | Zea mays | 37,702 | 01-OCT-1992 | ||
| GB_PL1: ZMCHHSP60 | 2138 | Z11546 | Z. mays mRNA for mitochondrial chaperonin hsp60. | Zea mays | 37,721 | 11-Jun-92 | ||
| rxa00127 | 588 | GB_PR4: AC005193 | 108400 | AC005193 | Homo sapiens clone DJ0655N24, complete sequence. | Homo sapiens | 37,500 | 1-Jul-99 |
| GB_PR4: AC005193 | 108400 | AC005193 | Homo sapiens clone DJ0655N24, complete sequence. | Homo sapiens | 36,796 | 1-Jul-99 | ||
| rxa00128 | 1827 | GB_GSS11: AQ299024 | 449 | AQ299024 | HS_3178_B1_B06_T7 CIT Approved Human Genomic Sperm Library D | Homo sapiens | 40,757 | 15-DEC-1998 |
| Homo sapiens genomic clone Plate = 3178 Col = 11 Row = D, | ||||||||
| genomic survey sequence. | ||||||||
| GB_GSS11: AQ299024 | 449 | AQ299024 | HS_3178_B1_B06_T7 CIT Approved Human Genomic Sperm Library D | Homo sapiens | 40,443 | 15-DEC-1998 | ||
| Homo sapiens genomic clone Plate = 3178 Col = 11 Row = D, | ||||||||
| genomic survey sequence. | ||||||||
| rxa00134 | 693 | GB_GSS10: AQ177172 | 393 | AQ177172 | HS_3225_A2_E10_MR CIT Approved Human Genomic Sperm Library D | Homo sapiens | 50,000 | 17-OCT-1998 |
| Homo sapiens genomic clone Plate = 3225 Col = 20 Row = I, | ||||||||
| genomic survey sequence. | ||||||||
| GB_PR3: AC005726 | 185215 | AC005726 | Homo sapiens chromosome 17, clone hRPK.192_H_23, complete sequence. | Homo sapiens | 37,778 | 30-OCT-1998 | ||
| GB_PR3: AC005726 | 185215 | AC005726 | Homo sapiens chromosome 17, clone hRPK.192_H_23, complete sequence. | Homo sapiens | 38,710 | 30-OCT-1998 | ||
| rxa00140 | 309 | GB_VI: OPU75930 | 131993 | U75930 | Orgyia pseudotsugata nuclear polyhedrosis virus complete genome. | Orgyia pseudotsugata | 39,007 | 06-MAR-1998 |
| nuclear polyhedrosis virus | ||||||||
| GB_HTG2: AC006319 | 156299 | AC006319 | Homo sapiens clone DJ0837C09, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 31,773 | 23-Apr-99 | ||
| 1 unordered pieces. | ||||||||
| GB_HTG2: AC006319 | 156299 | AC006319 | Homo sapiens clone DJ0837C09, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 31,773 | 23-Apr-99 | ||
| 1 unordered pieces. | ||||||||
| rxa00141 | 585 | GB_VI: OPU75930 | 131993 | U75930 | Orgyia pseudotsugata nuclear polyhedrosis virus complete genome. | Orgyia pseudotsugata | 38,079 | 06-MAR-1998 |
| nuclear polyhedrosis virus | ||||||||
| GB_PR4: AC004526 | 297898 | AC004526 | Homo sapiens chromosome 17, Neurofibromatosis 1 locus, complete sequence. | Homo sapiens | 37,336 | 25-Feb-99 | ||
| GB_PR2: HUMNEUROF | 100849 | L05367 | Human oligodendrocyte myelin glycoprotein (OMG) exons 1-2; neurofibromatosis 1 | Homo sapiens | 37,336 | 20-Sep-95 | ||
| (NF1) exons 28-49; ecotropic viral integration site 2B (EVI2B) exons 1-2; ecotropic | ||||||||
| viral integration site 2A (EVI2A) exons 1-2; adenylate kinase (AK3) exons 1-2. | ||||||||
| rxa00142 | 600 | GB_PR4: HUAC002331 | 139480 | AC002331 | Homo sapiens Chromosome 16 BAC clone | Homo sapiens | 38,898 | 23-Nov-99 |
| CIT987SK-A-A-218C7, complete sequence. | ||||||||
| GB_PR3: AF064861 | 133965 | AF064861 | Homo sapiens PAC 128M19 derived from chromosome 21q22.3, containing | Homo sapiens | 37,182 | 2-Jun-98 | ||
| the HMG-14 and CHD5 genes, complete cds, complete sequence. | ||||||||
| GB_HTG3: AC009451 | 165302 | AC009451 | Homo sapiens chromosome 17 clone 2286_H_12 map 17, *** SEQUENCING | Homo sapiens | 33,167 | 22-Aug-99 | ||
| IN PROGRESS ***, 26 unordered pieces. | ||||||||
| rxa00150 | 897 | GB_PR4: AF130343 | 292721 | AF130343 | Homo sapiens chromosome 8 clone PAC 87.2 map 8q24.1, complete sequence. | Homo sapiens | 36,032 | 9-Jul-99 |
| GB_HTG4: AC008578 | 98891 | AC008578 | Homo sapiens chromosome 5 clone CIT-HSPC_558D4, *** SEQUENCING | Homo sapiens | 38,129 | 31-OCT-1999 | ||
| IN PROGRESS ***, 143 unordered pieces. | ||||||||
| GB_HTG4: AC008578 | 98891 | AC008578 | Homo sapiens chromosome 5 clone CIT-HSPC_558D4, *** SEQUENCING | Homo sapiens | 38,129 | 31-OCT-1999 | ||
| IN PROGRESS ***, 143 unordered pieces. | ||||||||
| rxa00151 | 720 | GB_PL2: AF058914 | 111767 | AF058914 | Arabidopsis thaliana BAC F21E10. | Arabidopsis thaliana | 36,068 | 15-Apr-98 |
| GB_PR1: AB019440 | 200000 | AB019440 | Homo sapiens DNA for immunoglobulin heavy-chain variable region, | Homo sapiens | 36,517 | 24-Feb-99 | ||
| complete sequence, 4 of 5. | ||||||||
| GB_PR2: AP000098 | 100000 | AP000098 | Homo sapiens genomic DNA of 21q22.1, GART and AML related, Q78C10-149C3 | Homo sapiens | 39,224 | 25-Sep-99 | ||
| region, segment 1/20, complete sequence. | ||||||||
| rxa00153 | 549 | GB_PR4: AC006265 | 177707 | AC006265 | Homo sapiens chromosome 17, clone hRPK.566_B_16, complete sequence. | Homo sapiens | 34,862 | 28-Jan-99 |
| GB_HTG2: AC007389 | 207188 | AC007389 | Homo sapiens clone NH0418H16, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 36,044 | 5-Jun-99 | ||
| 6 unordered pieces. | ||||||||
| GB_HTG2: AC007389 | 207188 | AC007389 | Homo sapiens clone NH0418H16, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 36,044 | 5-Jun-99 | ||
| 6 unordered pieces. | ||||||||
| rxa00154 | ||||||||
| rxa00155 | 906 | GB_BA2: AE001707 | 19518 | AE001707 | Thermotoga maritima section 19 of 136 of the complete genome. | Thermotoga maritima | 36,854 | 2-Jun-99 |
| GB_PR2: HS1126I14 | 19544 | AL078589 | Human DNA sequence from clone 1126I14 on chromosome 6q16.1-16.3. | Homo sapiens | 36,723 | 23-Nov-99 | ||
| Contains an STS and GSSs, complete sequence. | ||||||||
| GB_BA1: MTCY01B2 | 35938 | Z95554 | Mycobacterium tuberculosis H37Rv complete genome; segment 72/162. | Mycobacterium | 40,435 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| rxa00159 | 1305 | GB_EST38: AW048718 | 475 | AW048718 | UI-M-BH1-amy-d-01-0-UI.s1 NIH_BMAP_M_S2 Mus musculus cDNA clone | Mus musculus | 39,789 | 18-Sep-99 |
| UI-M-BH1-amy-d-01-0-UI 3′, mRNA sequence. | ||||||||
| GB_EST21: AA993450 | 381 | AA993450 | ot32h09.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE: 1618529 | Homo sapiens | 38,684 | 27-Aug-98 | ||
| 3′, mRNA sequence. | ||||||||
| GB_BA1: AB007009 | 363 | AB007009 | Cytophaga sp. 16S rRNA gene, partial sequence. | Cytophaga sp. | 39,039 | 13-OCT-1997 | ||
| rxa00161 | 585 | GB_HTG3: AC009708 | 25123 | AC009708 | Homo sapiens chromosome 8 clone 318_G_5 map 8, LOW-PASS | Homo sapiens | 37,108 | 28-Aug-99 |
| SEQUENCE SAMPLING. | ||||||||
| GB_HTG3: AC009708 | 25123 | AC009708 | Homo sapiens chromosome 8 clone 318_G_5 map 8, | Homo sapiens | 37,108 | 28-Aug-99 | ||
| LOW-PASS SEQUENCE SAMPLING. | ||||||||
| GB_PR3: HSN104C4 | 40203 | Z83855 | Human DNA sequence from clone N104C4 on chromosome 22 | Homo sapiens | 37,634 | 23-Nov-99 | ||
| Contains GSSs, complete sequence. | ||||||||
| rxa00162 | 477 | GB_HTG1: CEY94A7 | 41009 | Z99294 | Caenorhabditis elegans chromosome V clone Y94A7, *** SEQUENCING | Caenorhabditis elegans | 41,502 | 18-Sep-97 |
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: CEY94A7 | 41009 | Z99294 | Caenorhabditis elegans chromosome V clone Y94A7, *** SEQUENCING | Caenorhabditis elegans | 41,502 | 18-Sep-97 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_BA2: AE001182 | 11228 | AE001182 | Borrelia burgdorferi (section 68 of 70) of the complete genome. | Borrelia burgdorferi | 39,655 | 15-DEC-1997 | ||
| rxa00167 | 621 | GB_HTG7: AC007937 | 206265 | AC007937 | Mus musculus chromosome 10 clone RP21-536F4 map 10, *** SEQUENCING | Mus musculus | 37,092 | 09-DEC-1999 |
| IN PROGRESS ***, 6 unordered pieces. | ||||||||
| GB_RO: MMU6590 | 6429 | AJ006590 | Mus musculus mRNA for GANP protein. | Mus musculus | 38,678 | 2-Jun-99 | ||
| GB_HTG3: AC008852 | 116219 | AC008852 | Homo sapiens chromosome 5 clone CITB-H1_2176I21, *** SEQUENCING | Homo sapiens | 35,691 | 3-Aug-99 | ||
| IN PROGRESS ***, 13 unordered pieces. | ||||||||
| rxa00169 | 2196 | GB_GSS3: B11032 | 896 | B11032 | T17F10-T7 TAMU Arabidopsis thaliana genomic clone T17F10, | Arabidopsis thaliana | 42,024 | 14-MAY-1997 |
| genomic survey sequence. | ||||||||
| GB_GSS3: B10120 | 909 | B10120 | T27N10-Sp6.1 TAMU Arabidopsis thaliana genomic clone T27N10, | Arabidopsis thaliana | 41,581 | 14-MAY-1997 | ||
| genomic survey sequence. | ||||||||
| GB_GSS3: B09409 | 916 | B09409 | T27M2-Sp6 TAMU Arabidopsis thaliana genomic clone T27M2, | Arabidopsis thaliana | 41,356 | 14-MAY-1997 | ||
| genomic survey sequence. | ||||||||
| rxa00170 | 1977 | GB_GSS8: AQ027582 | 456 | AQ027582 | CIT-HSP-2325M20. TR CIT-HSP Homo sapiens genomic clone | Homo sapiens | 40,749 | 30-Jun-98 |
| 2325M20, genomic survey sequence. | ||||||||
| GB_GSS6: AQ833529 | 484 | AQ833529 | HS_5304_B2_C02_T7A RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 38,017 | 27-Aug-99 | ||
| genomic clone Plate = 880 Col = 4 Row = F, genomic survey sequence. | ||||||||
| GB_PR2: HSM800174 | 2326 | AL049389 | Homo sapiens mRNA; cDNA DKFZp586O0118 (from clone DKFZp586O0118). | Homo sapiens | 37,556 | 21-MAY-1999 | ||
| rxa00171 | 281 | GB_EST38: AL118463 | 279 | AL118463 | w9112a43 Beddington mouse dissected endoderm Mus musculus cDNA clone | Mus musculus | 50,000 | 23-Sep-99 |
| 528_12E22 5′, mRNA sequence. | ||||||||
| GB_EST15: AA499834 | 419 | AA499834 | vg05e06.r1 Soares mouse NbMH Mus musculus cDNA clone IMAGE: 860482 | Mus musculus | 39,801 | 1-Jul-97 | ||
| 5′, mRNA sequence. | ||||||||
| GB_EST24: AI211527 | 431 | AI211527 | p0h01a1.r1 Aspergillus nidulans 24 hr asexual developmental and vegetative | Emericella nidulans | 41,584 | 19-OCT-1998 | ||
| cDNA lambda zap library Emericella nidulans cDNA clone p0h01a1 | ||||||||
| 5′, mRNA sequence. | ||||||||
| rxa00173 | 456 | GB_PR3: AC004400 | 33367 | AC004400 | Homo sapiens chromosome 19, cosmid F24069, complete sequence. | Homo sapiens | 38,902 | 12-MAR-1998 |
| GB_PL1: VFU14956 | 1474 | U14956 | Vicia faba ferredoxin NADP+ reductase precursor (fnr) mRNA, complete cds. | Vicia faba | 38,753 | 28-Sep-94 | ||
| GB_PR3: AC004400 | 33367 | AC004400 | Homo sapiens chromosome 19, cosmid F24069, complete sequence. | Homo sapiens | 40,515 | 12-MAR-1998 | ||
| rxa00174 | 408 | GB_PL2: AF075293 | 4332 | AF075293 | Candida albicans strain 1161 agglutinin-like protein 6 (ALS6) gene, complete cds. | Candida albicans | 41,235 | 2-Jul-99 |
| GB_PL2: JSPCHS1 | 1525 | X94995 | Juglans nigra x Juglans regia mRNA for chalcone synthase (CHS1). | Juglans nigra x Juglans | 39,558 | 19-Nov-99 | ||
| regia | ||||||||
| GB_PL2: JSPCHS2 | 1534 | X94706 | Juglans nigra x Juglans regia mRNA for chalcone synthase (CHS2). | Juglans nigra x Juglans | 38,821 | 19-Nov-99 | ||
| regia | ||||||||
| rxa00175 | ||||||||
| rxa00179 | 582 | GB_BA1: CGPUTP | 3791 | Y09163 | C. glutamicum putP gene. | Corynebacterium | 100,000 | 8-Sep-97 |
| glutamicum | ||||||||
| GB_IN2: L76038 | 2421 | L76038 | Anopheles gambiae prophenoloxidase mRNA, complete cds. | Anopheles gambiae | 35,751 | 23-Jul-98 | ||
| GB_IN2: AF031626 | 8486 | AF031626 | Anopheles gambiae prophenoloxidase (AgProPO) gene, complete cds. | Anopheles gambiae | 36,395 | 5-Jan-99 | ||
| rxa00180 | 663 | GB_BA1: CGPUTP | 3791 | Y09163 | C. glutamicum putP gene. | Corynebacterium | 100,000 | 8-Sep-97 |
| glutamicum | ||||||||
| GB_HTG1: HS120G22 | 57021 | AL031847 | Homo sapiens chromosome 1 clone RP1-120G22, *** SEQUENCING | Homo sapiens | 35,976 | 23-Nov-99 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: HS120G22 | 57021 | AL031847 | Homo sapiens chromosome 1 clone RP1-120G22, *** SEQUENCING | Homo sapiens | 35,976 | 23-Nov-99 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00183 | 975 | GB_IN2: AF049132 | 16005 | AF049132 | Florometra serratissima mitochondrion, complete genome. | Mitochondrion Florometra | 33,710 | 15-Jan-99 |
| serratissima | ||||||||
| GB_IN1: MTCE | 13794 | X54252 | C. elegans complete mitochondrial genome. | Mitochondrion | 35,036 | 30-Nov-97 | ||
| Caenorhabditis elegans | ||||||||
| GB_IN2: AF049132 | 16005 | AF049132 | Florometra serratissima mitochondrion, complete genome. | Mitochondrion Florometra | 36,021 | 15-Jan-99 | ||
| serratissima | ||||||||
| rxa00185 | 2751 | GB_EST31: AI693167 | 500 | AI693167 | wd68c11.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone IMAGE: 2336756 | Homo sapiens | 37,800 | 2-Jun-99 |
| 3′ similar to SW: HIOM_BOVIN P10950 HYDROXYINDOLE | ||||||||
| O-METHYLTRANSFERASE;, mRNA sequence. | ||||||||
| GB_GSS1: CNS010IZ | 1000 | AL099029 | Drosophila melanogaster genome survey sequence SP6 end of BAC | Drosophila melanogaster | 35,158 | 26-Jul-99 | ||
| BACN04K17 of DrosBAC library from Drosophila melanogaster (fruit fly), | ||||||||
| genomic survey sequence. | ||||||||
| GB_EST31: AI693167 | 500 | AI693167 | wd68c11.x1 NCI_CGAP_Lu24 Homo sapiens cDNA clone IMAGE: 2336756 | Homo sapiens | 39,052 | 2-Jun-99 | ||
| 3′ similar to SW: HIOM_BOVIN P10950 HYDROXYINDOLE | ||||||||
| O-METHYLTRANSFERASE;, mRNA sequence. | ||||||||
| rxa00194 | 564 | GB_GSS10: AQ192671 | 396 | AQ192671 | HS_2251_B2_A04_MF CIT Approved Human Genomic Sperm Library D | Homo sapiens | 44,240 | 4-Nov-98 |
| Homo sapiens genomic clone Plate = 2251 Col = 8 Row = B, | ||||||||
| genomic survey sequence. | ||||||||
| GB_GSS8: AQ044307 | 644 | AQ044307 | CIT-HSP-2331N9.TR CIT-HSP Homo sapiens genomic clone 2331N9, | Homo sapiens | 36,150 | 14-Jul-98 | ||
| genomic survey sequence. | ||||||||
| GB_EST36: AI925874 | 564 | AI925874 | wo20d11.x1 NCI_CGAP_Pan1 Homo sapiens cDNA clone IMAGE: 2455893 | Homo sapiens | 45,588 | 2-Sep-99 | ||
| 3′ similar to TR: O67849 O67849 GTP-BINDING PROTEIN.;, | ||||||||
| mRNA sequence. | ||||||||
| rxa00197 | 1335 | GB_GSS12: AQ399208 | 436 | AQ399208 | mgxb0001M23f CUGI Rice Blast BAC Library Magnaporthe grisea genomic | Magnaporthe grisea | 63,529 | 06-MAR-1999 |
| clone mgxb0001M23f, genomic survey sequence. | ||||||||
| GB_GSS12: AQ398449 | 472 | AQ398449 | mgxb0001P11f CUGI Rice Blast BAC Library Magnaporthe grisea genomic | Magnaporthe grisea | 49,580 | 06-MAR-1999 | ||
| clone mgxb0001P11f, genomic survey sequence. | ||||||||
| GB_OM: BTMMP9 | 2350 | X78324 | B. taurus bmmp9 mRNA for matrix metalloproteinase. | Bos taurus | 40,440 | 30-MAR-1995 | ||
| rxa00199 | 1542 | GB_BA1: AB024708 | 8734 | AB024708 | Corynebacterium glutamicum gltB and gltD genes for glutamine 2-oxoglutarate | Corynebacterium | 36,237 | 13-MAR-1999 |
| aminotransferase large and small subunits, complete cds. | glutamicum | |||||||
| GB_HTG2: AC007837 | 103949 | AC007837 | Drosophila melanogaster chromosome 2 clone BACR04I07 (D644) RPCI-98 | Drosophila melanogaster | 36,045 | 2-Aug-99 | ||
| 04.I.7 map 57B2-B3 strain y; cn bw sp, *** SEQUENCING IN PROGRESS***, | ||||||||
| 49 unordered pieces. | ||||||||
| GB_HTG2: AC007837 | 103949 | AC007837 | Drosophila melanogaster chromosome 2 clone BACR04I07 (D644) RPCI-98 | Drosophila melanogaster | 36,045 | 2-Aug-99 | ||
| 04.I.7 map 57B2-B3 strain y; cn bw sp, *** SEQUENCING IN PROGRESS***, | ||||||||
| 49 unordered pieces. | ||||||||
| rxa00200 | 3561 | GB_BA2: MSU46844 | 16951 | U46844 | Mycobacterium smegmatis catalase-peroxidase (katG), putative | Mycobacterium smegmatis | 53,937 | 12-MAY-1997 |
| arabinosyl transferase (embC, embA, embB), genes complete cds and putative | ||||||||
| propionyl-coA carboxylase beta chain (pccB) genes, partial cds. | ||||||||
| GB_BA2: MAU66560 | 7853 | U66560 | Mycobacterium avium EmbR (embR), EmbA (embA) and EmbB (embB) | Mycobacterium avium | 52,241 | 8-Nov-96 | ||
| genes, complete cds. | ||||||||
| GB_BA1: MTY13D12 | 37085 | Z80343 | Mycobacterium tuberculosis H37Rv complete genome; segment 156/162. | Mycobacterium | 52,812 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| rxa00207 | 441 | GB_PR3: HTCRBCHR9 | 216293 | AF029308 | Homo sapiens chromosome 9 duplication of the T cell receptor beta locus | Homo sapiens | 39,286 | 13-Apr-98 |
| and trypsinogen gene families. | ||||||||
| GB_PR3: HTCRBCHR9 | 216293 | AF029308 | Homo sapiens chromosome 9 duplication of the T cell receptor beta locus | Homo sapiens | 37,116 | 13-Apr-98 | ||
| and trypsinogen gene families. | ||||||||
| rxa00211 | 786 | GB_PR2: HSU81831 | 38674 | U81831 | Human cosmid LL12NCO1-67C6, ETV6 gene, intron 1A, partial sequence. | Homo sapiens | 35,509 | 3-Jan-97 |
| GB_RO: MUSKROX2S2 | 2868 | M28845 | Mus musculus zinc finger protein (Krox-24) gene, exon 2. | Mus musculus | 40,566 | 21-MAY-1996 | ||
| GB_HTG2: AC007440 | 120642 | AC007440 | Drosophila melanogaster chromosome 2 clone BACR37I09 (D593) RPCI-98 | Drosophila melanogaster | 36,753 | 2-Aug-99 | ||
| 37.I.9 map 49A-49B strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 103 unordered pieces. | ||||||||
| rxa00218 | ||||||||
| rxa00220 | 627 | GB_BA1: ASU04436 | 4668 | U04436 | Anabaena sp. PCC 7120 putative polyketide synthase gene, complete cds. | Anabaena sp. | 33,766 | 21-DEC-1993 |
| GB_RO: AF068199 | 3490 | AF068199 | Mus musculus D-dopachrome tautomerase gene, complete cds. | Mus musculus | 38,833 | 26-Aug-98 | ||
| GB_RO: AF068199 | 3490 | AF068199 | Mus musculus D-dopachrome tautomerase gene, complete cds. | Mus musculus | 34,776 | 26-Aug-98 | ||
| rxa00222 | 1269 | GB_PL1: AB011477 | 78181 | AB011477 | Arabidopsis thaliana genomic DNA, chromosome 5, P1 clone: | Arabidopsis thaliana | 36,766 | 20-Nov-99 |
| MHK7, complete sequence. | ||||||||
| GB_EST17: AA615900 | 427 | AA615900 | vo91b05.r1 Barstead mouse irradiated colon MPLRB7 Mus musculus cDNA | Mus musculus | 39,782 | 07-OCT-1997 | ||
| clone IMAGE: 1066449 5′ similar to SW: MUCL_RAT P98089 INTESTINAL | ||||||||
| MUCIN-LIKE PROTEIN;, mRNA sequence. | ||||||||
| GB_EST38: AW039188 | 486 | AW039188 | EST281423 tomato mixed elicitor, BTI Lycopersicon esculentum cDNA | Lycopersicon esculentum | 41,286 | 18-OCT-1999 | ||
| clone cLET9F17, mRNA sequence. | ||||||||
| rxa00230 | 843 | GB_PR3: AC005255 | 94343 | AC005255 | Homo sapiens chromosome 19, CIT-HSP-146e8, complete sequence. | Homo sapiens | 35,990 | 6-Jul-98 |
| GB_PR3: AC005255 | 94343 | AC005255 | Homo sapiens chromosome 19, CIT-HSP-146e8, complete sequence. | Homo sapiens | 38,175 | 6-Jul-98 | ||
| rxa00232 | 633 | GB_HTG2: AC007118 | 200000 | AC007118 | Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 36,772 | 19-MAR-1999 |
| 45 unordered pieces. | ||||||||
| GB_HTG2: AC007118 | 200000 | AC007118 | Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 36,772 | 19-MAR-1999 | ||
| 45 unordered pieces. | ||||||||
| GB_GSS1: CNS004WZ | 978 | AL055537 | Drosophila melanogaster genome survey sequence TET3 end of BAC | Drosophila melanogaster | 34,518 | 3-Jun-99 | ||
| # BACR11G02 of RPCI-98 library from Drosophila melanogaster (fruit fly), | ||||||||
| genomic survey sequence. | ||||||||
| rxa00233 | 517 | GB_BA1: AB006206 | 7443 | AB006206 | Streptomyces griseus AmfR, AmfA and AmfB genes and 4 ORFs, complete cds. | Streptomyces griseus | 38,690 | 5-Feb-99 |
| GB_PR4: AC006999 | 112878 | AC006999 | Homo sapiens clone NH0462A19, complete sequence. | Homo sapiens | 40,244 | 17-Jul-99 | ||
| GB_HTG2: AC007042 | 132400 | AC007042 | Homo sapiens clone NH0399H17, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 40,244 | 06-MAR-1999 | ||
| 5 unordered pieces. | ||||||||
| rxa00234 | 663 | GB_PAT: E13059 | 3480 | E13059 | gDNA encoding cytochrome b5. | unidentified | 40,091 | 24-Jun-98 |
| GB_PL1: AB022444 | 2104 | AB022444 | Mortierella alpina gene for cytochrome b5, complete cds. | Mortierella alpina | 42,314 | 14-Jul-99 | ||
| GB_GSS9: AQ112619 | 443 | AQ112619 | CIT-HSP-2371D11.TR CIT-HSP Homo sapiens genomic clone 2371D11, | Homo sapiens | 39,623 | 29-Aug-98 | ||
| genomic survey sequence. | ||||||||
| rxa00236 | 849 | GB_BA1: CGPROMF34 | 60 | X90361 | C. glutamicum DNA for promoter fragment F34. | Corynebacterium | 98,333 | 4-Nov-96 |
| glutamicum | ||||||||
| GB_IN1: CEF56G4 | 38062 | Z81552 | Caenorhabditis elegans cosmid F56G4, complete sequence. | Caenorhabditis elegans | 36,190 | 08-OCT-1999 | ||
| GB_EST16: C51159 | 370 | C51159 | C51159 Yuji Kohara unpublished cDNA: Strain N2 hermaphrodite embryo | Caenorhabditis elegans | 41,096 | 18-OCT-1999 | ||
| Caenorhabditis elegans cDNA clone yk491h3 5′, mRNA sequence. | ||||||||
| rxa00237 | 501 | GB_GSS9: AQ148605 | 511 | AQ148605 | HS_3137_B2_A11_T7 CIT Approved Human Genomic Sperm Library D | Homo sapiens | 37,959 | 08-OCT-1998 |
| Homo sapiens genomic clone Plate = 3137 Col = 22 Row = B, | ||||||||
| genomic survey sequence. | ||||||||
| GB_GSS11: AQ274889 | 622 | AQ274889 | RPCI-5-1111N8T7 RPCI-5 Homo sapiens genomic clone RPCI-5-1111N8T7, | Homo sapiens | 44,628 | 10-Nov-98 | ||
| genomic survey sequence. | ||||||||
| GB_GSS11: AQ274889 | 622 | AQ274889 | RPCI-5-1111N8T7 RPCI-5 Homo sapiens genomic clone RPCI-5-1111N8T7, | Homo sapiens | 37,321 | 10-Nov-98 | ||
| genomic survey sequence. | ||||||||
| rxa00238 | 492 | GB_PL2: PBU91560 | 2605 | U91560 | Paracoccidioides brasiliensis heat shock protein 70 (Hsp70) gene, complete cds. | Paracoccidioides | 37,137 | 12-MAR-1999 |
| brasiliensis | ||||||||
| GB_HTG6: AC007957 | 212658 | AC007957 | Homo sapiens , *** SEQUENCING IN PROGRESS ***, 2 ordered pieces. | Homo sapiens | 38,285 | 26-Nov-99 | ||
| GB_PR4: AC009288 | 140876 | AC009288 | Homo sapiens , complete sequence. | Homo sapiens | 36,575 | 19-Nov-99 | ||
| rxa00239 | 708 | GB_PL2: PBU91560 | 2605 | U91560 | Paracoccidioides brasiliensis heat shock protein 70 (Hsp70) gene, complete cds. | Paracoccidioides | 45,545 | 12-MAR-1999 |
| brasiliensis | ||||||||
| GB_BA2: CJU96452 | 1450 | U96452 | Campylobacter jejuni major outer membrane porin gene, complete cds. | Campylobacter jejuni | 37,197 | 02-DEC-1998 | ||
| GB_RO: RATPF4 | 1675 | M15254 | Rat platelet factor 4 (PF4) gene. | Rattus norvegicus | 35,014 | 27-Apr-93 | ||
| rxa00240 | 333 | GB_BA1: CGLYSI | 4232 | X60312 | C. glutamicum lysI gene for L-lysine permease. | Corynebacterium | 46,207 | 30-Jan-92 |
| glutamicum | ||||||||
| GB_PR3: AC005358 | 184886 | AC005358 | Homo sapiens chromosome 17, clone hRPK.746_E_8, complete sequence. | Homo sapiens | 35,843 | 29-Aug-98 | ||
| GB_BA1: CGLYSI | 4232 | X60312 | C. glutamicum lysI gene for L-lysine permease. | Corynebacterium | 42,025 | 30-Jan-92 | ||
| glutamicum | ||||||||
| rxa00242 | 1401 | GB_BA1: CGLYSI | 4232 | X60312 | C. glutamicum lysI gene for L-lysine permease. | Corynebacterium | 100,000 | 30-Jan-92 |
| glutamicum | ||||||||
| GB_PR3: HSJ514B11 | 100494 | AL049554 | Human DNA sequence from clone 514B11 on chromosome 6q16.1-21 Contains | Homo sapiens | 37,010 | 23-Nov-99 | ||
| an EST, STSs and GSSs, complete sequence. | ||||||||
| GB_HTG3: AC009393 | 137353 | AC009393 | Drosophila melanogaster chromosome 3 clone BACR17F05 (D977) RPCI-98 | Drosophila melanogaster | 39,600 | 27-Aug-99 | ||
| 17.F.5 map 87D-87D strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 111 unordered pieces. | ||||||||
| rxa00244 | 759 | GB_HTG4: AC011290 | 148409 | AC011290 | Homo sapiens clone NH0064I02, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 38,102 | 15-OCT-1999 |
| 3 unordered pieces. | ||||||||
| GB_HTG4: AC011290 | 148409 | AC011290 | Homo sapiens clone NH0064I02, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 38,102 | 15-OCT-1999 | ||
| 3 unordered pieces. | ||||||||
| GB_EST23: AI077162 | 527 | AI077162 | TENU3384 T. cruzi epimastigote normalized cDNA Library Trypanosoma cruzi cDNA | Trypanosoma cruzi | 38,847 | 10-Aug-98 | ||
| clone 28o6 5′ similar to TRANSPLANTATION ANTIGEN P35B | ||||||||
| sp|P23591 |TUM3_MOUSE, mRNA sequence. | ||||||||
| rxa00245 | 1608 | GB_HTG2: AC007644 | 141048 | AC007644 | Homo sapiens chromosome 17 clone hRPK.19_F_16 map 17, *** SEQUENCING | Homo sapiens | 36,929 | 23-MAY-1999 |
| IN PROGRESS ***, 17 unordered pieces. | ||||||||
| GB_HTG2: AC007644 | 141048 | AC007644 | Homo sapiens chromosome 17 clone hRPK.19_F_16 map 17, *** SEQUENCING | Homo sapiens | 36,929 | 23-MAY-1999 | ||
| IN PROGRESS ***, 17 unordered pieces. | ||||||||
| GB_HTG2: AC007644 | 141048 | AC007644 | Homo sapiens chromosome 17 clone hRPK.19_F_16 map 17, *** SEQUENCING | Homo sapiens | 34,025 | 23-MAY-1999 | ||
| IN PROGRESS ***, 17 unordered pieces. | ||||||||
| rxa00247 | 1050 | GB_PR2: AP000119 | 100000 | AP000119 | Homo sapiens genomic DNA of 21q22.1, GART and AML related, | Homo sapiens | 36,187 | 25-Sep-99 |
| SLC5A3-f4A4 region, segment 2/8, complete sequence. | ||||||||
| GB_PR2: AP000051 | 100000 | AP000051 | Homo sapiens genomic DNA, chromosome 21q22.1, segment | Homo sapiens | 36,187 | 20-Nov-99 | ||
| 22/28, complete sequence. | ||||||||
| GB_PR2: AP000166 | 100000 | AP000166 | Homo sapiens genomic DNA, chromosome 21q22.1, D21S226-AML region, | Homo sapiens | 37,942 | 20-Nov-99 | ||
| clone B2344F14-f50E8, segment 2/9, complete sequence. | ||||||||
| rxa00248 | 846 | GB_PR4: AC006464 | 99908 | AC006464 | Homo sapiens BAC clone NH0436C12 from 2, complete sequence. | Homo sapiens | 36,797 | 22-OCT-1999 |
| GB_PR4: AC006238 | 211945 | AC006238 | Homo sapiens chromosome 18, clone hRPK.474_N_24, complete sequence. | Homo sapiens | 32,896 | 31-Jan-99 | ||
| GB_PR4: AC006238 | 211945 | AC006238 | Homo sapiens chromosome 18, clone hRPK.474_N_24, complete sequence. | Homo sapiens | 34,438 | 31-Jan-99 | ||
| rxa00250 | 870 | GB_GSS10: AQ244736 | 469 | AQ244736 | HS_2056_B1_F03_T7 CIT Approved Human Genomic Sperm Library D | Homo sapiens | 36,310 | 03-OCT-1998 |
| Homo sapiens genomic clone Plate = 2056 Col = 5 Row = L, | ||||||||
| genomic survey sequence. | ||||||||
| GB_PAT: I07323 | 340 | I07323 | Sequence 5 from Patent EP 0331961. | Unknown. | 38,125 | 02-DEC-1994 | ||
| GB_PR1: HS11Q13RP | 10777 | Y12377 | H. sapiens FGF/int-2 gene upstream flanking region. | Homo sapiens | 36,155 | 17-Apr-97 | ||
| rxa00252 | 366 | GB_BA1: MTCY20G9 | 37218 | Z77162 | Mycobacterium tuberculosis H37Rv complete genome; segment 25/162. | Mycobacterium | 39,554 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_BA1: MTV004 | 69350 | AL009198 | Mycobacterium tuberculosis H37Rv complete genome; segment 144/162. | Mycobacterium | 40,443 | 18-Jun-98 | ||
| tuberculosis | ||||||||
| GB_BA1: MTV004 | 69350 | AL009198 | Mycobacterium tuberculosis H37Rv complete genome; segment 144/162. | Mycobacterium | 41,803 | 18-Jun-98 | ||
| tuberculosis | ||||||||
| rxa00256 | 894 | GB_PR4: AC005343 | 137213 | AC005343 | Homo sapiens Chromosome 12p13.3 BAC RPCI11-21K20 (Roswell Park | Homo sapiens | 36,436 | 2-Apr-99 |
| Cancer Institute Human BAC Library) complete sequence. | ||||||||
| GB_PR3: AC003005 | 45084 | AC003005 | Human DNA from chromosome 19-specific cosmid F25419 containing ZNF | Homo sapiens | 36,395 | 22-OCT-1997 | ||
| gene family members, genomic sequence, complete sequence. | ||||||||
| GB_HTG3: AC007930 | 67668 | AC007930 | Drosophila melanogaster chromosome 2 clone BACR49A06 (D772) RPCI-98 | Drosophila melanogaster | 32,503 | 20-Sep-99 | ||
| 49.A.6 map 43B-43B strain y; cn bw sp, *** SEQUENCING IN PROGRESS***, | ||||||||
| 40 unordered pieces. | ||||||||
| rxa00257 | 579 | GB_PR4: AC005343 | 137213 | AC005343 | Homo sapiens Chromosome 12p13.3 BAC | Homo sapiens | 37,063 | 2-Apr-99 |
| RPCI11-21K20 (Roswell Park Cancer Institute Human | ||||||||
| BAC Library) complete sequence. | ||||||||
| GB_HTG1: HS1096J16 | 194423 | AL121721 | Homo sapiens chromosome 20 clone | Homo sapiens | 37,217 | 23-Nov-99 | ||
| RP5-1096J16, *** SEQUENCING IN PROGRESS ***, in | ||||||||
| unordered pieces. | ||||||||
| GB_HTG1: HS1096J16 | 194423 | AL121721 | Homo sapiens chromosome 20 clone | Homo sapiens | 37,217 | 23-Nov-99 | ||
| RP5-1096J16, *** SEQUENCING IN PROGRESS ***, in | ||||||||
| unordered pieces. | ||||||||
| rxa00258 | 795 | GB_PR3: HSJ747H23 | 114201 | AL049699 | Human DNA sequence from clone 747H23 | Homo sapiens | 36,469 | 23-Nov-99 |
| on chromosome 6q13-15. Contains the 3′ part of the | ||||||||
| ME1 gene for malic enzyme 1, soluble (NADP-dependent | ||||||||
| malic enzyme, malate oxidoreductase, EC | ||||||||
| 1.1.1.40), a novel gene and the 5′ part of the | ||||||||
| gene for N-acetylglucosamine-phosphate mutase. | ||||||||
| Contains ESTs, STSs, GSSs and two putative CpG islands, | ||||||||
| complete sequence. | ||||||||
| GB_HTG2: HSJ202D23 | 175496 | AL121716 | Homo sapiens chromosome 6 clone RP1-202D23 | Homo sapiens | 36,469 | 03-DEC-1999 | ||
| map q14.1-15, *** SEQUENCING IN PROGRESS | ||||||||
| ***, in unordered pieces. | ||||||||
| GB_HTG2: HSJ202D23 | 175496 | AL121716 | Homo sapiens chromosome 6 clone RP1-202D23 map | Homo sapiens | 36,469 | 03-DEC-1999 | ||
| q14.1-15, *** SEQUENCING IN PROGRESS | ||||||||
| ***, in unordered pieces. | ||||||||
| rxa00260 | 1299 | GB_PR3: HS360B4 | 23388 | AL031716 | Human DNA sequence from clone 360B4 on | Homo sapiens | 36,145 | 23-Nov-99 |
| chromosome 16. Contains part of a gene for a | ||||||||
| PUTATIVE novel protein similar to predicted bacterial and | ||||||||
| worm proteins and ESTs, complete sequence. | ||||||||
| GB_EST19: AA741904 | 423 | AA741904 | LmLv39p3/71A Leishmania major promastigote full | Leishmania major | 39,192 | 10-DEC-1998 | ||
| length cDNA library from early logarithmic stage | ||||||||
| (day 3) Leishmania major cDNA clone 71A 5′, mRNA sequence. | ||||||||
| GB_PR3: HS360B4 | 23388 | AL031716 | Human DNA sequence from clone 360B4 on | Homo sapiens | 39,494 | 23-Nov-99 | ||
| chromosome 16. Contains part of a gene for a | ||||||||
| PUTATIVE novel protein similar to predicted bacterial and | ||||||||
| worm proteins and ESTs, complete sequence. | ||||||||
| rxa00264 | ||||||||
| rxa00267 | 441 | GB_GSS10: AQ258013 | 761 | AQ258013 | nbxb0019H05f CUGI Rice BAC Library Oryza sativa genomic clone | Oryza sativa | 52,033 | 23-OCT-1998 |
| nbxb0019H05f, genomic survey sequence. | ||||||||
| GB_EST10: AA167894 | 552 | AA167894 | CpEST.021 uniZAPCpIOWAsporoLib1 | Cryptosporidium parvum | 40,462 | 19-DEC-1996 | ||
| Cryptosporidium parvum cDNA 5′ similar to lactate | ||||||||
| dehydrogenase, mRNA sequence. | ||||||||
| GB_HTG3: AC011591 | 129431 | AC011591 | Homo sapiens chromosome 17 clone 118_B_18 | Homo sapiens | 35,469 | 07-OCT-1999 | ||
| map 17, *** SEQUENCING IN PROGRESS ***, 25 | ||||||||
| unordered pieces. | ||||||||
| rxa00271 | 1113 | GB_PL1: CHTRP1 | 3480 | X70035 | C. heterostrophus gene for trifunctional tryptophan synthase. | Cochliobolus | 41,636 | 31-OCT-1996 |
| heterostrophus | ||||||||
| GB_VI: FLU47643 | 1492 | U47643 | Feline leukemia virus Notch2 gene, | Feline leukemia virus | 37,869 | 25-OCT-1996 | ||
| clone FeLV/Notch2-AP (subgenomic), partial cds. | ||||||||
| GB_VI: FLU47644 | 1641 | U47644 | Feline leukemia virus Notch2 gene, | Feline leukemia virus | 36,441 | 25-OCT-1996 | ||
| clone FeLV/Notch2-B, partial cds. | ||||||||
| rxa00272 | 495 | GB_GSS8: AQ041841 | 373 | AQ041841 | CIT-HSP-2335L1.TR CIT-HSP Homo sapiens genomic | Homo sapiens | 45,455 | 14-Jul-98 |
| clone 2335L1, genomic survey sequence. | ||||||||
| GB_GSS13: AQ429301 | 591 | AQ429301 | CITBI-E1-2562H16.TR CITBI-E1 Homo sapiens genomic | Homo sapiens | 63,636 | 24-MAR-1999 | ||
| clone 2562H16, genomic survey sequence. | ||||||||
| GB_GSS10: AQ237541 | 667 | AQ237541 | RPCI11-61O21.TJB.1 RPCI-11 Homo sapiens genomic | Homo sapiens | 62,222 | 21-Apr-99 | ||
| clone RPCI-11-61O21, genomic survey sequence. | ||||||||
| rxa00273 | 1236 | GB_BA1: CGBETPGEN | 2339 | X93514 | C. glutamicum betP gene. | Corynebacterium | 44,056 | 8-Sep-97 |
| glutamicum | ||||||||
| GB_PR2: HS142F18 | 141672 | AL031073 | Human DNA sequence from clone 142F18 on chromosome | Homo sapiens | 44,643 | 23-Nov-99 | ||
| Xq26.3-27.2 Contains part of a gene | ||||||||
| similar to melanoma-associated antigen, EST, | ||||||||
| GSS and an inverted repeat, complete sequence. | ||||||||
| GB_IN2: AC007177 | 101320 | AC007177 | Drosophila melanogaster , chromosome 2R, | Drosophila melanogaster | 36,721 | 27-MAR-1999 | ||
| region 59C1-59C5, P1 clones DS06621 and DS02186, | ||||||||
| complete sequence. | ||||||||
| rxa00274 | 2733 | GB_HTG3: AC011675 | 98026 | AC011675 | Homo sapiens clone 10_J_17, | Homo sapiens | 35,405 | 10-OCT-1999 |
| LOW-PASS SEQUENCE SAMPLING. | ||||||||
| GB_HTG3: AC011675 | 98026 | AC011675 | Homo sapiens clone 10_J_17, | Homo sapiens | 35,405 | 10-OCT-1999 | ||
| LOW-PASS SEQUENCE SAMPLING. | ||||||||
| GB_HTG3: AC010598 | 174019 | AC010598 | Homo sapiens chromosome 5 clone CIT-HSPC_560O9, | Homo sapiens | 36,908 | 16-Sep-99 | ||
| *** SEQUENCING IN PROGRESS ***, 50 | ||||||||
| unordered pieces. | ||||||||
| rxa00275 | 582 | GB_GSS14: AQ574926 | 666 | AQ574926 | nbxb0086K14f CUGI Rice BAC Library Oryza sativa genomic | Oryza sativa | 33,830 | 2-Jun-99 |
| clone nbxb0086K14f, genomic survey sequence. | ||||||||
| GB_HTG2: AC004396 | 43686 | AC004396 | Homo sapiens , | Homo sapiens | 38,298 | 19-Jul-99 | ||
| *** SEQUENCING IN PROGRESS ***, 2 unordered pieces. | ||||||||
| GB_HTG2: AC004396 | 43686 | AC004396 | Homo sapiens , | Homo sapiens | 38,298 | 19-Jul-99 | ||
| *** SEQUENCING IN PROGRESS ***, 2 unordered pieces. | ||||||||
| rxa00276 | 465 | GB_PL1: SC9952X | 29286 | Z49212 | S. cerevisiae chromosome XIII cosmid 9952. | Saccharomyces cerevisiae | 37,118 | 11-Aug-97 |
| GB_PL1: S45357 | 4017 | S45357 | PSE-1 = protein secretion enhancer | Saccharomyces cerevisiae | 41,394 | 08-MAY-1993 | ||
| [ Saccharomyces cerevisiae , Genomic, 4017 nt]. | ||||||||
| GB_PL1: SCPSE1G | 4017 | Z11538 | S. cerevisiae PSE-1 gene. | Saccharomyces cerevisiae | 41,394 | 13-Aug-96 | ||
| rxa00279 | 1509 | GB_HTG3: AC009911 | 99707 | AC009911 | Drosophila melanogaster chromosome 2 | Drosophila melanogaster | 33,023 | 05-OCT-1999 |
| clone BACR01N17 (D1036) RPCI-98 01.N.17 map 38A-38A | ||||||||
| strain y; cn bw sp, *** SEQUENCING IN PROGRESS | ||||||||
| ***, 69 unordered pieces. | ||||||||
| GB_HTG3: AC009911 | 99707 | AC009911 | Drosophila melanogaster chromosome 2 clone BACR01N17 | Drosophila melanogaster | 33,023 | 05-OCT-1999 | ||
| (D1036) RPCI-98 01.N.17 map 38A-38A | ||||||||
| strain y; cn bw sp, *** SEQUENCING IN | ||||||||
| PROGRESS ***, 69 unordered pieces. | ||||||||
| GB_HTG4: AC008397 | 230451 | AC008397 | Homo sapiens chromosome 19 clone CIT-HSPC_251H24, | Homo sapiens | 37,432 | 31-OCT-1999 | ||
| *** SEQUENCING IN PROGRESS ***, | ||||||||
| 81 unordered pieces. | ||||||||
| rxa00282 | 889 | GB_PR3: HSB11B7 | 37290 | Z82171 | Human DNA sequence from cosmid B11B7 on | Homo sapiens | 35,845 | 23-Nov-99 |
| chromosome 22 contains ESTs. | ||||||||
| GB_PR3: HSB11B7 | 37290 | Z82171 | Human DNA sequence from cosmid B11B7 on chromosome 22 contains ESTs. | Homo sapiens | 37,126 | 23-Nov-99 | ||
| GB_RO: RATMTA | 4197 | L39264 | Rattus norvegicus beta-2 adrenergic receptor gene, | Rattus norvegicus | 41,259 | 23-Feb-96 | ||
| complete cds and promoter region. | ||||||||
| rxa00283 | 1155 | GB_GSS8: AQ030327 | 411 | AQ030327 | HS_2177_B1_H06_MF CIT Approved Human | Homo sapiens | 37,656 | 1-Jul-98 |
| Genomic Sperm Library D Homo sapiens genomic | ||||||||
| clone Plate = 2177 Col = 11 Row = P, | ||||||||
| genomic survey sequence. | ||||||||
| GB_PR3: HSL118GB | 27858 | Z68883 | Human DNA sequence from cosmid L118G10, Huntington's | Homo sapiens | 37,412 | 23-Nov-99 | ||
| Disease Region, chromosome 4p16.3. | ||||||||
| GB_PR3: HSJ513G18 | 110770 | AL109760 | Human DNA sequence from clone 513G18 on chromosome 4, complete sequence. | Homo sapiens | 37,412 | 23-Nov-99 | ||
| rxa00286 | 687 | GB_EST10: AA157040 | 414 | AA157040 | zo51c05.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA | Homo sapiens | 37,136 | 11-DEC-1996 |
| clone IMAGE: 590408 5′ similar to gb: M84711 | ||||||||
| 40S RIBOSOMAL PROTEIN S3A (HUMAN);, mRNA sequence. | ||||||||
| GB_EST11: AA213935 | 629 | AA213935 | zn57a04.r1 Stratagene muscle 937209 Homo sapiens cDNA | Homo sapiens | 34,219 | 1-Aug-97 | ||
| clone IMAGE: 562254 5′ similar to | ||||||||
| gb: M84711 40S RIBOSOMAL PROTEIN S3A (HUMAN);, mRNA sequence. | ||||||||
| GB_STS: BLYBG | 459 | L43987 | Hordeum vulgare (clone ABG380) chromosome 4H, 6H, | Hordeum vulgare | 37,786 | 27-Jul-95 | ||
| 7H STS mRNA, sequence tagged site. | ||||||||
| rxa00294 | 552 | GB_PR2: HSAC000121 | 93163 | AC000121 | Human BAC clone RG249A12 from 7q22, complete sequence. | Homo sapiens | 36,735 | 31-Jan-97 |
| GB_BA2: CGU31281 | 1614 | U31281 | Corynebacterium glutamicum biotin synthase (bioB) gene, complete cds. | Corynebacterium | 100,000 | 21-Nov-96 | ||
| glutamicum | ||||||||
| GB_PR2: HSAC000121 | 93163 | AC000121 | Human BAC clone RG249A12 from 7q22, complete sequence. | Homo sapiens | 37,662 | 31-Jan-97 | ||
| rxa00297 | 1035 | GB_HTG2: AC006938 | 82665 | AC006938 | Drosophila melanogaster chromosome 2 clone DS01630 | Drosophila melanogaster | 37,241 | 2-Aug-99 |
| (D506) map 60C7-60C8 strain y; cn bw sp, | ||||||||
| *** SEQUENCING IN PROGRESS ***, 9 unordered pieces. | ||||||||
| GB_HTG2: AC007116 | 25478 | AC007116 | Drosophila melanogaster chromosome 2 clone DS04467 (D447) | Drosophila melanogaster | 38,630 | 30-Jul-99 | ||
| map 60C6-60C8 strain y; cn bw sp, | ||||||||
| *** SEQUENCING IN PROGRESS ***, 5 unordered pieces. | ||||||||
| GB_HTG2: AC006938 | 82665 | AC006938 | Drosophila melanogaster chromosome 2 clone DS01630 (D506) | Drosophila melanogaster | 37,241 | 2-Aug-99 | ||
| map 60C7-60C8 strain y; cn bw sp, | ||||||||
| *** SEQUENCING IN PROGRESS ***, 9 unordered pieces. | ||||||||
| rxa00320 | 303 | GB_GSS14: AQ585202 | 564 | AQ585202 | RPCI-11-451L11.TJ RPCI-11 Homo sapiens genomic | Homo sapiens | 37,319 | 7-Jun-99 |
| clone RPCI-11-451L11, genomic survey | ||||||||
| sequence. | ||||||||
| GB_BA1: NGPILC1 | 3144 | Y13022 | N. gonorrhoeae pilC1 gene, strain 640. | Neisseria gonorrhoeae | 38,667 | 07-OCT-1997 | ||
| GB_BA1: NGPILC1 | 3144 | Y13022 | N. gonorrhoeae pilC1 gene, strain 640. | Neisseria gonorrhoeae | 36,000 | 07-OCT-1997 | ||
| rxa00321 | ||||||||
| rxa00322 | 1227 | GB_HTG2: AC007533 | 153053 | AC007533 | Homo sapiens chromosome 16 clone 474B12, | Homo sapiens | 39,469 | 12-MAY-1999 |
| *** SEQUENCING IN PROGRESS ***, 5 ordered | ||||||||
| pieces. | ||||||||
| GB_HTG2: AC007533 | 153053 | AC007533 | Homo sapiens chromosome 16 clone 474B12, | Homo sapiens | 39,469 | 12-MAY-1999 | ||
| *** SEQUENCING IN PROGRESS ***, 5 ordered | ||||||||
| pieces. | ||||||||
| GB_PR2: HUM133K23 | 82512 | AC000061 | Human BAC clone 133K23 from 7q31.2, complete sequence. | Homo sapiens | 38,950 | 14-Nov-96 | ||
| rxa00325 | 768 | GB_BA2: CDU73860 | 1273 | U73860 | Corynebacterium diphtheriae heme oxygenase | Corynebacterium | 52,604 | 7-Feb-97 |
| homolog (hmuO) gene, complete cds. | ||||||||
| diphtheriae | ||||||||
| GB_BA1: AB019621 | 652 | AB019621 | Corynebacterium diphtheriae mRNA for Heme oxygenase, complete cds. | Corynebacterium | 55,675 | 31-Jul-99 | ||
| diphtheriae | ||||||||
| GB_EST23: AI096171 | 554 | AI096171 | 28 EcoRI Rice Etiolated Leaf cDNA Library | Oryza sativa | 38,536 | 19-Aug-98 | ||
| Oryza sativa cDNA clone RZ513, mRNA sequence. | ||||||||
| rxa00326 | 603 | GB_PH: MYP4CG | 11624 | X51522 | Bacteriophage P4 complete DNA genome. | Bacteriophage P4 | 40,577 | 17-Feb-97 |
| GB_PH: MYP4ALPH | 3063 | X05623 | Bacteriophage P4 alpha gene and cis replication region crr. | Bacteriophage P4 | 38,640 | 12-Sep-93 | ||
| GB_IN1: CEF22B3 | 30480 | Z68336 | Caenorhabditis elegans cosmid F22B3, complete sequence. | Caenorhabditis elegans | 39,012 | 2-Sep-99 | ||
| rxa00334 | 459 | GB_BA1: CGGLNA | 3686 | Y13221 | Corynebacterium glutamicum glnA gene. | Corynebacterium | 37,640 | 28-Aug-97 |
| glutamicum | ||||||||
| GB_GSS10: AQ248516 | 259 | AQ248516 | T5J22-Sp6 TAMU Arabidopsis thaliana genomic | Arabidopsis thaliana | 38,525 | 06-OCT-1998 | ||
| clone T5J22, genomic survey sequence. | ||||||||
| GB_BA1: CGGLNA | 3686 | Y13221 | Corynebacterium glutamicum glnA gene. | Corynebacterium | 40,487 | 28-Aug-97 | ||
| glutamicum | ||||||||
| rxa00336 | 594 | GB_BA1: CGGLNA | 3686 | Y13221 | Corynebacterium glutamicum glnA gene. | Corynebacterium | 34,797 | 28-Aug-97 |
| glutamicum | ||||||||
| GB_OV: XLFIMB1GN | 7026 | X95549 | X. laevis FIM-B.1 gene. | Xenopus laevis | 33,217 | 13-Feb-97 | ||
| GB_BA1: CGGLNA | 3686 | Y13221 | Corynebacterium glutamicum glnA gene. | Corynebacterium | 37,371 | 28-Aug-97 | ||
| glutamicum | ||||||||
| rxa00337 | 1173 | GB_BA1: CGU43536 | 3464 | U43536 | Corynebacterium glutamicum heat shock, ATP-binding | Corynebacterium | 36,406 | 13-MAR-1997 |
| protein (clpB) gene, complete cds. | ||||||||
| glutamicum | ||||||||
| GB_BA1: CGAJ4934 | 1160 | AJ004934 | Corynebacterium glutamicum dapD gene, complete CDS. | Corynebacterium | 39,734 | 17-Jun-98 | ||
| glutamicum | ||||||||
| GB_EST37: AI944838 | 396 | AI944838 | bs06a08.y1 Drosophila melanogaster adult testis | Drosophila melanogaster | 37,626 | 17-Aug-99 | ||
| library Drosophila melanogaster cDNA clone | ||||||||
| bs06a08 5′, mRNA sequence. | ||||||||
| rxa00338 | 1263 | GB_BA1: BLTRP | 7725 | X04960 | Brevibacterium lactofermentum tryptophan operon. | Corynebacterium | 39,790 | 10-Feb-99 |
| glutamicum | ||||||||
| GB_PAT: E01688 | 7725 | E01688 | Genomic DNA of trp operon of prepibacterium latophelmentamn. | unidentified | 39,871 | 29-Sep-97 | ||
| GB_PAT: E01375 | 7726 | E01375 | DNA sequence of tryptophan operon. | Corynebacterium | 39,871 | 29-Sep-97 | ||
| glutamicum | ||||||||
| rxa00339 | 840 | GB_VI: OPU75930 | 131993 | U75930 | Orgyia pseudotsugata nuclear polyhedrosis virus complete genome. | Orgyia pseudotsugata | 38,264 | 06-MAR-1998 |
| nuclear polyhedrosis virus | ||||||||
| GB_VI: OPU75930 | 131993 | U75930 | Orgyia pseudotsugata nuclear polyhedrosis virus complete genome. | Orgyia pseudotsugata | 38,620 | 06-MAR-1998 | ||
| nuclear polyhedrosis virus | ||||||||
| GB_HTG3: AC008340 | 126593 | AC008340 | Drosophila melanogaster chromosome 2 clone BACR07J20 | Drosophila melanogaster | 38,193 | 6-Aug-99 | ||
| (D918) RPCI-98 07.J.20 map 42D-42E | ||||||||
| strain y; cn bw sp, *** SEQUENCING IN | ||||||||
| PROGRESS ***, 92 unordered pieces. | ||||||||
| rxa00342 | 552 | GB_EST34: AI794353 | 636 | AI794353 | fc43d12.y1 Zebrafish WashU MPIMG EST Danio rerio cDNA | Danio rerio | 40,283 | 2-Jul-99 |
| 5′ similar to TR: Q62868 Q62868 ROK- | ||||||||
| ALPHA.;, mRNA sequence. | ||||||||
| GB_PR2: U73635 | 33676 | U73635 | Human Chromosome 11 Cosmid cSRL156b6, complete sequence. | Homo sapiens | 39,366 | 25-Jul-97 | ||
| GB_PR2: U73635 | 33676 | U73635 | Human Chromosome 11 Cosmid cSRL156b6, complete sequence. | Homo sapiens | 37,970 | 25-Jul-97 | ||
| rxa00344 | 1002 | GB_HTG2: HS312E8 | 33595 | AL032819 | Homo sapiens chromosome 16 clone LA16-312E8, | Homo sapiens | 40,415 | 03-DEC-1999 |
| *** SEQUENCING IN PROGRESS ***, in | ||||||||
| unordered pieces. | ||||||||
| GB_HTG2: HS312E8 | 33595 | AL032819 | Homo sapiens chromosome 16 clone LA16-312E8, | Homo sapiens | 40,415 | 03-DEC-1999 | ||
| *** SEQUENCING IN PROGRESS ***, in | ||||||||
| unordered pieces. | ||||||||
| GB_OM: BOVINOPHOS | 1573 | M55916 | Bovine inositol polyphosphate 1-phosphatase | Bos taurus | 38,420 | 27-Apr-93 | ||
| (inositol polyphosphate 1-phosphatase gene) mRNA, | ||||||||
| complete cds. | ||||||||
| rxa00349 | 1590 | GB_PR3: HS353E16 | 189765 | AL031591 | Human DNA sequence from clone 353E16 on | Homo sapiens | 34,766 | 23-Nov-99 |
| chromosome 22q11.22-12.3, complete sequence. | ||||||||
| GB_HTG2: AC005059 | 170128 | AC005059 | Homo sapiens clone RG074A24, *** SEQUENCING | Homo sapiens | 37,011 | 13-MAR-1999 | ||
| IN PROGRESS ***, 25 unordered pieces. | ||||||||
| GB_HTG2: AC005059 | 170128 | AC005059 | Homo sapiens clone RG074A24, | Homo sapiens | 37,011 | 13-MAR-1999 | ||
| *** SEQUENCING IN PROGRESS ***, 25 unordered pieces. | ||||||||
| rxa00353 | 816 | GB_BA1: D87976 | 2352 | D87976 | Brevibacterium lactofermentum DNA for D-2-hydroxyisocaproate | Corynebacterium | 39,290 | 7-Feb-99 |
| dehydrogenase (ddh), complete cds. | glutamicum | |||||||
| GB_BA1: CGDDH | 1829 | Y00151 | Corynebacterium glutamicum ddh gene for | Corynebacterium | 39,342 | 12-Sep-93 | ||
| meso-diaminopimelate D-dehydrogenase (EC 1.4.1.16). | glutamicum | |||||||
| GB_BA1: CGDDH | 1829 | Y00151 | Corynebacterium glutamicum ddh gene for | Corynebacterium | 38,624 | 12-Sep-93 | ||
| meso-diaminopimelate D-dehydrogenase (EC 1.4.1.16). | glutamicum | |||||||
| rxa00355 | 1143 | GB_BA1: CGDDH | 1829 | Y00151 | Corynebacterium glutamicum ddh gene for | Corynebacterium | 100,000 | 12-Sep-93 |
| meso-diaminopimelate D-dehydrogenase (EC 1.4.1.16). | glutamicum | |||||||
| GB_BA1: D87976 | 2352 | D87976 | Brevibacterium lactofermentum DNA for | Corynebacterium | 98,411 | 7-Feb-99 | ||
| D-2-hydroxyisocaproate dehydrogenase (ddh), complete cds. | glutamicum | |||||||
| GB_PAT: E14511 | 1034 | E14511 | DNA encoding Brevibacterium | Corynebacterium | 100,000 | 28-Jul-99 | ||
| diaminopimelic acid dehydrogenase. | glutamicum | |||||||
| rxa00362 | 1470 | GB_HTG4: AC009043 | 170748 | AC009043 | Homo sapiens chromosome 16 clone RPCI-11_184F14, | Homo sapiens | 37,337 | 31-OCT-1999 |
| *** SEQUENCING IN PROGRESS ***, 122 unordered pieces. | ||||||||
| GB_HTG4: AC009043 | 170748 | AC009043 | Homo sapiens chromosome 16 clone RPCI-11_184F14, | Homo sapiens | 37,337 | 31-OCT-1999 | ||
| *** SEQUENCING IN PROGRESS ***, 122 unordered pieces. | ||||||||
| GB_PR4: HSZO2TJP09 | 811 | AF177521 | Homo sapiens tight junction protein ZO-2 (TJP2) gene, exons 8 and 9. | Homo sapiens | 40,758 | 28-Sep-99 | ||
| rxa00373 | 439 | GB_PAT: AR004983 | 2277 | AR004983 | Sequence 5 from patent U.S. Pat. No. 5747317. | Unknown. | 41,638 | 04-DEC-1998 |
| GB_EST37: AI967505 | 380 | AI967505 | Ljirnpest03-215-c10 Ljirnp Lambda HybriZap two-hybrid library | Lotus japonicus | 45,882 | 24-Aug-99 | ||
| Lotus japonicus cDNA clone LP215-03-c10 5′ | ||||||||
| similar to 60S ribosomal protein L39, mRNA sequence. | ||||||||
| GB_EST27: AI399460 | 670 | AI399460 | NCSP4F6T7 Subtracted Perithecial Neurospora crassa cDNA | Neurospora crassa | 38,571 | 8-Feb-99 | ||
| clone SP4F6 3′, mRNA sequence. | ||||||||
| rxa00375 | 624 | GB_IN2: AC004445 | 61852 | AC004445 | Drosophila melanogaster DNA sequence | Drosophila melanogaster | 37,236 | 01-MAY-1998 |
| (P1 DS00445 (D93)), complete sequence. | ||||||||
| GB_HTG6: AC011694 | 160557 | AC011694 | Homo sapiens clone RP11-19D19, | Homo sapiens | 34,087 | 03-DEC-1999 | ||
| *** SEQUENCING IN PROGRESS ***, 33 unordered pieces. | ||||||||
| GB_HTG6: AC011694 | 160557 | AC011694 | Homo sapiens clone RP11-19D19, | Homo sapiens | 40,523 | 03-DEC-1999 | ||
| *** SEQUENCING IN PROGRESS ***, 33 unordered pieces. | ||||||||
| rxa00380 | 744 | GB_BA1: COXHSPAB | 2302 | M20482 | C. burnetii heat shock operon encoding two heat | Coxiella burnetii | 37,788 | 26-Apr-93 |
| shock proteins (htpA and htpB), complete cds. | ||||||||
| GB_RO: CBGPIMR | 1735 | Z37977 | C. barabensis (griseus) mRNA for glucose phosphate isomerase. | Cricetulus griseus | 37,823 | 14-Sep-95 | ||
| GB_GSS10: AQ172617 | 505 | AQ172617 | HS_3197_A2_G09_T7 CIT Approved Human Genomic | Homo sapiens | 37,580 | 17-OCT-1998 | ||
| Sperm Library D Homo sapiens genomic | ||||||||
| clone Plate = 3197 Col = 18 Row = M, genomic survey sequence. | ||||||||
| rxa00387 | 978 | GB_BA1: MTY25D10 | 40838 | Z95558 | Mycobacterium tuberculosis H37Rv | Mycobacterium | 60,477 | 17-Jun-98 |
| complete genome; segment 28/162. | tuberculosis | |||||||
| GB_BA1: MSGY224 | 40051 | AD000004 | Mycobacterium tuberculosis sequence from clone y224. | Mycobacterium | 60,270 | 03-DEC-1996 | ||
| tuberculosis | ||||||||
| GB_BA1: U00018 | 42991 | U00018 | Mycobacterium leprae cosmid B2168. | Mycobacterium leprae | 37,913 | 01-MAR-1994 | ||
| rxa00390 | 528 | GB_IN1: DMU29153 | 8230 | U29153 | Drosophila melanogaster nudel (ndl) mRNA, complete cds. | Drosophila melanogaster | 36,190 | 08-DEC-1995 |
| GB_IN1: DMU29153 | 8230 | U29153 | Drosophila melanogaster nudel (ndl) mRNA, complete cds. | Drosophila melanogaster | 37,202 | 08-DEC-1995 | ||
| rxa00392 | 987 | GB_IN2: AE001274 | 268984 | AE001274 | Leishmania major chromosome 1, complete sequence. | Leishmania major | 37,885 | 24-MAR-1999 |
| GB_EST11: AA270543 | 516 | AA270543 | va68h06.r1 Soares mouse 3NME12 5 | Mus musculus | 40,546 | 26-MAR-1997 | ||
| Mus musculus cDNA clone IMAGE: 736571 5′, mRNA sequence. | ||||||||
| GB_IN2: AE001274 | 268984 | AE001274 | Leishmania major chromosome 1, complete sequence. | Leishmania major | 36,103 | 24-MAR-1999 | ||
| rxa00394 | 456 | GB_GSS9: AQ158990 | 728 | AQ158990 | nbxb0012L11r CUGI Rice BAC Library Oryza sativa genomic | Oryza sativa | 41,463 | 12-Sep-98 |
| clone nbxb0012L11r, genomic survey sequence. | ||||||||
| GB_GSS12: AQ342952 | 761 | AQ342952 | RPCI11-122O15.TV RPCI-11 Homo sapiens genomic | Homo sapiens | 37,556 | 07-MAY-1999 | ||
| clone RPCI-11-122O15, genomic survey sequence. | ||||||||
| GB_GSS9: AQ158990 | 728 | AQ158990 | nbxb0012L11r CUGI Rice BAC Library Oryza sativa genomic | Oryza sativa | 37,923 | 12-Sep-98 | ||
| clone nbxb0012L11r, genomic survey sequence. | ||||||||
| rxa00395 | 423 | GB_PR2: HS1052M9 | 134245 | AL022718 | Human DNA sequence from clone 1052M9 on chromosome Xq25. | Homo sapiens | 43,564 | 23-Nov-99 |
| Contains the SH2D1A gene for | ||||||||
| SH2 domain protein 1A, Duncan's disease | ||||||||
| (lymphoproliferative syndrome) (DSHP), part of a 60S | ||||||||
| Acidic Ribosomal protein 1 (RPLP1) LIKE gene and | ||||||||
| part of a mouse DOC4 LIKE gene. Contains | ||||||||
| ESTs and GSSs, complete sequence. | ||||||||
| GB_BA2: RCPHSYNG | 45959 | Z11165 | R. capsulatus complete photosynthesis gene cluster. | Rhodobacter capsulatus | 36,930 | 2-Sep-99 | ||
| GB_PR2: HS1052M9 | 134245 | AL022718 | Human DNA sequence from clone 1052M9 on chromosome Xq25. | Homo sapiens | 33,981 | 23-Nov-99 | ||
| Contains the SH2D1A gene for | ||||||||
| SH2 domain protein 1A, Duncan's disease | ||||||||
| (lymphoproliferative syndrome) (DSHP), part of a 60S | ||||||||
| Acidic Ribosomal protein 1 (RPLP1) LIKE gene and | ||||||||
| part of a mouse DOC4 LIKE gene. Contains | ||||||||
| ESTs and GSSs, complete sequence. | ||||||||
| rxa00396 | 594 | GB_PL2: AC002311 | 85855 | AC002311 | Arabidopsis thaliana chromosome I BAC | Arabidopsis thaliana | 38,957 | 4-Feb-98 |
| T26J12 genomic sequence, complete sequence. | ||||||||
| GB_PL2: AC002311 | 85855 | AC002311 | Arabidopsis thaliana chromosome I BAC T26J12 | Arabidopsis thaliana | 36,300 | 4-Feb-98 | ||
| genomic sequence, complete sequence. | ||||||||
| rxa00397 | 924 | GB_PL1: HASMT | 27694 | D31785 | Hansenula wingei mitochondrial DNA, complete sequence. | Mitochondrion Pichia | 33,985 | 10-Jun-99 |
| canadensis | ||||||||
| GB_PL1: HASMT | 27694 | D31785 | Hansenula wingei mitochondrial DNA, complete sequence. | Mitochondrion Pichia | 33,775 | 10-Jun-99 | ||
| canadensis | ||||||||
| rxa00398 | 873 | GB_HTG1: CNS01DRT | 222150 | AL118557 | Homo sapiens chromosome 14 clone R-1033H12, | Homo sapiens | 35,417 | 25-Sep-99 |
| *** SEQUENCING IN PROGRESS ***, in ordered pieces. | ||||||||
| GB_HTG1: CNS01DRT | 222150 | AL118557 | Homo sapiens chromosome 14 clone R-1033H12, | Homo sapiens | 35,417 | 25-Sep-99 | ||
| *** SEQUENCING IN PROGRESS ***, in ordered pieces. | ||||||||
| GB_HTG1: CNS01DRT | 222150 | AL118557 | Homo sapiens chromosome 14 clone R-1033H12, | Homo sapiens | 38,005 | 25-Sep-99 | ||
| *** SEQUENCING IN PROGRESS ***, in ordered pieces. | ||||||||
| rxa00399 | 438 | GB_IN1: CELC32B5 | 42545 | U80843 | Caenorhabditis elegans cosmid C32B5. | Caenorhabditis elegans | 36,468 | 05-DEC-1996 |
| GB_IN1: CELC32B5 | 42545 | U80843 | Caenorhabditis elegans cosmid C32B5. | Caenorhabditis elegans | 40,000 | 05-DEC-1996 | ||
| rxa00408 | 570 | GB_PR4: AC005940 | 158414 | AC005940 | Homo sapiens chromosome 17, clone | Homo sapiens | 35,219 | 18-MAR-1999 |
| hRPK.167_N_20, complete sequence. | ||||||||
| GB_PR1: HSSERCA11 | 3050 | Y15726 | Homo sapiens SERCA3 gene, exons 11-14. | Homo sapiens | 35,036 | 30-Jun-98 | ||
| GB_PR4: AC005940 | 158414 | AC005940 | Homo sapiens chromosome 17, clone | Homo sapiens | 36,926 | 18-MAR-1999 | ||
| hRPK.167_N_20, complete sequence. | ||||||||
| rxa00409 | 1536 | GB_PR1: HSSERCA11 | 3050 | Y15726 | Homo sapiens SERCA3 gene, exons 11-14. | Homo sapiens | 38,555 | 30-Jun-98 |
| GB_PR4: AC005940 | 158414 | AC005940 | Homo sapiens chromosome 17, clone hRPK.167_N_20, complete sequence. | Homo sapiens | 36,370 | 18-MAR-1999 | ||
| GB_PR3: HS591B8 | 142552 | AL035410 | Human DNA sequence from clone 591B8 on chromosome 1p13.1, complete sequence. | Homo sapiens | 35,891 | 23-Nov-99 | ||
| rxa00411 | 798 | GB_BA1: AP000003 | 233000 | AP000003 | Pyrococcus horikoshii OT3 | Pyrococcus horikoshii | 36,849 | 8-Feb-99 |
| genomic DNA, 544001-777000 nt. position (3/7). | ||||||||
| GB_PL2: F25A4 | 115721 | AC008263 | Arabidopsis thaliana chromosome 1 BAC F25A4 sequence, | Arabidopsis thaliana | 37,628 | 15-Sep-99 | ||
| complete sequence. | ||||||||
| GB_PR3: HS413H6 | 142599 | AL022724 | Human DNA sequence from clone 413H6 on chromosome | Homo sapiens | 36,755 | 23-Nov-99 | ||
| 6p22.3-24.3. Contains a hamster | ||||||||
| Androgen-dependent Expressed Protein like protein gene, | ||||||||
| ESTs and GSSs, complete sequence. | ||||||||
| rxa00416 | 1673 | GB_EST8: C10137 | 360 | C10137 | C10137 Yuji Kohara unpublished cDNA: Strain | Caenorhabditis elegans | 35,574 | 18-OCT-1999 |
| N2 hermaphrodite embryo Caenorhabditis elegans | ||||||||
| cDNA clone yk188a1 5′, mRNA sequence. | ||||||||
| GB_EST36: AV186952 | 376 | AV186952 | AV186952 Yuji Kohara unpublished cDNA: Strain N2 | Caenorhabditis elegans | 36,702 | 22-Jul-99 | ||
| hermaphrodite embryo Caenorhabditis elegans | ||||||||
| cDNA clone yk506a5 5′, mRNA sequence. | ||||||||
| GB_EST16: C48235 | 383 | C48235 | C48235 Yuji Kohara unpublished cDNA: Strain N2 | Caenorhabditis elegans | 42,440 | 18-OCT-1999 | ||
| hermaphrodite embryo Caenorhabditis elegans | ||||||||
| cDNA clone yk459h10 5′, mRNA sequence. | ||||||||
| rxa00422 | 1017 | GB_BA1: MTCY227 | 35946 | Z77724 | Mycobacterium tuberculosis H37Rv complete genome; segment 114/162. | Mycobacterium | 39,822 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_BA1: MTV023 | 47852 | AL022022 | Mycobacterium tuberculosis H37Rv complete genome; segment 148/162. | Mycobacterium | 39,841 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| GB_PR3: AC003091 | 137817 | AC003091 | Human BAC clone RG326G04 from 7p21, complete sequence. | Homo sapiens | 36,653 | 6-Nov-97 | ||
| rxa00423 | 576 | GB_BA1: AP000063 | 185300 | AP000063 | Aeropyrum pernix genomic DNA, section 6/7. | Aeropyrum pernix | 38,908 | 22-Jun-99 |
| GB_IN1: LDHSP100 | 7726 | Z94053 | L. donovani hsp100 gene. | Leishmanla donovani | 39,646 | 28-Apr-97 | ||
| GB_GSS11: AQ274393 | 572 | AQ274393 | nbxb0035G12r CUGI Rice BAC Library Oryza sativa | Oryza sativa | 35,714 | 3-Nov-98 | ||
| genomic clone nbxb0035G12r, genomic survey sequence. | ||||||||
| rxa00424 | 594 | GB_BA1: AP000063 | 185300 | AP000063 | Aeropyrum pernix genomic DNA, section 6/7. | Aeropyrum pernix | 38,225 | 22-Jun-99 |
| GB_BA1: AP000063 | 185300 | AP000063 | Aeropyrum pernix genomic DNA, section 6/7. | Aeropyrum pernix | 36,735 | 22-Jun-99 | ||
| GB_IN1: LDHSP100 | 7726 | Z94053 | L. donovani hsp100 gene. | Leishmania donovani | 35,125 | 28-Apr-97 | ||
| rxa00425 | 348 | GB_EST30: AV021214 | 281 | AV021214 | AV021214 Mus musculus 18-day embryo C57BL/6J | Mus musculus | 35,849 | 28-Aug-99 |
| Mus musculus cDNA clone 1190021P08, mRNA sequence. | ||||||||
| GB_HTG3: AC009278 | 164119 | AC009278 | Homo sapiens clone 44_J_4, | Homo sapiens | 36,705 | 12-Aug-99 | ||
| *** SEQUENCING IN PROGRESS ***, 14 unordered pieces. | ||||||||
| GB_HTG3: AC009278 | 164119 | AC009278 | Homo sapiens clone 44_J_4, | Homo sapiens | 36,705 | 12-Aug-99 | ||
| *** SEQUENCING IN PROGRESS ***, 14 unordered pieces. | ||||||||
| rxa00428 | 756 | GB_BA2: AF127082 | 10847 | AF127082 | Myxococcus xanthus ATP-dependent protease | Myxococcus xanthus | 40,995 | 18-MAY-1999 |
| proteolytic subunit ClpP (clpP), ATP-dependent | ||||||||
| protease ATPase subunit ClpX (clpX), prolyl | ||||||||
| endopeptidase precursor Pep (pep), ATP-dependent | ||||||||
| protease LonV(lonV), oligopeptide permease | ||||||||
| homolog OppA (oppA), oligopeptide permease | ||||||||
| homolog OppB (oppB), and oligopeptide permease | ||||||||
| homolog OppC (oppC) genes, complete cds. | ||||||||
| GB_PL1: AB017080 | 653 | AB017080 | Porphyra sp. DNA, internal transcribed spacer 1 (ITS1). | Porphyra sp. | 38,491 | 10-Sep-99 | ||
| GB_EST27: AI442425 | 541 | AI442425 | sa26g05.y1 Gm-c1004 Glycine max cDNA | Glycine max | 40,000 | 01-DEC-1999 | ||
| clone GENOME SYSTEMS CLONE ID: Gm-c1004-465 5′ | ||||||||
| similar to SW: NDC1_RABIT Q28615 RENAL | ||||||||
| SODIUM/DICARBOXYLATE COTRANSPORTER;, | ||||||||
| mRNA sequence. | ||||||||
| rxa00429 | 525 | GB_EST3: R33129 | 440 | R33129 | yh81c08.s1 Soares placenta Nb2HP Homo sapiens cDNA | Homo sapiens | 37,216 | 28-Apr-95 |
| clone IMAGE: 136142 3′ similar to | ||||||||
| gb: X53742_rna1 FIBULIN 1, ISOFORM | ||||||||
| B PRECURSOR (HUMAN);, mRNA sequence. | ||||||||
| GB_PH: AF115103 | 40739 | AF115103 | Streptococcus thermophilus bacteriophage Sfi21, complete genome. | Streptococcus | 36,069 | 18-Jul-99 | ||
| thermophilus | ||||||||
| bacteriophage Sfi21 | ||||||||
| GB_PH: AF115102 | 37370 | AF115102 | Streptococcus thermophilus bacteriophage Sfi19, complete genome. | Streptococcus | 36,260 | 18-Jul-99 | ||
| thermophilus | ||||||||
| bacteriophage Sfi19 | ||||||||
| rxa00430 | 534 | GB_BA1: MSGY126 | 37164 | AD000012 | Mycobacterium tuberculosis sequence from clone y126. | Mycobacterium | 55,491 | 10-DEC-1996 |
| tuberculosis | ||||||||
| GB_BA1: MTY13D12 | 37085 | Z80343 | Mycobacterium tuberculosis H37Rv complete genome; segment 156/162. | Mycobacterium | 55,491 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| GB_BA1: MSGB971CS | 37566 | L78821 | Mycobacterium leprae cosmid B971 DNA sequence. | Mycobacterium leprae | 36,905 | 15-Jun-96 | ||
| rxa00433 | 648 | GB_PR2: AP000073 | 100000 | AP000073 | Homo sapiens genomic DNA, chromosome 8p11.2, | Homo sapiens | 38,043 | 20-Nov-99 |
| senescence gene region, section 9/19, complete sequence. | ||||||||
| GB_IN1: CELF29G9 | 42751 | AF016440 | Caenorhabditis elegans cosmid F29G9. | Caenorhabditis elegans | 35,474 | 7-Aug-97 | ||
| GB_BA1: MSGY414A | 40121 | AD000007 | Mycobacterium tuberculosis sequence from clone y414a. | Mycobacterium | 36,809 | 03-DEC-1996 | ||
| tuberculosis | ||||||||
| rxa00447 | ||||||||
| rxa00451 | 615 | GB_EST26: AI389267 | 643 | AI389267 | GH20396.5prime GH Drosophila melanogaster head | Drosophila melanogaster | 41,085 | 28-Jan-99 |
| pOT2 Drosophila melanogaster cDNA clone | ||||||||
| GH20396 5prime, mRNA sequence. | ||||||||
| GB_EST37: AI945493 | 574 | AI945493 | bs13e05.y1 Drosophila melanogaster adult testis library | Drosophila melanogaster | 44,040 | 17-Aug-99 | ||
| Drosophila melanogaster cDNA clone | ||||||||
| bs13e05 5′, mRNA sequence. | ||||||||
| GB_GSS11: AQ288118 | 630 | AQ288118 | nbxb0032I18r CUGI Rice BAC Library Oryza sativa genomic | Oryza sativa | 37,885 | 03-DEC-1998 | ||
| clone nbxb0032I18r, genomic survey sequence. | ||||||||
| rxa00455 | 873 | GB_IN1: DMOVO | 6655 | X59772 | D. melanogaster ovo gene required for female germ line development. | Drosophila melanogaster | 35,104 | 24-Feb-99 |
| GB_EST14: AA390588 | 513 | AA390588 | LD09657.5prime LD Drosophila melanogaster embryo | Drosophila melanogaster | 39,759 | 28-Nov-98 | ||
| BlueScript Drosophila melanogaster cDNA | ||||||||
| clone LD09657 5prime, mRNA sequence. | ||||||||
| GB_EST19: AA801874 | 621 | AA801874 | GM03519.5prime GM Drosophila melanogaster ovary BlueScript | Drosophila melanogaster | 35,437 | 25-Nov-98 | ||
| Drosophila melanogaster cDNA | ||||||||
| clone GM03519 5prime similar to U11383: ovo FBgn0003028 | ||||||||
| PID: g520527 SWISS-PROT: P51521, mRNA sequence. | ||||||||
| rxa00457 | 1203 | GB_GSS8: AQ000125 | 398 | AQ000125 | CIT-HSP-2282P3.TF CIT-HSP Homo sapiens | Homo sapiens | 41,730 | 26-Jun-98 |
| genomic clone 2282P3, genomic survey sequence. | ||||||||
| GB_IN1: DROADDLIKE | 4209 | L14330 | Drosophila melanogaster adducin-like protein, complete cds. | Drosophila melanogaster | 37,795 | 11-Jun-93 | ||
| GB_IN1: DROHTSC | 3922 | L05016 | Drosophila melanogaster hu-li tai shao (hts) mRNA, complete cds. | Drosophila melanogaster | 37,081 | 26-Apr-93 | ||
| rxa00462 | 1503 | GB_HTG3: AC009210 | 103814 | AC009210 | Drosophila melanogaster chromosome 2 clone | Drosophila melanogaster | 33,356 | 20-Aug-99 |
| BACR01I06 (D1054) RPCI-98 01.I.6 map 55D-55D | ||||||||
| strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 86 unordered pieces. | ||||||||
| GB_HTG3: AC009210 | 103814 | AC009210 | Drosophila melanogaster chromosome 2 clone | Drosophila melanogaster | 33,356 | 20-Aug-99 | ||
| BACR01I06 (D1054) RPCI-98 01.I.6 map 55D-55D | ||||||||
| strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 86 unordered pieces. | ||||||||
| GB_BA1: SCE9 | 37730 | AL049841 | Streptomyces coelicolor cosmid E9. | Streptomyces coelicolor | 37,308 | 19-MAY-1999 | ||
| rxa00463 | 945 | GB_BA2: AF052652 | 2096 | AF052652 | Corynebacterium glutamicum homoserine | Corynebacterium | 99,481 | 19-MAR-1998 |
| O-acetyltransferase (metA) gene, complete cds. | ||||||||
| glutamicum | ||||||||
| GB_GSS12: AQ407770 | 500 | AQ407770 | HS_5069_B1_F03_T7A RPCI-11 Human Male BAC Library | Homo sapiens | 40,081 | 17-MAR-1999 | ||
| Homo sapiens genomic clone Plate = 645 | ||||||||
| Col = 5 Row = L, genomic survey sequence. | ||||||||
| GB_GSS15: AQ596209 | 358 | AQ596209 | HS_5482_A2_H10_SP6E RPCI-11 Human | Homo sapiens | 40,000 | 8-Jun-99 | ||
| Male BAC Library Homo sapiens genomic clone | ||||||||
| Plate = 1058 Col = 20 Row = O, | ||||||||
| genomic survey sequence. | ||||||||
| rxa00468 | 942 | GB_EST32: AI763196 | 341 | AI763196 | wi65h04.x1 NCI_CGAP_Kid12 Homo sapiens cDNA | Homo sapiens | 38,824 | 24-Jun-99 |
| clone IMAGE: 2398231 3′, mRNA sequence. | ||||||||
| GB_EST17: AA652964 | 329 | AA652964 | ns62e02.s1 NCI_CGAP_Pr22 Homo sapiens cDNA | Homo sapiens | 41,104 | 13-Nov-97 | ||
| clone IMAGE: 1188218 3′, mRNA sequence. | ||||||||
| GB_EST20: AA864303 | 411 | AA864303 | oh54d02.s1 NCI_CGAP_GC4 Homo sapiens cDNA | Homo sapiens | 41,422 | 13-MAY-1998 | ||
| clone IMAGE: 1470435 3′, mRNA sequence. | ||||||||
| rxa00469 | 1299 | GB_PR4: AC005988 | 173126 | AC005988 | Homo sapiens chromosome 17, clone | Homo sapiens | 34,699 | 15-Jan-99 |
| hRPK.299_G_24, complete sequence. | ||||||||
| GB_PR4: AC005988 | 173126 | AC005988 | Homo sapiens chromosome 17, clone | Homo sapiens | 35,725 | 15-Jan-99 | ||
| hRPK.299_G_24, complete sequence. | ||||||||
| GB_HTG3: AC009116 | 186292 | AC009116 | Homo sapiens chromosome 16 clone RPCI-11_477D3, | Homo sapiens | 36,222 | 3-Aug-99 | ||
| *** SEQUENCING IN PROGRESS ***, 47 | ||||||||
| unordered pieces. | ||||||||
| rxa00472 | 942 | GB_HTG3: AC007882 | 214882 | AC007882 | Homo sapiens clone NH0499D05, | Homo sapiens | 38,245 | 8-Sep-99 |
| *** SEQUENCING IN PROGRESS ***, 2 unordered pieces. | ||||||||
| GB_HTG3: AC007882 | 214882 | AC007882 | Homo sapiens clone NH0499D05, | Homo sapiens | 38,245 | 8-Sep-99 | ||
| *** SEQUENCING IN PROGRESS ***, 2 unordered pieces. | ||||||||
| GB_PR2: HUAC002038 | 161973 | AC002038 | Homo sapiens chromosome | Homo sapiens | 37,961 | 30-Jun-97 | ||
| 2 clone 101B6 map 2p11, complete sequence. | ||||||||
| rxa00473 | 912 | GB_HTG3: AC011445 | 144370 | AC011445 | Homo sapiens chromosome 19 clone CIT-HSPC_246B18, | Homo sapiens | 38,470 | 07-OCT-1999 |
| *** SEQUENCING IN PROGRESS ***, 31 unordered pieces. | ||||||||
| GB_HTG3: AC011445 | 144370 | AC011445 | Homo sapiens chromosome 19 clone CIT-HSPC_246B18, | Homo sapiens | 38,470 | 07-OCT-1999 | ||
| *** SEQUENCING IN PROGRESS ***, 31 unordered pieces. | ||||||||
| GB_RO: AB026437 | 2097 | AB026437 | Mus musculus DNA, 5′ flanking region of interleukin 12 receptor beta 1. | Mus musculus | 40,000 | 02-OCT-1999 | ||
| rxa00474 | 1701 | GB_GSS10: AQ223838 | 543 | AQ223838 | HS_2218_A1_H03_MR CIT Approved | Homo sapiens | 40,189 | 20-Sep-98 |
| Human Genomic Sperm Library D Homo sapiens genomic | ||||||||
| clone Plate = 2218 Col = 5 Row = O, genomic survey sequence. | ||||||||
| GB_GSS10: AQ223838 | 543 | AQ223838 | HS_2218_A1_H03_MR CIT Approved Human | Homo sapiens | 37,944 | 20-Sep-98 | ||
| Genomic Sperm Library D Homo sapiens genomic | ||||||||
| clone Plate = 2218 Col = 5 Row = O, genomic survey sequence. | ||||||||
| rxa00475 | 783 | GB_PL2: GMAKHSDH2 | 10535 | AF049708 | Glycine max aspartokinase-homoserine dehydrogenase (AK-HSDH) gene, partial cds. | Glycine max | 36,446 | 7-Jul-99 |
| GB_EST14: AA386651 | 351 | AA386651 | vb54b04.r1 Ko mouse embryo 11 5dpc Mus musculus cDNA | Mus musculus | 41,311 | 23-Apr-97 | ||
| clone IMAGE: 760783 5′, mRNA sequence. | ||||||||
| GB_EST14: AA386603 | 498 | AA386603 | vb53c02.r1 Ko mouse embryo 11 5dpc Mus musculus cDNA | Mus musculus | 40,644 | 23-Apr-97 | ||
| clone IMAGE: 760706 5′ similar to | ||||||||
| TR: G56689 G56689 DIMETHYLGLYCINE | ||||||||
| DEHYDROGENASE.;, mRNA sequence. | ||||||||
| rxa00476 | 984 | GB_GSS5: AQ770769 | 554 | AQ770769 | HS_5357_B2_H01_T7A RPCI-11 Human Male BAC Library | Homo sapiens | 35,560 | 28-Jul-99 |
| Homo sapiens genomic clone Plate = 933 | ||||||||
| Col = 2 Row = P, genomic survey sequence. | ||||||||
| GB_IN1: CEM162 | 39977 | Z82278 | Caenorhabditis elegans cosmid M162, complete sequence. | Caenorhabditis elegans | 34,224 | 19-Nov-99 | ||
| GB_IN1: CEM162 | 39977 | Z82278 | Caenorhabditis elegans cosmid M162, complete sequence. | Caenorhabditis elegans | 33,777 | 19-Nov-99 | ||
| rxa00481 | 708 | GB_PR4: AC005013 | 195910 | AC005013 | Homo sapiens BAC clone GS165L15 from 7p15, complete sequence. | Homo sapiens | 35,755 | 28-Nov-98 |
| GB_HTG1: PFMAL4P4 | 224448 | AL035477 | Plasmodium falciparum chromosome 4 strain 3D7, | Plasmodium falciparum | 37,213 | 11-Aug-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: PFMAL4P4 | 224448 | AL035477 | Plasmodium falciparum chromosome 4 strain 3D7, | Plasmodium falciparum | 37,213 | 11-Aug-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00485 | 2418 | GB_EST30: AV017239 | 238 | AV017239 | AV017239 Mus musculus 18-day embryo | Mus musculus | 39,916 | 28-Aug-99 |
| C57BL/6J Mus musculus cDNA clone 1110069G23, mRNA sequence. | ||||||||
| GB_EST33: AV093875 | 254 | AV093875 | AV093875 Mus musculus C57BL/6J ES cell | Mus musculus | 38,189 | 22-Nov-99 | ||
| Mus musculus cDNA clone 2400006D21, mRNA sequence. | ||||||||
| GB_EST33: AV084536 | 287 | AV084536 | AV084536 Mus musculus tongue C57BL/6J adult | Mus musculus | 37,282 | 25-Jun-99 | ||
| Mus musculus cDNA clone 2310007K01, mRNA sequence. | ||||||||
| rxa00486 | 1032 | GB_RO: MUSP3VPR2 | 1089 | AF098867 | Mus sp. 129SV V3/V1b vasopressin receptor gene, exon 2 and complete cds. | Mus musculus | 38,163 | 28-Apr-99 |
| GB_GSS9: AQ166448 | 407 | AQ166448 | HS_3137_B2_A06_MR CIT Approved Human | Homo sapiens | 40,250 | 16-OCT-1998 | ||
| Genomic Sperm Library D Homo sapiens genomic | ||||||||
| clone Plate = 3137 Col = 12 Row = B, | ||||||||
| genomic survey sequence. | ||||||||
| GB_GSS15: AQ614261 | 505 | AQ614261 | HS_5123_B1_F11_SP6E RPCI-11 Human Male BAC | Homo sapiens | 37,905 | 15-Jun-99 | ||
| Library Homo sapiens genomic clone | ||||||||
| Plate = 699 Col = 21 Row = L, genomic survey sequence. | ||||||||
| rxa00490 | 1026 | GB_EST15: AA463205 | 282 | AA463205 | zx71c06.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone | Homo sapiens | 39,502 | 10-Jun-97 |
| IMAGE: 796906 3′, mRNA sequence. | ||||||||
| GB_BA1: SLLINC | 36270 | X79146 | S. lincolnensis (78-11) Lincomycin production genes. | Streptomyces lincolnensis | 37,278 | 15-MAY-1996 | ||
| GB_GSS3: B10984 | 646 | B10984 | F22I8-Sp6 IGF Arabidopsis thaliana genomic clone F22I8, genomic survey sequence. | Arabidopsis thaliana | 39,205 | 14-MAY-1997 | ||
| rxa00491 | 543 | GB_HTG1: CEY87G2 | 330612 | AL022597 | Caenorhabditis elegans chromosome I clone Y87G2, | Caenorhabditis elegans | 37,405 | 26-OCT-1999 |
| *** SEQUENCING IN PROGRESS ***, in | ||||||||
| unordered pieces. | ||||||||
| GB_HTG1: CEY87G2 | 330612 | AL022597 | Caenorhabditis elegans chromosome I clone Y87G2, | Caenorhabditis elegans | 37,405 | 26-OCT-1999 | ||
| *** SEQUENCING IN PROGRESS ***, in | ||||||||
| unordered pieces. | ||||||||
| GB_HTG1: CEY6B3 | 253516 | Z92865 | Caenorhabditis elegans chromosome I clone Y6B3, | Caenorhabditis elegans | 38,213 | 30-Jul-98 | ||
| *** SEQUENCING IN PROGRESS ***, in | ||||||||
| unordered pieces. | ||||||||
| rxa00493 | 1737 | GB_BA1: SC6G4 | 41055 | AL031317 | Streptomyces coelicolor cosmid 6G4. | Streptomyces coelicolor | 61,649 | 20-Aug-98 |
| GB_BA2: U00015 | 42325 | U00015 | Mycobacterium leprae cosmid B1620. | Mycobacterium leprae | 38,567 | 01-MAR-1994 | ||
| GB_BA1: U00020 | 36947 | U00020 | Mycobacterium leprae cosmid B229. | Mycobacterium leprae | 38,567 | 01-MAR-1994 | ||
| rxa00496 | 1149 | GB_VI: TVRNAP | 6404 | X68414 | Toscana Virus genomic RNA for RNA-dependent RNA polymerase. | Toscana virus | 35,428 | 27-OCT-1992 |
| GB_IN2: DMU09808 | 9239 | U09808 | Drosophila melanogaster twisted gastrulation (tsg) and serine protease | Drosophila melanogaster | 36,837 | 25-Jun-98 | ||
| (gd) genes, complete cds. | ||||||||
| GB_IN2: DMU09808 | 9239 | U09808 | Drosophila melanogaster twisted gastrulation (tsg) and serine protease | Drosophila melanogaster | 37,782 | 25-Jun-98 | ||
| (gd) genes, complete cds. | ||||||||
| rxa00504 | 543 | GB_BA1: MTCY159 | 33818 | Z83863 | Mycobacterium tuberculosis H37Rv complete genome; segment 111/162. | Mycobacterium | 36,961 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_PR1: HUMHM145 | 2214 | D10925 | Human mRNA for HM145. | Homo sapiens | 36,066 | 3-Feb-99 | ||
| GB_EST14: AA415083 | 332 | AA415083 | Mg0017 RCW Lambda Zap Express Library Pyricularia grisea cDNA | Pyricularia grisea | 40,181 | 09-DEC-1999 | ||
| clone RCW17 5′, mRNA sequence. | ||||||||
| rxa00505 | 618 | GB_PAT: I92047 | 551 | I92047 | Sequence 14 from patent U.S. Pat. No. 5726299. | Unknown. | 46,250 | 01-DEC-1998 |
| GB_PAT: I78759 | 549 | I78759 | Sequence 15 from patent U.S. Pat. No. 5693781. | Unknown. | 44,813 | 3-Apr-98 | ||
| GB_PAT: I92048 | 549 | I92048 | Sequence 15 from patent U.S. Pat. No. 5726299. | Unknown. | 44,813 | 01-DEC-1998 | ||
| rxa00507 | 978 | GB_PR2: HS1063B2 | 114596 | AL035683 | Human DNA sequence from clone 1063B2 on chromosome 20q13.1-13.2. | Homo sapiens | 36,449 | 23-Nov-99 |
| Contains the 3′ part of the gene for Beta-1,4-galactosyltransferase, ESTs, | ||||||||
| STSs and GSSs, complete sequence. | ||||||||
| GB_HTG2: AC007225 | 218892 | AC007225 | Homo sapiens chromosome 16 clone 480G7, | Homo sapiens | 36,646 | 6-Apr-99 | ||
| *** SEQUENCING IN PROGRESS ***, 38 unordered pieces. | ||||||||
| GB_HTG2: AC007225 | 218892 | AC007225 | Homo sapiens chromosome 16 clone 480G7, | Homo sapiens | 36,646 | 6-Apr-99 | ||
| *** SEQUENCING IN PROGRESS ***, 38 unordered pieces. | ||||||||
| rxa00510 | 1632 | GB_GSS4: AQ707590 | 499 | AQ707590 | HS_5560_B1_H02_SP6E RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 37,275 | 7-Jul-99 |
| genomic clone Plate = 1136 Col = 3 Row = P, genomic survey sequence. | ||||||||
| GB_GSS4: AQ707590 | 499 | AQ707590 | HS_5560_B1_H02_SP6E RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 37,275 | 7-Jul-99 | ||
| genomic clone Plate = 1136 Col = 3 Row = P, genomic survey sequence. | ||||||||
| rxa00515 | 825 | GB_BA1: CGICD | 3595 | X71489 | C. glutamicum icd gene for monomeric isocitrate dehydrogenase. | Corynebacterium | 100,000 | 17-Feb-95 |
| glutamicum | ||||||||
| GB_BA1: CGICD | 3595 | X71489 | C. glutamicum icd gene for monomeric isocitrate dehydrogenase. | Corynebacterium | 38,150 | 17-Feb-95 | ||
| glutamicum | ||||||||
| GB_GSS13: AQ451896 | 509 | AQ451896 | HS_5184_B1_C03_SP6E RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 36,638 | 21-Apr-99 | ||
| genomic clone Plate = 760 Col = 5 Row = F, genomic survey sequence. | ||||||||
| rxa00519 | 2337 | GB_BA1: CGICD | 3595 | X71489 | C. glutamicum icd gene for monomeric isocitrate dehydrogenase. | Corynebacterium | 100,000 | 17-Feb-95 |
| glutamicum | ||||||||
| GB_BA2: AF127018 | 2560 | AF127018 | Streptomyces coelicolor isocitrate dehydrogenase (idh) gene, idh-B allele, | Streptomyces coelicolor | 66,667 | 1-Jun-99 | ||
| complete cds. | ||||||||
| GB_BA1: AVIICD | 3550 | D73443 | Azotobacter vinelandii icd gene for isocitrate dehydrogenase, complete cds. | Azotobacter vinelandii | 63,652 | 4-Feb-99 | ||
| rxa00527 | 1887 | GB_PAT: I92049 | 2248 | I92049 | Sequence 16 from patent U.S. Pat. No. 5726299. | Unknown. | 39,250 | 01-DEC-1998 |
| GB_PAT: I92053 | 2213 | I92053 | Sequence 20 from patent U.S. Pat. No. 5726299. | Unknown. | 70,635 | 01-DEC-1998 | ||
| GB_BA1: MTCY98 | 31225 | Z83860 | Mycobacterium tuberculosis H37Rv complete genome; segment 103/162. | Mycobacterium | 37,741 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| rxa00528 | 1212 | GB_BA1: MSGY219 | 38721 | AD000013 | Mycobacterium tuberculosis sequence from clone y219. | Mycobacterium | 68,672 | 10-DEC-1996 |
| tuberculosis | ||||||||
| GB_BA1: MTCY21D4 | 20760 | Z80775 | Mycobacterium tuberculosis H37Rv complete genome; segment 3/262. | Mycobacterium | 39,762 | 24-Jun-99 | ||
| tuberculosis | ||||||||
| GB_BA1: SCH24 | 41625 | AL049826 | Streptomyces coelicolor cosmid H24. | Streptomyces coelicolor | 40,411 | 11-MAY-1999 | ||
| rxa00529 | 666 | GB_PR2: HSAC000109 | 41122 | AC000109 | Human Cosmid g0771a222 from 7q31.3, complete sequence. | Homo sapiens | 37,462 | 11-Sep-97 |
| GB_PR2: HSAC000110 | 45508 | AC000110 | Human Cosmid g0771a233, complete sequence. | Homo sapiens | 37,462 | 30-Jan-97 | ||
| GB_PR2: HSAC000109 | 41122 | AC000109 | Human Cosmid g0771a222 from 7q31.3, complete sequence. | Homo sapiens | 39,724 | 11-Sep-97 | ||
| rxa00530 | 1404 | GB_PR3: HS435C23 | 151798 | Z92844 | Human DNA sequence from PAC 435C23 on chromosome X. Contains ESTs. | Homo sapiens | 36,482 | 23-Nov-99 |
| GB_PR3: HS435C23 | 151798 | Z92844 | Human DNA sequence from PAC 435C23 on chromosome X. Contains ESTs. | Homo sapiens | 37,918 | 23-Nov-99 | ||
| GB_PL1: YSCADE3 | 4883 | M12878 | Saccharomyces cerevisiae C-1-tetrahydrofolate synthase (ADE3) gene, complete cds. | Saccharomyces cerevisiae | 37,034 | 11-MAY-1995 | ||
| rxa00535 | 840 | GB_BA1: CGLEUA | 3492 | X70959 | C. glutamicum gene leuA for isopropylmalate synthase. | Corynebacterium | 100,000 | 10-Feb-99 |
| glutamicum | ||||||||
| GB_BA1: CORASKD | 2957 | L16848 | Corynebacterium flavum aspartokinase (ask), and aspartate-semialdehyde | Corynebacterium | 43,750 | 11-Jun-93 | ||
| dehydrogenase (asd) genes, complete cds. | flavescens | |||||||
| GB_GSS10: AQ193141 | 515 | AQ193141 | HS_3060_B1_F11_MF CIT Approved Human Genomic Sperm Library D | Homo sapiens | 44,773 | 4-Nov-98 | ||
| Homo sapiens genomic clone Plate = 3060 Col = 21 Row = L, | ||||||||
| genomic survey sequence. | ||||||||
| rxa00540 | 366 | GB_PAT: I92052 | 2115 | I92052 | Sequence 19 from patent U.S. Pat. No. 5726299. | Unknown. | 74,795 | 01-DEC-1998 |
| GB_HTG2: AC008095 | 126322 | AC008095 | Drosophila melanogaster chromosome 2 clone BACR11H16 (D932) RPCI-98 11.H.16 | Drosophila melanogaster | 41,899 | 2-Aug-99 | ||
| map 52A-52A strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 95 unordered pieces. | ||||||||
| GB_HTG2: AC008095 | 126322 | AC008095 | Drosophila melanogaster chromosome 2 clone BACR11H16 (D932) RPCI-98 11.H.16 | Drosophila melanogaster | 41,899 | 2-Aug-99 | ||
| map 52A-52A strain y; cn bw sp, *** SEQUENCING IN PROGRESS***, | ||||||||
| 95 unordered pieces. | ||||||||
| rxa00547 | 1521 | GB_BA1: MSGY219 | 38721 | AD000013 | Mycobacterium tuberculosis sequence from clone y219. | Mycobacterium | 36,910 | 10-DEC-1996 |
| tuberculosis | ||||||||
| GB_BA1: MTCY21D4 | 20760 | Z80775 | Mycobacterium tuberculosis H37Rv complete genome; segment 3/262. | Mycobacterium | 51,125 | 24-Jun-99 | ||
| tuberculosis | ||||||||
| GB_EST27: AI415174 | 292 | AI415174 | mc05c02.x1 Soares mouse p3NMF19.5 Mus musculus cDNA clone | Mus musculus | 39,384 | 9-Feb-99 | ||
| IMAGE: 338018 3′, mRNA sequence. | ||||||||
| rxa00549 | 1797 | GB_PL2: ATAC007135 | 27313 | AC007135 | Arabidopsis thaliana chromosome II BAC F9C22 genomic sequence, | Arabidopsis thaliana | 35,584 | 26-MAY-1999 |
| complete sequence. | ||||||||
| GB_PL2: ATAC006921 | 76042 | AC006921 | Arabidopsis thaliana chromosome II BAC F2H17 genomic sequence, | Arabidopsis thaliana | 36,581 | 23-MAR-1999 | ||
| complete sequence. | ||||||||
| GB_PL2: ATAC007135 | 27313 | AC007135 | Arabidopsis thaliana chromosome II BAC F9C22 genomic sequence, | Arabidopsis thaliana | 35,827 | 26-MAY-1999 | ||
| complete sequence. | ||||||||
| rxa00550 | ||||||||
| rxa00552 | 1059 | GB_BA1: D90742 | 19201 | D90742 | Escherichia coli genomic DNA. (23.8-24.2 min). | Escherichia coli | 46,072 | 7-Feb-99 |
| GB_BA1: ECHTRB | 3129 | X61000 | E. coli K12 HtrB gene. | Escherichia coli | 39,164 | 30-Jun-93 | ||
| GB_BA2: AE000207 | 11148 | AE000207 | Escherichia coli K-12 MG1655 section 97 of 400 of the complete genome. | Escherichia coli | 46,072 | 12-Nov-98 | ||
| rxa00553 | 444 | GB_EST18: AB009093 | 479 | AB009093 | AB009093 Chlamydomonas W80 lambda ZAP II Chlamydomonas sp. cDNA similar | Chlamydomonas sp. | 41,808 | 05-DEC-1997 |
| to photosystem II 10 kDa protein, mRNA sequence. | ||||||||
| GB_EST30: AI640954 | 641 | AI640954 | AEMTAP02 Aedes aegypti MT pSPORT Library Aedes aegypti cDNA clone | Aedes aegypti | 38,991 | 28-Apr-99 | ||
| AP02 5′, mRNA sequence. | ||||||||
| GB_GSS13: AQ467517 | 206 | AQ467517 | HS_5219_A2_F02_SP6E RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 45,255 | 23-Apr-99 | ||
| genomic clone Plate = 795 Col = 4 Row = K, genomic survey sequence. | ||||||||
| rxa00554 | 594 | GB_EST6: W04418 | 364 | W04418 | za43c06.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone | Homo sapiens | 39,688 | 22-Apr-96 |
| IMAGE: 295306 5′, mRNA sequence. | ||||||||
| GB_EST35: AL041829 | 564 | AL041829 | DKFZp434C0318_s1 434 (synonym: htes3) Homo sapiens cDNA clone | Homo sapiens | 40,433 | 29-Sep-99 | ||
| DKFZp434C0318 3′, mRNA sequence. | ||||||||
| GB_EST35: AL041828 | 386 | AL041828 | DKFZp434C0318_r1 434 (synonym: htes3) Homo sapiens cDNA clone | Homo sapiens | 39,688 | 29-Sep-99 | ||
| DKFZp434C0318 5′, mRNA sequence. | ||||||||
| rxa00555 | ||||||||
| rxa00560 | 498 | GB_BA1: MTCY7H7A | 10451 | Z95618 | Mycobacterium tuberculosis H37Rv complete genome; segment 39/162. | Mycobacterium | 52,727 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_BA1: BAPURF | 1885 | X91252 | B. ammoniagenes purF gene. | Corynebacterium | 61,092 | 5-Jun-97 | ||
| ammoniagenes | ||||||||
| GB_PL1: YSCMET10A | 3650 | L26504 | Saccharomyces carlsbergensis assimilatory sulfite reductase (MET10) gene, | Saccharomyces | 41,273 | 7-Feb-95 | ||
| complete cds. | pastorianus | |||||||
| rxa00563 | 2762 | GB_BA1: BAFASAA | 10549 | X64795 | B. ammoniagenes FAS gene. | Corynebacterium | 66,910 | 14-OCT-1997 |
| ammoniagenes | ||||||||
| GB_BA1: MTCY159 | 33818 | Z83863 | Mycobacterium tuberculosis H37Rv complete genome; segment 111/162. | Mycobacterium | 40,066 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| GB_BA1: MBU36763 | 8391 | U36763 | Mycobacterium bovis fatty acid synthase gene, complete cds. | Mycobacterium bovis | 61,178 | 15-Jul-96 | ||
| rxa00564 | 528 | GB_PR3: HS833B7 | 86574 | AL008637 | Human DNA sequence from clone 833B7 on chromosome 22q12.3-13.2 | Homo sapiens | 39,015 | 23-Nov-99 |
| Contains genes for NCF4 (P40PHOX) protein, cytokine receptor common beta chain | ||||||||
| precursor CSF2RB (partial), ESTs, CA repeat, STS, GSS, complete sequence. | ||||||||
| GB_HTG3: AC008543 | 278334 | AC008543 | Homo sapiens chromosome 19 clone CIT-HSPC_499B15, | Homo sapiens | 36,328 | 2-Sep-99 | ||
| *** SEQUENCING IN PROGRESS ***, 134 unordered pieces. | ||||||||
| GB_HTG3: AC008543 | 278334 | AC008543 | Homo sapiens chromosome 19 clone CIT-HSPC_499B15, | Homo sapiens | 36,328 | 2-Sep-99 | ||
| *** SEQUENCING IN PROGRESS ***, 134 unordered pieces. | ||||||||
| rxa00573 | ||||||||
| rxa00574 | 1002 | GB_GSS11: AQ301816 | 481 | AQ301816 | HS_3174_A1_B04_T7 CIT Approved Human Genomic Sperm Library | Homo sapiens | 43,137 | 16-DEC-1998 |
| D Homo sapiens genomic clone Plate = 3174 Col = 7 Row = C, | ||||||||
| genomic survey sequence. | ||||||||
| GB_PR3: AC004537 | 88872 | AC004537 | Homo sapiens PAC clone DJ0872F07 from 7q31, complete sequence. | Homo sapiens | 34,712 | 9-Apr-98 | ||
| GB_EST29: AI563059 | 339 | AI563059 | EST00183 watermelon lambda zap library Citrullus lanatus cDNA clone WMLS355 | Citrullus lanatus | 37,758 | 26-MAR-1999 | ||
| 5′ similar to unknown protein, mRNA sequence. | ||||||||
| rxa00576 | 795 | GB_EST37: AI947508 | 533 | AI947508 | 603022E09.x1 603 - stressed root cDNA library from Wang/Bohnert lab Zea mays | Zea mays | 38,728 | 19-Aug-99 |
| cDNA, mRNA sequence. | ||||||||
| GB_GSS11: AQ296770 | 347 | AQ296770 | HS_3087_A2_B12_MF CIT Approved Human Genomic Sperm Library D Homo | Homo sapiens | 40,058 | 15-DEC-1998 | ||
| sapiens genomic clone Plate = 3087 Col = 24 Row = C, genomic survey sequence. | ||||||||
| GB_GSS13: AQ503769 | 589 | AQ503769 | RPCI-11-282O13.TV RPCI-11 Homo sapiens genomic clone RPCI-11-282O13, | Homo sapiens | 37,993 | 29-Apr-99 | ||
| genomic survey sequence. | ||||||||
| rxa00577 | 471 | GB_GSS14: AQ533027 | 638 | AQ533027 | RPCI-11-351M24.TJ RPCI-11 Homo sapiens genomic clone RPCI-11-351M24, | Homo sapiens | 34,944 | 18-MAY-1999 |
| genomic survey sequence. | ||||||||
| GB_PR3: HS440B3 | 28047 | AL022331 | Homo sapiens DNA sequence from clone 440B3 on chromosome 22q12.1-3 | Homo sapiens | 33,626 | 23-Nov-99 | ||
| Contains a pseudogene similar to 60S Ribosomal protein L17. | ||||||||
| Contains ESTs and an STS (genomic marker D22S1176), complete sequence. | ||||||||
| GB_PL2: ZEU19267 | 1230 | U19267 | Zinnia elegans cysteine proteinase mRNA, complete cds. | Zinnia elegans | 35,456 | 26-Aug-96 | ||
| rxa00578 | ||||||||
| rxa00582 | 642 | GB_BA1: CORAHPS | 2570 | L07603 | Corynebacterium glutamicum 3-deoxy-D-arabinoheptulosonate-7-phosphate | Corynebacterium | 98,901 | 26-Apr-93 |
| synthase gene, complete cds. | glutamicum | |||||||
| GB_PR3: AC005389 | 120359 | AC005389 | Homo sapiens chromosome 17, clone hRPK.601_N_13, complete sequence. | Homo sapiens | 38,315 | 14-Aug-98 | ||
| GB_HTG6: AC008002 | 126629 | AC008002 | Drosophila melanogaster chromosome 2 clone BACR48E08 (D843) RPCI-98 48.E.8 | Drosophila melanogaster | 32,437 | 07-DEC-1999 | ||
| map 21D-21E strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 85 unordered pieces. | ||||||||
| rxa00585 | 441 | GB_BA1: CORAHPS | 2570 | L07603 | Corynebacterium glutamicum 3-deoxy-D-arabinoheptulosonate-7-phosphate | Corynebacterium | 98,039 | 26-Apr-93 |
| synthase gene, complete cds. | glutamicum | |||||||
| GB_PR4: AC004970 | 149951 | AC004970 | Homo sapiens BAC clone DJ1122F04 from 7q11.23-q21.2, complete sequence. | Homo sapiens | 39,900 | 27-Aug-99 | ||
| GB_PR2: HS102G20 | 99207 | Z99127 | Human DNA sequence from PAC 102G20 on chromosome 1q24-q25. Contains ESTS, | Homo sapiens | 41,509 | 23-Nov-99 | ||
| STSs and a predicted CpG island. | ||||||||
| rxa00586 | 1005 | GB_BA1: MTV017 | 67200 | AL021897 | Mycobacterium tuberculosis H37Rv complete genome; segment 48/162. | Mycobacterium | 56,219 | 24-Jun-99 |
| tuberculosis | ||||||||
| GB_BA1: MLU15183 | 36800 | U15183 | Mycobacterium leprae cosmid B1740. | Mycobacterium leprae | 55,622 | 09-MAR-1995 | ||
| GB_BA1: MTV017 | 67200 | AL021897 | Mycobacterium tuberculosis H37Rv complete genome; segment 48/162. | Mycobacterium | 37,838 | 24-Jun-99 | ||
| tuberculosis | ||||||||
| rxa00587 | 459 | GB_EST37: AI993539 | 514 | AI993539 | 701496589 A. thaliana , Ohio State clone set Arabidopsis thaliana cDNA | Arabidopsis thaliana | 40,153 | 8-Sep-99 |
| clone 701496589, mRNA sequence. | ||||||||
| GB_GSS10: AQ224941 | 511 | AQ224941 | HS_2009_B1_B06_T7 CIT Approved Human Genomic Sperm Library D | Homo sapiens | 43,750 | 20-Sep-98 | ||
| Homo sapiens genomic clone Plate = 2009 Col = 11 Row = D, | ||||||||
| genomic survey sequence. | ||||||||
| GB_EST23: AI099719 | 475 | AI099719 | 33872 Lambda-PRL2 Arabidopsis thaliana cDNA clone 120M10XP 3′, | Arabidopsis thaliana | 36,752 | 21-Aug-98 | ||
| mRNA sequence. | ||||||||
| rxa00589 | 573 | GB_PL2: ATAC003673 | 70575 | AC003673 | Arabidopsis thaliana chromosome II BAC F19F24 genomic sequence, | Arabidopsis thaliana | 39,785 | 1-Apr-98 |
| complete sequence. | ||||||||
| GB_PR3: HS427A4 | 149466 | Z98049 | Human DNA sequence from PAC 427A4 on chromosome 6q26-q27. Contains | Homo sapiens | 35,145 | 23-Nov-99 | ||
| ribosomal protein S6 kinase, RSK3, ESTs, CpG island. | ||||||||
| GB_PL2: ATAC005724 | 86671 | AC005724 | Arabidopsis thaliana chromosome II P1 MSF3 genomic sequence, complete sequence. | Arabidopsis thaliana | 39,785 | 24-Jan-99 | ||
| rxa00595 | ||||||||
| rxa00597 | 393 | GB_PR3: AC004659 | 129577 | AC004659 | Homo sapiens chromosome 19, CIT-HSP-87m17 BAC clone, complete sequence. | Homo sapiens | 39,459 | 02-MAY-1998 |
| GB_GSS14: AQ575039 | 927 | AQ575039 | nbxb0086L01r CUGI Rice BAC Library Oryza sativa genomic clone | Oryza sativa | 37,786 | 2-Jun-99 | ||
| nbxb0086L01r, genomic survey sequence. | ||||||||
| GB_BA1: NMRRNA | 5209 | X72495 | N. magadii rRNA operon. | Natrialba magadii | 39,788 | 10-Feb-95 | ||
| rxa00598 | ||||||||
| rxa00601 | 414 | GB_BA2: AF175719 | 1368 | AF175719 | Porphyromonas gingivalis strain W50 immunoreactive 51 kD antigen | Porphyromonas gingivalis | 35,331 | 23-Aug-99 |
| PG52 gene, complete cds. | ||||||||
| GB_GSS9: AQ140775 | 464 | AQ140775 | HS_3128_A1_B11_MR CIT Approved Human Genomic Sperm Library D | Homo sapiens | 40,431 | 24-Sep-98 | ||
| Homo sapiens genomic clone Plate = 3128 Col = 21 Row = C, | ||||||||
| genomic survey sequence. | ||||||||
| GB_EST8: AA018824 | 542 | AA018824 | ze57e09.s1 Soares retina N2b4HR Homo sapiens cDNA clone IMAGE: 363112 3′, | Homo sapiens | 40,590 | 30-Jan-97 | ||
| mRNA sequence. | ||||||||
| rxa00602 | 876 | GB_EST30: AI642687 | 479 | AI642687 | vw02h03.x1 Soares mouse mammary gland NbMMG Mus musculus cDNA clone | Mus musculus | 40,042 | 29-Apr-99 |
| IMAGE: 1230773 3′, mRNA sequence. | ||||||||
| GB_EST20: AA879989 | 412 | AA879989 | vw03a05.r1 Soares mouse mammary gland NbMMG Mus musculus cDNA clone | Mus musculus | 39,948 | 26-MAR-1998 | ||
| IMAGE: 1230800 5′, mRNA sequence. | ||||||||
| GB_EST28: AI481047 | 438 | AI481047 | vf91a05.x1 Soares mouse mammary gland NbMMG Mus musculus cDNA clone | Mus musculus | 38,128 | 09-MAR-1999 | ||
| IMAGE: 851120 3′, mRNA sequence. | ||||||||
| rxa00604 | 414 | GB_HTG2: AC008205 | 131658 | AC008205 | Drosophila melanogaster chromosome 3 clone BACR33F18 (D764) RPCI-98 | Drosophila melanogaster | 33,907 | 2-Aug-99 |
| 33.F.18 map 96A-96B strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 118 unordered pieces. | ||||||||
| GB_HTG2: AC008205 | 131658 | AC008205 | Drosophila melanogaster chromosome 3 clone BACR33F18 (D764) RPCI-98 33.F.18 | Drosophila melanogaster | 33,907 | 2-Aug-99 | ||
| map 96A-96B strain y; cn bw sp, *** SEQUENCING IN PROGRESS***, | ||||||||
| 118 unordered pieces. | ||||||||
| GB_IN1: DMBR7C10 | 56820 | AL121804 | Drosophila melanogaster clone BACR7C10. | Drosophila melanogaster | 44,267 | 10-OCT-1999 | ||
| rxa00610 | 987 | GB_BA1: SME242575 | 1403 | AJ242575 | Sinorhizobium meliloti partial oxi1 and dehydrogenase genes, isolate lpu119. | Sinorhizobium meliloti | 41,760 | 26-MAY-1999 |
| GB_PR3: AC004655 | 134929 | AC004655 | Homo sapiens Xp22-140-141 BAC GSHB-128G5 (Genome Systems Human | Homo sapiens | 38,422 | 17-Sep-98 | ||
| BAC library) complete sequence. | ||||||||
| GB_PR3: HS598F2 | 99886 | AL021579 | Human DNA sequence from clone 598F2 on chromosome 1q23.1-24.3 Contains | Homo sapiens | 38,351 | 23-Nov-99 | ||
| ESTs, STS and GSS, complete sequence. | ||||||||
| rxa00611 | 1599 | GB_HTG2: AC007108 | 190000 | AC007108 | Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 17,451 | 17-MAR-1999 |
| 24 unordered pieces. | ||||||||
| GB_HTG2: AC007108 | 190000 | AC007108 | Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 17,451 | 17-MAR-1999 | ||
| 24 unordered pieces. | ||||||||
| GB_HTG4: AC010893 | 176178 | AC010893 | Homo sapiens chromosome unknown clone NH0480A20, | Homo sapiens | 35,819 | 29-OCT-1999 | ||
| WORKING DRAFT SEQUENCE, in unordered pieces. | ||||||||
| rxa00613 | 576 | GB_IN2: AC004361 | 87747 | AC004361 | Drosophila melanogaster DNA sequence (P1 DS07851 (D49)), complete sequence. | Drosophila melanogaster | 35,081 | 29-MAY-1998 |
| GB_PL2: AC006268 | 105420 | AC006268 | Arabidopsis thaliana BAC T24G23 from chromosome IV near 21 cM, | Arabidopsis thaliana | 43,682 | 1-Jan-99 | ||
| complete sequence. | ||||||||
| GB_BA1: MLCB596 | 38426 | AL035472 | Mycobacterium leprae cosmid B596. | Mycobacterium leprae | 35,026 | 27-Aug-99 | ||
| rxa00614 | 1038 | GB_BA1: MTV025 | 121125 | AL022121 | Mycobacterium tuberculosis H37Rv complete genome; segment 155/162. | Mycobacterium | 53,061 | 24-Jun-99 |
| tuberculosis | ||||||||
| GB_BA1: SCH66 | 9153 | AL049731 | Streptomyces coelicolor cosmid H66. | Streptomyces coelicolor | 52,817 | 29-Apr-99 | ||
| GB_EST14: AA446728 | 411 | AA446728 | zw84f03.r1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone | Homo sapiens | 36,548 | 3-Jun-97 | ||
| IMAGE: 783677 5′, mRNA sequence. | ||||||||
| rxa00616 | ||||||||
| rxa00617 | 351 | GB_PL1: AB009030 | 2589 | AB009030 | Panax ginseng OSCPNY1 mRNA for beta-Amyrin Synthase, complete cds. | Panax ginseng | 39,048 | 03-OCT-1998 |
| GB_PR3: HS905G11 | 122469 | AL035045 | Human DNA sequence from clone 905G11 on chromosome 20p11.2-12.1. | Homo sapiens | 39,255 | 23-Nov-99 | ||
| Contains STSs, GSSs and genomic marker D20S182, complete sequence. | ||||||||
| GB_RO: MMT1CPS | 8147 | X15147 | Mouse Tla region T1c pseudogene for class I antigen major | Mus musculus | 36,311 | 19-Feb-90 | ||
| histocompatibility complex. | ||||||||
| rxa00628 | 531 | GB_HTG5: AC010674 | 220575 | AC010674 | Homo sapiens chromosome 15 clone RP11-430B1 map 15q21, | Homo sapiens | 37,714 | 5-Nov-99 |
| *** SEQUENCING IN PROGRESS ***, 46 ordered pieces. | ||||||||
| GB_HTG5: AC010674 | 220575 | AC010674 | Homo sapiens chromosome 15 clone RP11-430B1 map 15q21, | Homo sapiens | 39,293 | 5-Nov-99 | ||
| *** SEQUENCING IN PROGRESS ***, 46 ordered pieces. | ||||||||
| rxa00631 | 1578 | GB_BA1: BRLBIOAD | 2272 | D14083 | Brevibacterium flavum genes for 7,8-diaminopelargonic acid aminotransferase | Corynebacterium | 47,368 | 3-Feb-99 |
| and dethiobiotin synthetase, complete cds. | glutamicum | |||||||
| GB_PAT: E04041 | 675 | E04041 | DNA sequence coding for desthiobiotinsynthetase. | Corynebacterium | 46,552 | 29-Sep-97 | ||
| glutamicum | ||||||||
| GB_EST20: AA820386 | 453 | AA820386 | LD23968.5prime LD Drosophila melanogaster embryo pOT2 | Drosophila melanogaster | 45,679 | 25-Feb-99 | ||
| Drosophila melanogaster cDNA clone LD23968 5prime, mRNA sequence. | ||||||||
| rxa00637 | 876 | GB_HTG2: AC007589 | 134659 | AC007589 | Drosophila melanogaster chromosome 3 clone BACR20D10 (D667) RPCI-98 | Drosophila melanogaster | 32,102 | 2-Aug-99 |
| 20.D.10 map 82D-82E strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 73 unordered pieces. | ||||||||
| GB_HTG2: AC007589 | 134659 | AC007589 | Drosophila melanogaster chromosome 3 clone BACR20D10 (D667) RPCI-98 20.D.10 | Drosophila melanogaster | 32,102 | 2-Aug-99 | ||
| map 82D-82E strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***, | ||||||||
| 73 unordered pieces. | ||||||||
| GB_HTG3: AC009212 | 125452 | AC009212 | Drosophila melanogaster chromosome 3 clone BACR01A18 (D669) RPCI-98 01.A.18 | Drosophila melanogaster | 37,126 | 23-Aug-99 | ||
| map 82E-82F strain y; cn bw sp, *** SEQUENCING IN PROGRESS***, | ||||||||
| 119 unordered pieces. | ||||||||
| rxa00646 | 541 | GB_HTG1: AP000488 | 123363 | AP000488 | Homo sapiens chromosome 11 clone B759H8 map 11q23, | Homo sapiens | 38,264 | 13-Sep-99 |
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: AP000488 | 123363 | AP000488 | Homo sapiens chromosome 11 clone B759H8 map 11q23, | Homo sapiens | 38,264 | 13-Sep-99 | ||
| *** SEQUENCING IN PROGRESS***, in unordered pieces. | ||||||||
| GB_HTG1: AP000488 | 123363 | AP000488 | Homo sapiens chromosome 11 clone B759H8 map 11q23, | Homo sapiens | 36,484 | 13-Sep-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00647 | 756 | GB_GSS13: AQ431426 | 536 | AQ431426 | HS_5140_A2_E01_T7A RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 35,635 | 31-MAR-1999 |
| genomic clone Plate = 716 Col = 2 Row = I, genomic survey sequence. | ||||||||
| GB_OV: CHKP4HA | 3149 | M26217 | Chicken prolyl 4-hydroxylase alpha subunit gene, 3′ end. | Gallus gallus | 40,655 | 28-Apr-93 | ||
| GB_HTG2: AC008271 | 168302 | AC008271 | Homo sapiens clone NH0123E16, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 37,417 | 31-Jul-99 | ||
| 2 unordered pieces. | ||||||||
| rxa00649 | 579 | GB_PR2: AC002563 | 136436 | AC002563 | Human PAC clone 127H14 from 12q, complete sequence. | Homo sapiens | 37,937 | 26-Sep-97 |
| GB_HTG3: AC011466 | 165953 | AC011466 | Homo sapiens chromosome 19 clone CIT-HSPC_453G23, | Homo sapiens | 38,179 | 07-OCT-1999 | ||
| *** SEQUENCING IN PROGRESS ***, 74 unordered pieces. | ||||||||
| GB_HTG3: AC011466 | 165953 | AC011466 | Homo sapiens chromosome 19 clone CIT-HSPC_453G23, | Homo sapiens | 38,179 | 07-OCT-1999 | ||
| *** SEQUENCING IN PROGRESS ***, 74 unordered pieces. | ||||||||
| rxa00652 | ||||||||
| rxa00653 | ||||||||
| rxa00654 | 1389 | GB_EST1: Z34080 | 271 | Z34080 | ATTS3128 Grenoble-B Arabidopsis thaliana cDNA clone GBGe328 5′, | Arabidopsis thaliana | 40,370 | 6-Jun-94 |
| mRNA sequence. | ||||||||
| GB_PR3: AC004460 | 113803 | AC004460 | Homo sapiens PAC clone DJ1086D14, complete sequence. | Homo sapiens | 36,150 | 24-MAR-1998 | ||
| GB_GSS6: AQ835185 | 571 | AQ835185 | HS_4832_A1_E02_T7A CIT Approved Human Genomic Sperm Library D Homo | Homo sapiens | 39,429 | 27-Aug-99 | ||
| sapiens genomic clone Plate = 4832 Col = 3 Row = I, genomic survey sequence. | ||||||||
| rxa00656 | 384 | GB_HTG3: AC009948 | 172463 | AC009948 | Homo sapiens clone NH0065L03, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 43,164 | 25-Sep-99 |
| 2 unordered pieces. | ||||||||
| GB_HTG3: AC009948 | 172463 | AC009948 | Homo sapiens clone NH0065L03, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 43,164 | 25-Sep-99 | ||
| 2 unordered pieces. | ||||||||
| GB_GSS13: AQ462899 | 522 | AQ462899 | HS_5212_A1_C09_T7A RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 42,529 | 23-Apr-99 | ||
| genomic clone Plate = 788 Col = 17 Row = E, genomic survey sequence. | ||||||||
| rxa00657 | 1026 | GB_BA2: AF064700 | 3481 | AF064700 | Rhodococcus sp. NO1-1 CprS and CprR genes, complete cds. | Rhodococcus sp. NO1-1 | 40,558 | 15-Jul-98 |
| GB_PR3: AC005346 | 38849 | AC005346 | Homo sapiens chromosome 16, cosmid clone 2H2 (LANL), complete sequence. | Homo sapiens | 35,553 | 31-Jul-98 | ||
| GB_HTG3: AC008905 | 129915 | AC008905 | Homo sapiens chromosome 5 clone CITB-H1_2259I14, *** SEQUENCING IN | Homo sapiens | 37,179 | 3-Aug-99 | ||
| PROGRESS ***, 40 unordered pieces. | ||||||||
| rxa00661 | 813 | GB_PL2: AC006193 | 118335 | AC006193 | Arabidopsis thaliana chromosome 1 BAC F13O11 genomic sequence, | Arabidopsis thaliana | 35,513 | 11-Jun-99 |
| complete sequence. | ||||||||
| GB_RO: MMFABPE | 6593 | AJ223066 | Mus musculus Fabpe gene. | Mus musculus | 37,500 | 27-Jul-98 | ||
| GB_PL2: AC006193 | 118335 | AC006193 | Arabidopsis thaliana chromosome 1 BAC F13O11 genomic sequence, | Arabidopsis thaliana | 33,552 | 11-Jun-99 | ||
| complete sequence. | ||||||||
| rxa00662 | 1392 | GB_EST29: AI551960 | 718 | AI551960 | vi48d09.y1 Beddington mouse embryonic region Mus musculus cDNA clone | Mus musculus | 39,972 | 23-MAR-1999 |
| IMAGE: 907025 5′ similar to gb: D10576 Mouse mRNA for ubiquitin activating | ||||||||
| enzyme E1 (MOUSE);, mRNA sequence. | ||||||||
| GB_BA2: AE000633 | 19734 | AE000633 | Helicobacter pylori 26695 section 111 of 134 of the complete genome. | Helicobacter pylori 26695 | 36,606 | 6-Apr-99 | ||
| GB_GSS10: AQ216730 | 529 | AQ216730 | HS_2262_A1_G06_MR CIT Approved Human Genomic Sperm Library D Homo | Homo sapiens | 32,703 | 19-Sep-98 | ||
| sapiens genomic clone Plate = 2262 Col = 11 Row = M, | ||||||||
| genomic survey sequence. | ||||||||
| rxa00666 | 1038 | GB_HTG3: AC009205 | 113482 | AC009205 | Drosophila melanogaster chromosome 2 clone BACR04C20 (D1035) | Drosophila melanogaster | 36,713 | 17-Sep-99 |
| RPCI-98 04.C.20 map 36E-37C strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 101 unordered pieces. | ||||||||
| GB_EST25: AI259480 | 626 | AI259480 | LP02903.5prime LP Drosophila melanogaster larval-early pupal pOT2 | Drosophila melanogaster | 37,173 | 17-Nov-98 | ||
| Drosophila melanogaster cDNA clone LP02903 5prime, mRNA sequence. | ||||||||
| GB_HTG3: AC009205 | 113482 | AC009205 | Drosophila melanogaster chromosome 2 clone BACR04C20 (D1035) | Drosophila melanogaster | 36,713 | 17-Sep-99 | ||
| RPCI-98 04.C.20 map 36E-37C strain y; cn bw sp, | ||||||||
| *** SEQUENCING IN PROGRESS ***, 101 unordered pieces. | ||||||||
| rxa00667 | 1137 | GB_PAT: AR048317 | 2627 | AR048317 | Sequence 3 from patent U.S. Pat. No. 5821090. | Unknown. | 39,805 | 29-Sep-99 |
| GB_PAT: A46560 | 2627 | A46560 | Sequence 3 from Patent WO9526406. | Eremothecium gossypii | 39,805 | 07-MAR-1997 | ||
| GB_VI: HEHCMVCG | 229354 | X17403 | Human cytomegalovirus strain AD169 complete genome. | human herpesvirus 5 | 39,854 | 10-Feb-99 | ||
| rxa00676 | 870 | GB_HTG1: CEY38F1 | 178443 | Z98861 | Caenorhabditis elegans chromosome II clone Y38F1, *** SEQUENCING | Caenorhabditis elegans | 35,880 | 03-DEC-1998 |
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: CEY38F1 | 178443 | Z98861 | Caenorhabditis elegans chromosome II clone Y38F1, *** SEQUENCING IN | Caenorhabditis elegans | 35,880 | 03-DEC-1998 | ||
| PROGRESS ***, in unordered pieces. | ||||||||
| GB_PR3: HS934G17 | 107603 | AL021155 | Homo sapiens DNA sequence from PAC 934G17 on chromosome 1p36.21. | Homo sapiens | 38,489 | 23-Nov-99 | ||
| Contains the alternatively spliced CLCN6 gene for chloride chanel proteins CLC-6A | ||||||||
| (KIAA0046) -B, -C and -D, the alternatively spliced NPPA gene coding for Atrial | ||||||||
| Natriuretic Factor ANF precursor (Atrial Natriuretic peptide ANP, Prepronatriodilatin), | ||||||||
| the NPPB gene for Brain Natriuretic Protein BNP, and a | ||||||||
| pseudogene similar to SBF1 (and other Myotubularin-related protein | ||||||||
| genes). Contains ESTs, STSs and the genomic marker D1S2740, complete sequence. | ||||||||
| rxa00678 | 858 | GB_PR2: CNS00004 | 205573 | AL049778 | Human chromosome 14 DNA sequence *** IN PROGRESS *** BAC R-643C12 of | Homo sapiens | 33,138 | 17-Jun-99 |
| RPCI-11 library from chromosome 14 of Homo sapiens (Human), complete sequence. | ||||||||
| GB_GSS1: AG000894 | 723 | AG000894 | Homo sapiens genomic DNA, 21q region, clone: 64E11X19, | Homo sapiens | 37,391 | 6-Feb-99 | ||
| genomic survey sequence. | ||||||||
| GB_IN1: TSMIEXRNA | 481 | X90847 | Trypanosoma simiae mini-exon DNA. | Trypanosoma simiae | 35,135 | 15-Feb-99 | ||
| rxa00691 | 1053 | GB_EST26: AA899042 | 505 | AA899042 | UI-R-E0-bz-a-06-0-UI.s2 UI-R-E0 Rattus norvegicus cDNA clone | Rattus norvegicus | 41,400 | 4-Jul-99 |
| UI-R-E0-bz-a-06-0-UI 3′ similar to gi|485266|gb|U09256|RNU09256 | ||||||||
| Rattus norvegicus Sprague-Dawley transketolase mRNA, complete cds, | ||||||||
| mRNA sequence. | ||||||||
| GB_RO: RNU09256 | 2098 | U09256 | Rattus norvegicus Sprague-Dawley transketolase mRNA, complete cds. | Rattus norvegicus | 39,652 | 11-MAY-1994 | ||
| GB_EST29: AI599628 | 510 | AI599628 | EST251331 Normalized rat embryo, Bento Soares Rattus sp, cDNA clone REMEH65 | Rattus sp. | 39,096 | 21-Apr-99 | ||
| 3′ end, mRNA sequence. | ||||||||
| rxa00692 | 1257 | GB_PL2: SPU66305 | 8226 | U66305 | Schizosaccharomyces pombe ABC transporter (mam1) gene, complete cds. | Schizosaccharomyces | 36,842 | 30-Jul-97 |
| pombe | ||||||||
| GB_PL1: SPBC25B2 | 26016 | AL031853 | S. pombe chromosome II cosmid c25B2. | Schizosaccharomyces | 36,803 | 09-OCT-1998 | ||
| pombe | ||||||||
| GB_PL1: SPBC2G5 | 23645 | AL033385 | S. pombe chromosome II cosmid c2G5. | Schizosaccharomyces | 36,803 | 04-DEC-1998 | ||
| pombe | ||||||||
| rxa00693 | 606 | GB_BA2: RRU65510 | 16259 | U65510 | Rhodospirillum rubrum CO-induced hydrogenase operon (cooM, cooK, cooL, | Rhodospirillum rubrum | 41,970 | 9-Apr-97 |
| cooX, cooU, cooH) genes, iron sulfur protein (cooF) gene, carbon monoxide | ||||||||
| dehydrogenase (cooS) gene, carbon monoxide dehydrogenase accessory proteins | ||||||||
| (cooC, cooT, cooJ) genes, putative transcriptional activator (cooA) gene, | ||||||||
| nicotinate-nucleotide pyrophosphorylase (nadC) gene, complete cds, | ||||||||
| L-aspartate oxidase (nadB) gene, and alkyl hydroperoxide reductase (ahpC) | ||||||||
| gene, partial cds. | ||||||||
| GB_PL1: LETHM27 | 1152 | X95296 | L. esculentum mRNA for THM27 protein. | Lycopersicon esculentum | 38,919 | 10-Jun-96 | ||
| GB_EST38: AW033855 | 646 | AW033855 | EST277426 tomato callus, TAMU Lycopersicon esculentum cDNA clone cLEC29F6 | Lycopersicon esculentum | 35,945 | 15-Sep-99 | ||
| similar to transcription factor, myb-related, mRNA sequence. | ||||||||
| rxa00701 | 498 | GB_EST34: AI785570 | 454 | AI785570 | uj44d03.x1 Sugano mouse liver mlia Mus musculus cDNA clone IMAGE: 1922789 3′ | Mus musculus | 37,565 | 2-Jul-99 |
| similar to gb: Z28407 60S RIBOSOMAL PROTEIN L8 (HUMAN);, mRNA sequence. | ||||||||
| GB_EST25: AI256147 | 684 | AI256147 | ui95e12.x1 Sugano mouse liver mlia Mus musculus cDNA clone IMAGE: 1890190 | Mus musculus | 41,232 | 12-Nov-98 | ||
| 3′ similar to gb: Z28407 60S RIBOSOMAL PROTEIN L8 (HUMAN);, | ||||||||
| mRNA sequence. | ||||||||
| GB_BA1: CARCG12 | 2079 | X14979 | C. aurantiacus reaction center genes 1 and 2. | Chloroflexus aurantiacus | 36,943 | 23-Apr-91 | ||
| rxa00704 | 750 | GB_EST15: AA497266 | 456 | AA497266 | fa04f08.s1 Zebrafish ICRFzfis Danio rerio cDNA clone 3A13 3′, mRNA sequence. | Danio rerio | 38,631 | 30-Jun-97 |
| GB_EST36: AI884217 | 515 | AI884217 | fc75e10.x1 Zebrafish WashU MPIMG EST Danio rerio cDNA 3′, mRNA sequence. | Danio rerio | 38,012 | 26-Jul-99 | ||
| GB_HTG1: CEY43F8_1 | 110000 | Z95393 | Caenorhabditis elegans chromosome V clone Y43F8, *** SEQUENCING IN | Caenorhabditis elegans | 37,889 | Z95393 | ||
| PROGRESS ***, in unordered pieces. | ||||||||
| rxa00707 | 906 | GB_GSS8: AQ013755 | 715 | AQ013755 | RPCI11-23F24.TKBF RPCI-11 Homo sapiens genomic clone RPCI-11-23F24, | Homo sapiens | 41,724 | 14-Apr-99 |
| genomic survey sequence. | ||||||||
| GB_GSS3: B86449 | 434 | B86449 | RPCI11-23F24.TV RPCI-11 Homo sapiens genomic clone RPCI-11-23F24, | Homo sapiens | 42,936 | 9-Apr-99 | ||
| genomic survey sequence. | ||||||||
| GB_GSS5: AQ797072 | 449 | AQ797072 | nbxb0071D10f CUGI Rice BAC Library Oryza sativa genomic clone nbxb0071D10f, | Oryza sativa | 39,101 | 4-Aug-99 | ||
| genomic survey sequence. | ||||||||
| rxa00712 | 819 | GB_BA2: AF011544 | 7527 | AF011544 | Bacillus subtilis phosphoribosylaminoimidazole-carboxamide formyltransferase | Bacillus subtilis | 36,927 | 06-OCT-1997 |
| (purH-J) gene, partial cds, phosphoribosylglycinamide synthetase (purD), | ||||||||
| YecA (yecA), putative adenine deaminase (yecB), YecC (yecC), and | ||||||||
| YecD (yecD) genes, complete cds, and putative glutamate synthase | ||||||||
| (yecE) gene, partial cds. | ||||||||
| GB_BA2: AF011544 | 7527 | AF011544 | Bacillus subtilis phosphoribosylaminoimidazole-carboxamide formyltransferase | Bacillus subtilis | 39,752 | 06-OCT-1997 | ||
| (purH-J) gene, partial cds, phosphoribosylglycinamide synthetase (purD), | ||||||||
| YecA (yecA), putative adenine deaminase (yecB), YecC (yecC), and | ||||||||
| YecD (yecD) genes, complete cds, and putative glutamate synthase | ||||||||
| (yecE) gene, partial cds. | ||||||||
| rxa00713 | 1056 | GB_PAT: I92037 | 241 | I92037 | Sequence 4 from patent U.S. Pat. No. 5726299. | Unknown. | 99,048 | 01-DEC-1998 |
| GB_PAT: I78748 | 241 | I78748 | Sequence 4 from patent U.S. Pat. No. 5693781. | Unknown. | 99,048 | 3-Apr-98 | ||
| GB_HTG3: AC009281 | 221178 | AC009281 | Homo sapiens chromosome 15 clone 8_C_22 map 15, *** SEQUENCING IN | Homo sapiens | 36,255 | 12-Aug-99 | ||
| PROGRESS ***, 49 unordered pieces. | ||||||||
| rxa00714 | 684 | GB_PL1: CCR5839 | 871 | AJ005839 | Cyclotella cryptica mRNA for fucoxanthin chlorophyll a/c binding protein, fcp12. | Cyclotella cryptica | 36,364 | 30-Jul-98 |
| GB_PR2: HS1002M8 | 111768 | AL035454 | Human DNA sequence from clone 1002M8 on chromosome 20p11.21-11.23, | Homo sapiens | 36,444 | 23-Nov-99 | ||
| complete sequence. | ||||||||
| GB_PR2: HS1002M8 | 111768 | AL035454 | Human DNA sequence from clone 1002M8 on chromosome 20p11.21-11.23, | Homo sapiens | 34,894 | 23-Nov-99 | ||
| complete sequence. | ||||||||
| rxa00716 | 636 | GB_PAT: I78753 | 1187 | I78753 | Sequence 9 from patent U.S. Pat. No. 5693781. | Unknown. | 36,022 | 3-Apr-98 |
| GB_PAT: I92042 | 1187 | I92042 | Sequence 9 from patent U.S. Pat. No. 5726299. | Unknown. | 36,022 | 01-DEC-1998 | ||
| GB_HTG3: AC005769 | 200000 | AC005769 | Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, | Homo sapiens | 36,745 | 21-Aug-99 | ||
| 5 unordered pieces. | ||||||||
| rxa00719 | 1752 | GB_BA2: U32687 | 11847 | U32687 | Haemophilus influenzae Rd section 2 of 163 of the complete genome. | Haemophilus influenzae Rd | 36,937 | 29-MAY-1998 |
| GB_EST13: AA333602 | 357 | AA333602 | EST37710 Embryo, 8 week I Homo sapiens cDNA 5′ end similar to guanine | Homo sapiens | 45,938 | 21-Apr-97 | ||
| nucleotide-binding protein rap2, ras-oncogene related, mRNA sequence. | ||||||||
| GB_BA2: U32687 | 11847 | U32687 | Haemophilus influenzae Rd section 2 of 163 of the complete genome. | Haemophilus influenzae Rd | 36,390 | 29-MAY-1998 | ||
| rxa00720 | 789 | GB_EST1: M61974 | 437 | M61974 | EST00024 Fetal brain, Stratagene (cat#936206) Homo sapiens cDNA | Homo sapiens | 40,138 | 26-MAY-1992 |
| clone HFBA87, mRNA sequence. | ||||||||
| GB_EST3: R73776 | 389 | R73776 | yi55h07.r1 Soares placenta Nb2HP Homo sapiens cDNA | Homo sapiens | 41,818 | 5-Jun-95 | ||
| clone IMAGE: 143197 5′, mRNA sequence. | ||||||||
| GB_EST35: AL043192 | 793 | AL043192 | DKFZp434G0723_r1 434 (synonym: htes3) Homo sapiens | Homo sapiens | 38,571 | 29-Sep-99 | ||
| cDNA clone DKFZp434G0723 5′, mRNA sequence. | ||||||||
| rxa00722 | 1088 | GB_HTG3: AC008573 | 205755 | AC008573 | Homo sapiens chromosome 5 clone CIT-HSPC_551I11, | Homo sapiens | 38,506 | 3-Aug-99 |
| *** SEQUENCING IN PROGRESS ***, 95 unordered pieces. | ||||||||
| GB_HTG3: AC008573 | 205755 | AC008573 | Homo sapiens chromosome 5 clone CIT-HSPC_551I11, | Homo sapiens | 38,506 | 3-Aug-99 | ||
| *** SEQUENCING IN PROGRESS ***, 95 unordered pieces. | ||||||||
| GB_BA1: MTV014 | 58280 | AL021646 | Mycobacterium tuberculosis H37Rv complete genome; segment 137/162. | Mycobacterium | 41,392 | 18-Jun-98 | ||
| tuberculosis | ||||||||
| rxa00724 | 2100 | GB_BA1: SC7A1 | 32039 | AL034447 | Streptomyces coelicolor cosmid 7A1. | Streptomyces coelicolor | 54,858 | 15-DEC-1998 |
| GB_BA1: BSY13937 | 27779 | Y13937 | Bacillus subtilis genomic DNA from the spoVM region. | Bacillus subtilis | 47,010 | 30-MAR-1998 | ||
| GB_BA2: L78127 | 1225 | L78127 | Enterococcus faecium genomic DNA fragment. | Enterococcus faecium | 36,880 | 18-Aug-99 | ||
| rxa00726 | 614 | GB_BA1: BACJH642 | 282700 | D84432 | Bacillus subtilis DNA, 283 Kb region containing skin element. | Bacillus subtilis | 56,694 | 6-Feb-99 |
| GB_BA1: BSUB0013 | 218470 | Z99116 | Bacillus subtilis complete genome (section 13 of 21): from 2395261 to 2613730. | Bacillus subtilis | 36,513 | 26-Nov-97 | ||
| GB_BA1: SC4H8 | 15560 | AL020958 | Streptomyces coelicolor cosmid 4H8. | Streptomyces coelicolor | 35,073 | 10-DEC-1997 | ||
| rxa00729 | ||||||||
| rxa00730 | 930 | GB_HTG3: AC010758 | 145821 | AC010758 | Homo sapiens clone 1_B_18, | Homo sapiens | 35,738 | 22-Sep-99 |
| *** SEQUENCING IN PROGRESS ***, 20 unordered pieces. | ||||||||
| GB_HTG3: AC010758 | 145821 | AC010758 | Homo sapiens clone 1_B_18, | Homo sapiens | 35,738 | 22-Sep-99 | ||
| *** SEQUENCING IN PROGRESS ***, 20 unordered pieces. | ||||||||
| GB_GSS13: AQ469090 | 414 | AQ469090 | CITBI-E1-2596D12.TF CITBI-E1 Homo sapiens | Homo sapiens | 36,842 | 23-Apr-99 | ||
| genomic clone 2596D12, genomic survey sequence. | ||||||||
| rxa00731 | 2619 | GB_BA1: CGLYSI | 4232 | X60312 | C. glutamicum lysl gene for L-lysine permease. | Corynebacterium | 100,000 | 30-Jan-92 |
| glutamicum | ||||||||
| GB_BA1: CGLYSI | 4232 | X60312 | C. glutamicum lysl gene for L-lysine permease. | Corynebacterium | 37,645 | 30-Jan-92 | ||
| glutamicum | ||||||||
| rxa00738 | 386 | GB_BA1: MTCY10G2 | 38970 | Z92539 | Mycobacterium tuberculosis H37Rv complete genome; segment 47/162. | Mycobacterium | 54,427 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_HTG1: HSJ564F22 | 106277 | AL080249 | Homo sapiens chromosome 20 clone RP4-564F22, | Homo sapiens | 44,000 | 23-Nov-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: HSJ564F22 | 106277 | AL080249 | Homo sapiens chromosome 20 clone RP4-564F22, *** SEQUENCING | Homo sapiens | 44,000 | 23-Nov-99 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00740 | 702 | GB_PL2: AF100167 | 1557 | AF100167 | Glycine max unknown mRNA. | Glycine max | 35,823 | 4-Nov-98 |
| GB_EST28: AI465702 | 268 | AI465702 | vw83g01.y1 Stratagene mouse skin (#937313) Mus musculus cDNA | Mus musculus | 43,226 | 09-MAR-1999 | ||
| clone IMAGE: 1261584 5′, mRNA sequence. | ||||||||
| GB_EST20: AA856157 | 359 | AA856157 | vw83g01.r1 Stratagene mouse skin (#937313) Mus musculus cDNA | Mus musculus | 43,226 | 06-MAR-1998 | ||
| clone IMAGE: 1261584 5′, mRNA sequence. | ||||||||
| rxa00741 | 1056 | GB_HTG2: AC007185 | 199340 | AC007185 | Drosophila melanogaster chromosome 2 clone BACR44N04 (D545) | Drosophila melanogaster | 39,583 | 2-Aug-99 |
| RPCI-98 44.N.4 map 36A-36A strain y; cn bw sp, | ||||||||
| *** SEQUENCING IN PROGRESS ***, 50 unordered pieces. | ||||||||
| GB_HTG2: AC007185 | 199340 | AC007185 | Drosophila melanogaster chromosome 2 clone BACR44N04 (D545) RPCI-98 | Drosophila melanogaster | 39,583 | 2-Aug-99 | ||
| 44. N.4 map 36A-36A strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS***, 50 unordered pieces. | ||||||||
| GB_PL2: F17I23 | 134784 | AF160182 | Arabidopsis thaliana BAC F17I23. | Arabidopsis thaliana | 37,788 | 20-Jun-99 | ||
| rxa00742 | 1773 | GB_IN1: CEC05C10 | 26263 | Z48178 | Caenorhabditis elegans cosmid C05C10, complete sequence. | Caenorhabditis elegans | 39,243 | 2-Sep-99 |
| GB_IN1: CEC05C10 | 26263 | Z48178 | Caenorhabditis elegans cosmid C05C10, complete sequence. | Caenorhabditis elegans | 38,041 | 2-Sep-99 | ||
| rxa00743 | 546 | GB_GSS9: AQ093649 | 320 | AQ093649 | HS_3022_A1_E06_MR CIT Approved Human Genomic Sperm Library | Homo sapiens | 34,277 | 27-Aug-98 |
| D Homo sapiens genomic clone Plate = 3022 Col = 11 Row = I, | ||||||||
| genomic survey sequence. | ||||||||
| GB_GSS9: AQ093649 | 320 | AQ093649 | HS_3022_A1_E06_MR CIT Approved Human Genomic Sperm | Homo sapiens | 34,277 | 27-Aug-98 | ||
| Library D Homo sapiens genomic clone Plate = 3022 Col = 11 Row = I, | ||||||||
| genomic survey sequence. | ||||||||
| rxa00745 | 657 | GB_HTG2: AC008195 | 130309 | AC008195 | Drosophila melanogaster chromosome 3 clone BACR42I20 (D748) RPCI-98 | Drosophila melanogaster | 38,095 | 2-Aug-99 |
| 42.I.20 map 93F-93F strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 77 unordered pieces. | ||||||||
| GB_IN2: DMU53190 | 3477 | U53190 | Drosophila melanogaster Camguk (cmg) mRNA, complete cds. | Drosophila melanogaster | 39,623 | 30-Nov-98 | ||
| GB_HTG2: AC008195 | 130309 | AC008195 | Drosophila melanogaster chromosome 3 clone BACR42I20 (D748) | Drosophila melanogaster | 38,095 | 2-Aug-99 | ||
| RPCI-98 42.I.20 map 93F-93F strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 77 unordered pieces. | ||||||||
| rxa00746 | 1314 | GB_HTG3: AC010076 | 148614 | AC010076 | Homo sapiens chromosome 15 clone | Homo sapiens | 36,336 | 11-Sep-99 |
| BAC 64K10 map 14q25, LOW-PASS SEQUENCE SAMPLING. | ||||||||
| GB_HTG3: AC010076 | 148614 | AC010076 | Homo sapiens chromosome 15 clone BAC 64K10 map | Homo sapiens | 36,336 | 11-Sep-99 | ||
| 14q25, LOW-PASS SEQUENCE SAMPLING. | ||||||||
| GB_PR3: HS402G11 | 177241 | AL022328 | Human DNA sequence from clone 402G11 on chromosome | Homo sapiens | 38,752 | 23-Nov-99 | ||
| 22q13.31-13.33 Contains genes for SAPK3 (stress-activated protein kinase 3), | ||||||||
| PRKM11 (protein kinase mitogen-activated 11), | ||||||||
| KIAA0315, ESTs, GSSs and CpG islands, complete sequence. | ||||||||
| rxa00747 | 711 | GB_HTG4: AC010081 | 176777 | AC010081 | Homo sapiens clone NH0065E07, *** SEQUENCING IN | Homo sapiens | 37,016 | 29-OCT-1999 |
| PROGRESS ***, 1 unordered pieces. | ||||||||
| GB_HTG4: AC010081 | 176777 | AC010081 | Homo sapiens clone NH0065E07, *** SEQUENCING IN | Homo sapiens | 37,016 | 29-OCT-1999 | ||
| PROGRESS ***, 1 unordered pieces. | ||||||||
| GB_HTG3: AC011194 | 196098 | AC011194 | Mus musculus chromosome 11 clone 196_F_5 map 11, *** SEQUENCING | Mus musculus | 38,735 | 01-OCT-1999 | ||
| IN PROGRESS ***, 32 unordered pieces. | ||||||||
| rxa00748 | 567 | GB_GSS13: AQ457887 | 478 | AQ457887 | HS_5189_B2_B06_SP6E RPCI-11 Human Male BAC Library | Homo sapiens | 37,844 | 23-Apr-99 |
| Homo sapiens genomic clone Plate = 765 | ||||||||
| Col = 12 Row = D, genomic survey sequence. | ||||||||
| GB_IN1: EHEXRIDRI | 170 | X58630 | E. histolytica extrachromosomal ribosomal DNA for DRA I repeat unit. | Entamoeba histolytica | 42,353 | 13-Aug-91 | ||
| GB_IN1: EHEXRDNA | 3699 | X61182 | E. histolytica extrachromosomal ribosomal DNA downstream of rRNA genes. | Entamoeba histolytica | 38,905 | 2-Sep-96 | ||
| rxa00749 | 822 | GB_BA1: BSUB0003 | 209100 | Z99106 | Bacillus subtilis complete genome (section 3 of 21): from 402751 to 611850. | Bacillus subtilis | 37,238 | 26-Nov-97 |
| GB_BA1: AB001488 | 148068 | AB001488 | Bacillus subtilis genome sequence, 148 kb sequence of the region | Bacillus subtilis | 37,238 | 13-Feb-99 | ||
| between 35 and 47 degree. | ||||||||
| GB_HTG3: AC008060 | 161486 | AC008060 | Homo sapiens clone DJ0912I13, *** SEQUENCING IN | Homo sapiens | 39,474 | 13-Aug-99 | ||
| PROGRESS ***, 4 unordered pieces. | ||||||||
| rxa00750 | ||||||||
| rxa00751 | 951 | GB_PR4: AC006449 | 286758 | AC006449 | Homo sapiens chromosome 17, clone hCIT.58_E_17, complete sequence. | Homo sapiens | 38,223 | 23-OCT-1999 |
| GB_HTG2: AC002118 | 170891 | AC002118 | Homo sapiens chromosome 17 clone 303_E_14, *** SEQUENCING | Homo sapiens | 37,112 | 13-Feb-98 | ||
| IN PROGRESS ***, 20 unordered pieces. | ||||||||
| GB_HTG2: AC002118 | 170891 | AC002118 | Homo sapiens chromosome 17 clone 303_E_14, *** SEQUENCING | Homo sapiens | 37,112 | 13-Feb-98 | ||
| IN PROGRESS ***, 20 unordered pieces. | ||||||||
| rxa00752 | 552 | GB_PL2: F5K24 | 109786 | AF128395 | Arabidopsis thaliana BAC F5K24. | Arabidopsis thaliana | 38,899 | 03-MAR-1999 |
| GB_BA1: MBHRDED | 6300 | Y09870 | M. barkeri hdrE & hdrD genes, ORF1, ORF2, ORF3 & ORF4. | Methanosarcina barkeri | 40,609 | 04-DEC-1998 | ||
| GB_PL1: SC9920 | 23498 | Z48639 | S. cerevisiae chromosome XIII cosmid 9920. | Saccharomyces cerevisiae | 35,754 | 11-Aug-97 | ||
| rxa00757 | 1377 | GB_PAT: E13655 | 2260 | E13655 | gDNA encoding glucose-6-phosphate dehydrogenase. | Corynebacterium | 46,045 | 24-Jun-98 |
| glutamicum | ||||||||
| GB_GSS9: AQ103710 | 369 | AQ103710 | HS_3092_B1_C01_MF CIT Approved Human Genomic Sperm Library D | Homo sapiens | 36,339 | 27-Aug-98 | ||
| Homo sapiens genomic clone Plate = 3092 | ||||||||
| Col = 1 Row = F, genomic survey sequence. | ||||||||
| GB_HTG3: AC009305 | 167705 | AC009305 | Homo sapiens clone NH0153B21, *** SEQUENCING IN | Homo sapiens | 36,691 | 13-Aug-99 | ||
| PROGRESS ***, 3 unordered pieces. | ||||||||
| rxa00763 | 906 | GB_BA1: SC7B7 | 13800 | AL009199 | Streptomyces coelicolor cosmid 7B7. | Streptomyces coelicolor | 39,013 | 02-DEC-1997 |
| GB_HTG2: HSJ473J16 | 203460 | AL109942 | Homo sapiens chromosome 6 clone RP3-473J16 map q25.3-26, | Homo sapiens | 38,192 | 03-DEC-1999 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG2: HSJ473J16 | 203460 | AL109942 | Homo sapiens chromosome 6 clone RP3-473J16 map q25.3-26, | Homo sapiens | 38,192 | 03-DEC-1999 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00765 | 810 | GB_BA1: MTV043 | 68848 | AL022004 | Mycobacterium tuberculosis H37Rv complete genome; segment 40/162. | Mycobacterium | 38,568 | 24-Jun-99 |
| tuberculosis | ||||||||
| GB_BA2: PAU93274 | 8008 | U93274 | Pseudomonas aeruginosa YafE (yafE), LeuB (leuB), Asd (asd), FimV (fimV), | Pseudomonas aeruginosa | 37,656 | 23-Jun-98 | ||
| and HisT (hisT) genes, complete cds; TrpF (trpF) gene, partial cds; and unknown gene. | ||||||||
| GB_BA1: MTCY31 | 37630 | Z73101 | Mycobacterium tuberculosis H37Rv complete genome; segment 41/162. | Mycobacterium | 38,209 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| rxa00768 | 1242 | GB_HTG5: AC008194 | 194555 | AC008194 | Drosophila melanogaster chromosome X clone BACR49A05 (D745) | Drosophila melanogaster | 34,078 | 15-Nov-99 |
| RPCI-98 49.A.5 map 18A-18A strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 90 unordered pieces. | ||||||||
| GB_HTG5: AC008194 | 194555 | AC008194 | Drosophila melanogaster chromosome X clone BACR49A05 (D745) | Drosophila melanogaster | 31,194 | 15-Nov-99 | ||
| RPCI-98 49.A.5 map 18A-18A strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 90 unordered pieces. | ||||||||
| GB_BA2: AF044495 | 9599 | AF044495 | Agrobacterium tumefaciens chemotaxis operon, complete sequence. | Agrobacterium tumefaciens | 40,165 | 2-Jul-98 | ||
| rxa00769 | 336 | GB_PR3: AC003068 | 42184 | AC003068 | Human Cosmid g5129z059 from 7q31.3, complete sequence. | Homo sapiens | 35,152 | 6-Nov-97 |
| GB_PR2: HSAC000374 | 41585 | AC000374 | Human cosmid g1980a170, complete sequence. | Homo sapiens | 35,152 | 12-MAR-1997 | ||
| GB_PR3: AC003068 | 42184 | AC003068 | Human Cosmid g5129z059 from 7q31.3, complete sequence. | Homo sapiens | 37,309 | 6-Nov-97 | ||
| rxa00771 | 942 | GB_PR2: HS172K2 | 131234 | Z84814 | Human DNA sequence from PAC 172K2 on chromosome 6 contains | Homo sapiens | 34,719 | 23-Nov-99 |
| HLA CLASS II DRA pseudogene, DRB3*01012 genes, DRB9 | ||||||||
| pseudogene butyrophilin precursor and ESTs. | ||||||||
| GB_HTG1: HSA555E18 | 1177 | AL121780 | Homo sapiens chromosome 20 clone RP11-555E18, *** SEQUENCING IN | Homo sapiens | 41,450 | 23-Nov-99 | ||
| PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: HSA555E18 | 1177 | AL121780 | Homo sapiens chromosome 20 clone RP11-555E18, *** SEQUENCING | Homo sapiens | 41,450 | 23-Nov-99 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00781 | 411 | GB_PR3: HS48A11 | 129294 | AL031132 | Human DNA sequence from clone 48A11 on chromosome 20p12 | Homo sapiens | 37,284 | 23-Nov-99 |
| Contains EST, STS, GSS, complete sequence. | ||||||||
| GB_IN1: CELC03B1 | 42297 | U40952 | Caenorhabditis elegans cosmid C03B1. | Caenorhabditis elegans | 38,177 | 25-Nov-95 | ||
| GB_PR3: HS48A11 | 129294 | AL031132 | Human DNA sequence from clone 48A11 on chromosome 20p12 | Homo sapiens | 35,162 | 23-Nov-99 | ||
| Contains EST, STS, GSS, complete sequence. | ||||||||
| rxa00785 | 680 | GB_EST11: AA223451 | 349 | AA223451 | zr06d01.r1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA | Homo sapiens | 38,682 | 19-Feb-97 |
| clone IMAGE: 650689 5′, mRNA sequence. | ||||||||
| GB_EST9: AA081255 | 446 | AA081255 | zn33d08.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone IMAGE: | Homo sapiens | 40,271 | 21-OCT-1996 | ||
| 549231 5′, mRNA sequence. | ||||||||
| GB_EST9: C16722 | 314 | C16722 | C16722 Clontech human aorta polyA+ mRNA (#6572) Homo sapiens cDNA clone | Homo sapiens | 44,013 | 30-Sep-96 | ||
| GEN-522C02 5′, mRNA sequence. | ||||||||
| rxa00788 | 348 | GB_PL2: UMU62738 | 13812 | U62738 | Ustilago maydis ferrichrome siderophore peptide synthetase (sid2) gene, complete cds. | Ustilago maydis | 31,792 | 30-DEC-1997 |
| GB_PR1: AB012723 | 40850 | AB012723 | Homo sapiens gene for kinesin-like protein, complete cds. | Homo sapiens | 35,398 | 8-Jan-99 | ||
| GB_HTG3: AC008625 | 16830 | AC008625 | Homo sapiens chromosome 5 clone CIT978SKB_157D17, *** SEQUENCING | Homo sapiens | 42,560 | 3-Aug-99 | ||
| IN PROGRESS ***, 19 unordered pieces. | ||||||||
| rxa00795 | 651 | GB_IN2: AC003120 | 59991 | AC003120 | Drosophila melanogaster DNA sequence (P1 DS01523 (D34)), complete sequence. | Drosophila melanogaster | 39,252 | 17-Jul-98 |
| GB_EST19: AA802212 | 574 | AA802212 | GM04027.5 prime GM Drosophila melanogaster ovary BlueScript | Drosophila melanogaster | 37,828 | 25-Nov-98 | ||
| Drosophila melanogaster cDNA clone GM04027 5prime, mRNA sequence. | ||||||||
| GB_IN2: AF168467 | 4652 | AF168467 | Drosophila melanogaster dual specificity kinase DYRK2 mRNA, complete cds. | Drosophila melanogaster | 36,933 | 5-Aug-99 | ||
| rxa00804 | 567 | GB_GSS12: AQ356039 | 499 | AQ356039 | CITBI-E1-2535P11.TR CITBI-E1 Homo sapiens genomic clone | Homo sapiens | 40,569 | 24-Jan-99 |
| 2535P11, genomic survey sequence. | ||||||||
| GB_PR4: AC005037 | 190508 | AC005037 | Homo sapiens clone NH0469M07, complete sequence. | Homo sapiens | 41,209 | 14-MAY-1999 | ||
| GB_HTG5: AC007272 | 175463 | AC007272 | Homo sapiens clone NH0013J08, *** SEQUENCING IN | Homo sapiens | 41,209 | 2-Nov-99 | ||
| PROGRESS ***, 5 unordered pieces. | ||||||||
| rxa00805 | 1005 | GB_GSS1: CNS00U61 | 320 | AL090583 | Arabidopsis thaliana genome survey sequence SP6 end of BAC T6D17 of TAMU | Arabidopsis thaliana | 36,364 | 28-Jun-99 |
| library from strain Columbia of | ||||||||
| Arabidopsis thaliana , genomic survey sequence. | ||||||||
| GB_PL1: AB026639 | 63921 | AB026639 | Arabidopsis thaliana genomic DNA, chromosome 5, TAC clone: | Arabidopsis thaliana | 38,485 | 07-MAY-1999 | ||
| K21L13, complete sequence. | ||||||||
| GB_PL1: AB026639 | 63921 | AB026639 | Arabidopsis thaliana genomic DNA, chromosome 5, TAC clone: | Arabidopsis thaliana | 35,451 | 07-MAY-1999 | ||
| K21L13, complete sequence. | ||||||||
| rxa00808 | 1581 | GB_BA1: MLCB2548 | 38916 | AL023093 | Mycobacterium leprae cosmid B2548. | Mycobacterium leprae | 50,854 | 27-Aug-99 |
| GB_BA1: MLCL373 | 37304 | AL035500 | Mycobacterium leprae cosmid L373. | Mycobacterium leprae | 40,295 | 27-Aug-99 | ||
| GB_PL2: SCE9781 | 68302 | U18916 | Saccharomyces cerevisiae chromosome V cosmids 9781, 8198, 9115, | Saccharomyces cerevisiae | 37,677 | 1-Aug-97 | ||
| 9981, and lambda clones 3955 and 6052. | ||||||||
| rxa00812 | 1182 | GB_HTG2: AC006003 | 114949 | AC006003 | Homo sapiens clone DJ0782K24, *** SEQUENCING IN | Homo sapiens | 35,284 | 22-Nov-98 |
| PROGRESS ***, 16 unordered pieces. | ||||||||
| GB_HTG2: AC006003 | 114949 | AC006003 | Homo sapiens clone DJ0782K24, *** SEQUENCING IN | Homo sapiens | 35,284 | 22-Nov-98 | ||
| PROGRESS ***, 16 unordered pieces. | ||||||||
| GB_GSS9: AQ090529 | 323 | AQ090529 | HS_3007_B1_E09_MR CIT Approved Human Genomic Sperm | Homo sapiens | 41,176 | 26-Aug-98 | ||
| Library D Homo sapiens genomic clone Plate = 3007 Col = 17 | ||||||||
| Row = J, genomic survey sequence. | ||||||||
| rxa00814 | 897 | GB_VI: EHVU20824 | 184427 | U20824 | Equine herpesvirus 2, complete genome. | Equine herpesvirus 2 | 35,274 | 2-Feb-96 |
| GB_VI: EHVU20824 | 184427 | U20824 | Equine herpesvirus 2, complete genome. | Equine herpesvirus 2 | 38,808 | 2-Feb-96 | ||
| GB_PR3: HS466N1 | 79528 | Z97630 | Human DNA sequence from clone 466N1 on chromosome 22q12-13 Contains | Homo sapiens | 38,496 | 23-Nov-99 | ||
| H1F0(H1 histone family, member 0) gene, 2-amino-3-ketobutyrate-CoA | ||||||||
| ligase(nuclear gene encoding mitochondrial | ||||||||
| protein), GALR3 (galanin receptor) gene, ESTs, | ||||||||
| GSSs and CpG islands, complete sequence. | ||||||||
| rxa00815 | 696 | GB_PR3: CNS01DRL | 174928 | AL117355 | Human chromosome 14 DNA sequence *** IN PROGRESS *** BAC | Homo sapiens | 36,578 | 26-Nov-99 |
| R-354E14 of RPCI-11 library from chromosome 14 of | ||||||||
| Homo sapiens (Human), complete sequence. | ||||||||
| GB_PR4: AC007283 | 127361 | AC007283 | Homo sapiens clone NH0536I18, complete sequence. | Homo sapiens | 37,609 | 28-Sep-99 | ||
| GB_EST14: AA406984 | 477 | AA406984 | MBAFCZ7H08T3 Brugia malayi adult female cDNA (SAW96MLW-BmAF) | Brugia malayi | 41,919 | 01-MAY-1997 | ||
| Brugia malayi cDNA clone AFCZ7H08 5′, mRNA sequence. | ||||||||
| rxa00816 | 420 | GB_EST27: AI414036 | 467 | AI414036 | ma03e08.x1 Soares mouse p3NMF19.5 Mus musculus cDNA clone IMAGE: | Mus musculus | 40,176 | 9-Feb-99 |
| 303494 3′ similar to TR: Q85299 Q85299 HOMOLOGUE OF | ||||||||
| RETROVIRAL PSEUDOPROTEASE.;, mRNA sequence. | ||||||||
| GB_GSS15: AQ642295 | 501 | AQ642295 | RPCI93-Dpnll-28G21.TV RPCI93-Dpnll Trypanosoma brucei genomic clone | Trypanosoma brucei | 37,540 | 8-Jul-99 | ||
| RPCI93-Dpnll-28G21, genomic survey sequence. | ||||||||
| GB_PL2: ZMU82481 | 2750 | U82481 | Zea mays KI domain interacting kinase 1 (KIK1) mRNA, complete cds. | Zea mays | 41,783 | 1-Jan-98 | ||
| rxa00826 | 654 | GB_PR4: AC008179 | 181745 | AC008179 | Homo sapiens clone NH0576F01, complete sequence. | Homo sapiens | 35,736 | 28-Sep-99 |
| GB_HTG1: AC002413 | 63369 | AC002413 | Homo sapiens chromosome X clone bWXD111, *** SEQUENCING IN | Homo sapiens | 37,600 | 12-Aug-97 | ||
| PROGRESS ***, 2 unordered pieces. | ||||||||
| GB_HTG1: AC002413 | 63369 | AC002413 | Homo sapiens chromosome X clone bWXD111, *** SEQUENCING IN | Homo sapiens | 37,600 | 12-Aug-97 | ||
| PROGRESS ***, 2 unordered pieces. | ||||||||
| rxa00830 | 846 | GB_GSS6: AQ823465 | 535 | AQ823465 | HS_3217_A1_D08_T7C CIT Approved Human Genomic Sperm Library | Homo sapiens | 40,417 | 26-Aug-99 |
| D Homo sapiens genomic clone Plate = 3217 Col = 15 | ||||||||
| Row = G, genomic survey sequence. | ||||||||
| GB_GSS6: AQ825402 | 381 | AQ825402 | HS_5498_A1_G01_SP6E RPCI-11 Human Male BAC Library | Homo sapiens | 43,068 | 26-Aug-99 | ||
| Homo sapiens genomic clone Plate = 1074 Col = 1 | ||||||||
| Row = M, genomic survey sequence. | ||||||||
| GB_HTG1: HSU242F8 | 92944 | AL022167 | Homo sapiens chromosome X clone LL0XNC01-242F8, *** SEQUENCING | Homo sapiens | 38,321 | 23-Nov-99 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00831 | ||||||||
| rxa00835 | 1077 | GB_EST35: AI864917 | 468 | AI864917 | wj66f11.x1 NCI_CGAP_Lu19 Homo sapiens cDNA clone IMAGE: | Homo sapiens | 37,607 | 30-Aug-99 |
| 2407821 3′ similar to WP: F01F1.9 CE01235 | ||||||||
| VACUOLAR AMINOPEPTIDASE;, mRNA sequence. | ||||||||
| GB_EST35: AI864917 | 468 | AI864917 | wj66f11.x1 NCI_CGAP_Lu19 Homo sapiens cDNA clone IMAGE: | Homo sapiens | 38,444 | 30-Aug-99 | ||
| 2407821 3′ similar to WP: F01F1.9 CE01235 | ||||||||
| VACUOLAR AMINOPEPTIDASE;, mRNA sequence. | ||||||||
| rxa00836 | 1816 | GB_EST11: AA212728 | 424 | AA212728 | mw81g02.r1 Soares mouse NML Mus musculus cDNA clone IMAGE: | Mus musculus | 40,284 | 18-Feb-97 |
| 677138 5′, mRNA sequence. | ||||||||
| GB_EST26: AI390258 | 557 | AI390258 | mw81g02.y1 Soares mouse NML Mus musculus cDNA clone IMAGE: | Mus musculus | 41,261 | 2-Feb-99 | ||
| 677138 5′, mRNA sequence. | ||||||||
| GB_PR3: AC003669 | 159446 | AC003669 | Homo sapiens Xp22 BAC GS-594A7 (Genome Systems Human BAC | Homo sapiens | 34,914 | 24-MAR-1998 | ||
| library) contains Bmx gene, complete sequence. | ||||||||
| rxa00840 | ||||||||
| rxa00841 | ||||||||
| rxa00846 | 993 | GB_BA1: U00017 | 42157 | U00017 | Mycobacterium leprae cosmid B2126. | Mycobacterium leprae | 35,635 | 01-MAR-1994 |
| GB_BA1: MLCB2533 | 40245 | AL035310 | Mycobacterium leprae cosmid B2533. | Mycobacterium leprae | 38,280 | 27-Aug-99 | ||
| GB_RO: AB022047S7 | 18721 | AB022053 | Mus musculus gene for prolyl oligopeptidase, exon | Mus musculus | 36,633 | 20-Aug-99 | ||
| 11, 12, 13, 14, 15 and complete cds. | ||||||||
| rxa00853 | 726 | GB_PR3: HS531H16 | 155116 | AL031664 | Human DNA sequence *** SEQUENCING IN PROGRESS *** from | Homo sapiens | 41,110 | 23-Nov-99 |
| clone 531H16, complete sequence. | ||||||||
| GB_PR3: HS531H16 | 155116 | AL031664 | Human DNA sequence *** SEQUENCING IN PROGRESS *** from | Homo sapiens | 37,343 | 23-Nov-99 | ||
| clone 531H16, complete sequence. | ||||||||
| GB_HTG3: AC010264 | 81671 | AC010264 | Homo sapiens chromosome 5 clone CIT-HSPC_468K18, *** SEQUENCING | Homo sapiens | 38,776 | 15-Sep-99 | ||
| IN PROGRESS ***, 66 unordered pieces. | ||||||||
| rxa00854 | 336 | GB_IN1: CELM04G7 | 41778 | AF036700 | Caenorhabditis elegans cosmid M04G7. | Caenorhabditis elegans | 37,349 | 05-DEC-1997 |
| GB_EST20: AA850405 | 451 | AA850405 | EST193172 Normalized rat ovary, Bento Soares Rattus sp. cDNA clone | Rattus sp. | 40,789 | 30-Apr-98 | ||
| ROVAF27 3′ end, mRNA sequence. | ||||||||
| GB_HTG2: AF165144 | 110891 | AF165144 | Homo sapiens chromosome 8 clone BAC 393A07 map 8q, *** SEQUENCING | Homo sapiens | 34,234 | 16-Jul-99 | ||
| IN PROGRESS ***, in ordered pieces. | ||||||||
| rxa00855 | 408 | GB_HTG2: AC007173 | 140775 | AC007173 | Drosophila melanogaster chromosome 2 clone BACR01A03 (D538) | Drosophila melanogaster | 36,341 | 2-Aug-99 |
| RPCI-98 01.A.3 map 36E-36E strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 36 unordered pieces. | ||||||||
| GB_HTG2: AC007173 | 140775 | AC007173 | Drosophila melanogaster chromosome 2 clone BACR01A03 (D538) | Drosophila melanogaster | 36,341 | 2-Aug-99 | ||
| RPCI-98 01.A.3 map 36E-36E strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 36 unordered pieces. | ||||||||
| GB_PL2: YSCH8179 | 44113 | U00062 | Saccharomyces cerevisiae chromosome VIII cosmid 8179. | Saccharomyces cerevisiae | 38,560 | 4-Sep-97 | ||
| rxa00861 | 426 | GB_BA1: CGORF4GEN | 2398 | X95649 | C. glutamicum ORF4 gene. | Corynebacterium | 100,000 | 10-MAR-1998 |
| glutamicum | ||||||||
| GB_BA1: SC9A10 | 9000 | AL031260 | Streptomyces coelicolor cosmid 9A10. | Streptomyces coelicolor | 63,830 | 11-Aug-98 | ||
| GB_BA2: AF039028 | 2475 | AF039028 | Streptomyces toyocaensis D-ala-D-ala dipeptidase (vanXst) gene, | Streptomyces toyocaensis | 61,939 | 5-Jan-99 | ||
| complete cds; and unknown gene. | ||||||||
| rxa00862 | 682 | GB_PAT: E14520 | 2001 | E14520 | DNA encoding Brevibacterium dihydrodipicolinic acid synthase. | Corynebacterium | 36,154 | 28-Jul-99 |
| glutamicum | ||||||||
| GB_PAT: E12773 | 2001 | E12773 | DNA encoding Brevibacterium dihydrodipicolinic acid reductase. | Corynebacterium | 36,154 | 24-Jun-98 | ||
| glutamicum | ||||||||
| GB_PAT: E16749 | 2001 | E16749 | gDNA encoding dihydrodipicolinate synthase (DDPS). | Corynebacterium | 36,154 | 28-Jul-99 | ||
| glutamicum | ||||||||
| rxa00869 | 1044 | GB_EST24: AI166579 | 645 | AI166579 | xylem.est.398 Poplar xylem Lambda ZAPII library Populus balsamifera subsp. | Populus balsamifera | 39,854 | 03-DEC-1998 |
| trichocarpa cDNA 5′, mRNA sequence. | subsp. trichocarpa | |||||||
| GB_BA1: MTCY06H11 | 38000 | Z85982 | Mycobacterium tuberculosis H37Rv complete genome; segment 73/162. | Mycobacterium | 42,801 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| GB_EST34: AV153098 | 283 | AV153098 | AV153098 Mus musculus hippocampus C57BL/6J adult Mus musculus | Mus musculus | 39,576 | 7-Jul-99 | ||
| cDNA clone 2900052L10, mRNA sequence. | ||||||||
| rxa00874 | 1212 | GB_HTG2: AC007885 | 108561 | AC007885 | Drosophila melanogaster chromosome 2 clone BACR02G15 (D643) RPCI-98 | Drosophila melanogaster | 38,276 | 2-Aug-99 |
| 02.G.15 map 60F-60F strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 65 unordered pieces. | ||||||||
| GB_HTG2: AC007582 | 127205 | AC007582 | Drosophila melanogaster chromosome 2 clone BACR17E16 (D642) RPCI-98 | Drosophila melanogaster | 36,246 | 2-Aug-99 | ||
| 17.E.16 map 60F-60F strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 81 unordered pieces. | ||||||||
| GB_HTG2: AC007885 | 108561 | AC007885 | Drosophila melanogaster chromosome 2 clone BACR02G15 (D643) RPCI-98 | Drosophila melanogaster | 38,276 | 2-Aug-99 | ||
| 02.G.15 map 60F-60F strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 65 unordered pieces. | ||||||||
| rxa00876 | 1878 | GB_EST10: AA144736 | 479 | AA144736 | mr72d08.r1 Stratagene mouse testis (#937308) Mus musculus cDNA | Mus musculus | 41,474 | 11-Feb-97 |
| clone IMAGE: 602991 5′, mRNA sequence. | ||||||||
| GB_EST32: AU069076 | 316 | AU069076 | AU069076 Rice callus Oryza sativa cDNA clone C51993_1A, mRNA sequence. | Oryza sativa | 46,330 | 7-Jun-99 | ||
| GB_EST10: AA144736 | 479 | AA144736 | mr72d08.r1 Stratagene mouse testis (#937308) Mus musculus cDNA | Mus musculus | 43,243 | 11-Feb-97 | ||
| clone IMAGE: 602991 5′, mRNA sequence. | ||||||||
| rxa00881 | 501 | GB_HTG4: AC010103 | 192320 | AC010103 | Homo sapiens chromosome unknown clone NH0508H21, WORKING | Homo sapiens | 36,620 | 29-OCT-1999 |
| DRAFT SEQUENCE, in unordered pieces. | ||||||||
| GB_HTG4: AC010103 | 192320 | AC010103 | Homo sapiens chromosome unknown clone NH0508H21, WORKING | Homo sapiens | 36,620 | 29-OCT-1999 | ||
| DRAFT SEQUENCE, in unordered pieces. | ||||||||
| GB_HTG4: AC010103 | 192320 | AC010103 | Homo sapiens chromosome unknown clone NH0508H21, WORKING | Homo sapiens | 34,280 | 29-OCT-1999 | ||
| DRAFT SEQUENCE, in unordered pieces. | ||||||||
| rxa00882 | 801 | GB_BA1: MTCY48 | 35377 | Z74020 | Mycobacterium tuberculosis H37Rv complete genome; segment 69/162. | Mycobacterium | 37,927 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_PAT: AR005211 | 3453 | AR005211 | Sequence 1 from patent U.S. Pat. No.5747651. | Unknown. | 39,620 | 04-DEC-1998 | ||
| GB_PAT: I40600 | 3453 | I40600 | Sequence 1 from patent U.S. Pat. No.5621090. | Unknown. | 39,620 | 13-MAY-1997 | ||
| rxa00883 | 642 | GB_PR2: HS217O16 | 87552 | AL031771 | Human DNA sequence from clone 217O16 on chromosome 6q24 | Homo sapiens | 33,866 | 23-Nov-99 |
| Contains GSS, complete sequence. | ||||||||
| GB_PR2: HS217O16 | 87552 | AL031771 | Human DNA sequence from clone 217O16 on chromosome | Homo sapiens | 35,479 | 23-Nov-99 | ||
| 6q24 Contains GSS, complete sequence. | ||||||||
| rxa00887 | ||||||||
| rxa00889 | 711 | GB_BA1: MTCY27 | 27548 | Z95208 | Mycobacterium tuberculosis H37Rv complete genome; segment 104/162. | Mycobacterium | 36,978 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_BA1: U00016 | 42931 | U00016 | Mycobacterium leprae cosmid B1937. | Mycobacterium leprae | 55,651 | 01-MAR-1994 | ||
| GB_PR4: AC007326 | 102898 | AC007326 | Homo sapiens , complete sequence. | Homo sapiens | 40,205 | 2-Nov-99 | ||
| rxa00893 | 720 | GB_PL1: HVCPMII | 6225 | Y09602 | H. vulgare gene encoding serine carboxypeptidase II, CP-MII. | Hordeum vulgare | 35,704 | 10-MAR-1997 |
| GB_EST35: AI814621 | 441 | AI814621 | wj75d04.x1 NCI_CGAP_Lu19 Homo sapiens cDNA clone IMAGE: 2408647 | Homo sapiens | 37,788 | 24-Aug-99 | ||
| 3′ similar to TR: O00578 O00578 KIAA0167. [1];, mRNA sequence. | ||||||||
| GB_EST3: R51723 | 376 | R51723 | yg77h06.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE: | Homo sapiens | 41,489 | 18-MAY-1995 | ||
| 39671 5′ similar to gb: M77016 TROPOMODULIN (HUMAN);, mRNA sequence. | ||||||||
| rxa00895 | 714 | GB_HTG3: AC009414 | 188673 | AC009414 | Homo sapiens clone NH0490M08, *** SEQUENCING IN | Homo sapiens | 36,775 | 17-Sep-99 |
| PROGRESS ***, 5 unordered pieces. | ||||||||
| GB_HTG3: AC009414 | 188673 | AC009414 | Homo sapiens clone NH0490M08, *** SEQUENCING IN | Homo sapiens | 36,775 | 17-Sep-99 | ||
| PROGRESS ***, 5 unordered pieces. | ||||||||
| GB_PR3: HSJ824F16 | 139330 | AL050325 | Human DNA sequence from clone 824F16 on chromosome 20, complete sequence. | Homo sapiens | 37,286 | 23-Nov-99 | ||
| rxa00904 | 815 | GB_HTG5: AC006447 | 141662 | AC006447 | Mus musculus , *** SEQUENCING IN PROGRESS ***, 2 unordered pieces. | Mus musculus | 35,945 | 17-Nov-99 |
| GB_HTG5: AC011064 | 233428 | AC011064 | Drosophila melanogaster chromosome X clone BACN05G06 (D1107) | Drosophila melanogaster | 37,783 | 16-Nov-99 | ||
| RPCI-98 05.G.6 map 12F-13A strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 220 unordered pieces. | ||||||||
| GB_HTG6: AC008334 | 154566 | AC008334 | Drosophila melanogaster chromosome X clone BACR08K05 (D885) RPCI-98 | Drosophila melanogaster | 37,783 | 02-DEC-1999 | ||
| 08.K.5 map 12F-12F strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 84 unordered pieces. | ||||||||
| rxa00908 | 681 | GB_GSS12: AQ409791 | 561 | AQ409791 | HS_5090_B2_B12_T7A RPCI-11 Human Male BAC Library | Homo sapiens | 39,711 | 17-MAR-1999 |
| Homo sapiens genomic clone Plate = 666 Col = 24 Row = D, | ||||||||
| genomic survey sequence. | ||||||||
| GB_GSS3: B83773 | 535 | B83773 | CpG0110A CpIOWAgDNA1 Cryptosporidium parvum genomic, | Cryptosporidium parvum | 44,615 | 06-MAY-1999 | ||
| genomic survey sequence. | ||||||||
| GB_GSS12: AQ409791 | 561 | AQ409791 | HS_5090_B2_B12_T7A RPCI-11 Human Male BAC Library Homo sapiens | Homo sapiens | 41,333 | 17-MAR-1999 | ||
| genomic clone Plate = 666 Col = 24 | ||||||||
| Row = D, genomic survey sequence. | ||||||||
| rxa00915 | 753 | GB_HTG2: HS1118M15 | 190466 | AL109964 | Homo sapiens chromosome 20 clone RP5-1118M15, *** SEQUENCING | Homo sapiens | 40,027 | 30-Nov-99 |
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG2: HS1057B20 | 204291 | AL109823 | Homo sapiens chromosome 20 clone RP5-1057B20 map q11.21-12, | Homo sapiens | 38,535 | 30-Nov-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG2: HS1118M15 | 190466 | AL109964 | Homo sapiens chromosome 20 clone RP5-1118M15, | Homo sapiens | 40,027 | 30-Nov-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00916 | 3714 | GB_EST28: AI543268 | 568 | AI543268 | SD09973.5prime SD Drosophila melanogaster Schneider L2 cell | Drosophila melanogaster | 40,426 | 22-MAR-1999 |
| culture pOT2 Drosophila melanogaster cDNA clone | ||||||||
| SD09973 5prime, mRNA sequence. | ||||||||
| GB_IN2: AC004301 | 68620 | AC004301 | Drosophila melanogaster DNA sequence (P1 DS07134 (D192)), complete sequence. | Drosophila melanogaster | 37,696 | 29-MAY-1998 | ||
| GB_EST37: AI994315 | 524 | AI994315 | 701502677 A. thaliana , Ohio State clone set Arabidopsis thaliana | Arabidopsis thaliana | 40,076 | 8-Sep-99 | ||
| cDNA clone 701502677, mRNA sequence. | ||||||||
| rxa00917 | 2802 | GB_BA1: SYCSLRB | 146271 | D64000 | Synechocystis sp. PCC6803 complete genome, 19/27, 2392729-2538999. | Synechocystis sp. | 38,447 | 13-Feb-99 |
| GB_HTG1: CEY39E4_2 | 110000 | Z94158 | Caenorhabditis elegans chromosome III clone Y39E4, *** SEQUENCING | Caenorhabditis elegans | 38,218 | Z94158 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: CEY39E4_2 | 110000 | Z94158 | Caenorhabditis elegans chromosome III clone Y39E4, *** SEQUENCING | Caenorhabditis elegans | 38,218 | Z94158 | ||
| IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa00921 | ||||||||
| rxa00926 | 486 | GB_OM: SSU75316 | 5996 | U75316 | Sus scrofa beta-myosin heavy chain mRNA, complete cds. | Sus scrofa | 38,958 | 03-DEC-1996 |
| GB_EST21: AA970971 | 371 | AA970971 | op10b11.s1 NCI_CGAP_Kid6 Homo sapiens cDNA clone IMAGE: | Homo sapiens | 40,841 | 13-Apr-99 | ||
| 1575261 3′, mRNA sequence. | ||||||||
| GB_OM: SSU75316 | 5996 | U75316 | Sus scrofa beta-myosin heavy chain mRNA, complete cds. | Sus scrofa | 38,578 | 03-DEC-1996 | ||
| rxa00930 | 876 | GB_BA1: MTCI270A | 1670 | Z98045 | Mycobacterium tuberculosis H37Rv complete genome; segment 116/162. | Mycobacterium | 37,927 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_BA1: U00011 | 40429 | U00011 | Mycobacterium leprae cosmid B1177. | Mycobacterium leprae | 38,623 | 01-MAR-1994 | ||
| GB_RO: S58745 | 817 | S58745 | thyrotroph embryonic factor = leucine zipper transcription factor [rats, | Rattus sp. | 41,483 | 07-MAY-1993 | ||
| pituitary, mRNA, 817 nt]. | ||||||||
| rxa00932 | 597 | GB_PR4: AC009509 | 192690 | AC009509 | Homo sapiens 12p11-37.2-54.4 BAC RP11-1060J15 (Roswell Park | Homo sapiens | 38,776 | 01-DEC-1999 |
| Cancer Institute Human BAC Library) complete sequence. | ||||||||
| GB_PR3: AC004072 | 170658 | AC004072 | Human Chromosome X clone bWXD342, complete sequence. | Homo sapiens | 35,000 | 08-MAR-1998 | ||
| GB_PR4: AC004617 | 176552 | AC004617 | Homo sapiens chromosome Y, clone 264, M, 20, complete sequence. | Homo sapiens | 35,702 | 13-OCT-1999 | ||
| rxa00933 | 585 | GB PL1: MGNGAGPOLI | 5638 | L35053 | Transposon MAGGY gag and pol gene homologues, partial cds's. | Magnaporthe grisea | 40,283 | 4-Aug-94 |
| GB PL1: MGNGAGPOLI | 5638 | L35053 | Transposon MAGGY gag and pol gene homologues, partial cds's. | Magnaporthe grisea | 37,739 | 4-Aug-94 | ||
| rxa00940 | 519 | GB_PR2: HS179N16 | 172048 | Z95152 | Homo sapiens DNA sequence from PAC 179N16 on chromosome | Homo sapiens | 38,252 | 23-Nov-99 |
| 6p21.1-21.33. Contains the SAPK4 (MAPK p38delta) gene, and the alternatively | ||||||||
| spliced SAPK2 gene coding for CSaids binding | ||||||||
| protein CSBP2 and a MAPK p38beta LIKE protein. | ||||||||
| Contains ESTs, STSs and two predicted CpG | ||||||||
| islands, complete sequence. | ||||||||
| GB_EST26: AU001018 | 304 | AU001018 | AU001018 Bombyx mori p50(Daizo) Bombyx mori cDNA | Bombyx mori | 45,745 | 15-Jan-99 | ||
| clone fbf0932f, mRNA sequence. | ||||||||
| GB_EST26: AU001019 | 304 | AU001019 | AU001019 Bombyx mori p50(Daizo) Bombyx mori cDNA clone | Bombyx mori | 45,745 | 15-Jan-99 | ||
| fbf0934f, mRNA sequence. | ||||||||
| rxa00943 | 1035 | GB_BA2: AF079317 | 184457 | AF079317 | Sphingomonas aromaticivorans plasmid pNL1, complete plasmid sequence. | Sphingomonas | 38,151 | 12-Jan-99 |
| aromaticivorans | ||||||||
| GB_HTG3: AC008329 | 114408 | AC008329 | Drosophila melanogaster chromosome 2 clone BACR31D05 (D861) RPCI-98 | Drosophila melanogaster | 34,317 | 17-Aug-99 | ||
| 31.D.5 map 28C-28D strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 105 unordered pieces. | ||||||||
| GB_HTG3: AC008329 | 114408 | AC008329 | Drosophila melanogaster chromosome 2 clone BACR31D05 (D861) RPCI-98 | Drosophila melanogaster | 34,317 | 17-Aug-99 | ||
| 31.D.5 map 28C-28D strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 105 unordered pieces. | ||||||||
| rxa00946 | 897 | GB_BA1: MTV008 | 63033 | AL021246 | Mycobacterium tuberculosis H37Rv complete genome; segment 108/162. | Mycobacterium | 36,045 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_GSS14: AQ571765 | 526 | AQ571765 | HS_2094_A2_B09_MR CIT Approved Human Genomic Sperm Library | Homo sapiens | 38,021 | 1-Jun-99 | ||
| D Homo sapiens genomic clone Plate = 2094 Col = 18 | ||||||||
| Row = C, genomic survey sequence. | ||||||||
| GB_RO: RRFE65G | 2464 | X60468 | R. rattus FE65 gene for adaptor protein interacting with the | Rattus rattus | 38,417 | 1-Feb-96 | ||
| beta-amyloid precursor protein intracellular domain. | ||||||||
| rxa00949 | 771 | GB_VI: PPCCGAAA | 5366 | M26281 | Hamster papovavirus complete genome. | Hamster papovavirus | 36,579 | 22-MAY-1995 |
| GB_VI: HAPVXX | 5366 | X02449 | Hamster Papovavirus (HapV) genome. | Hamster papovavirus | 36,579 | 22-OCT-1999 | ||
| GB_BA2: AE000878 | 15432 | AE000878 | Methanobacterium thermoautotrophicum from bases 976801 to 992232 | Methanobacterium | 36,856 | 15-Nov-97 | ||
| (section 84 of 148) of the complete genome. | thermoautotrophicum | |||||||
| rxa00959 | 579 | GB_BA1: CGMTRAR | 951 | X75083 | C. glutamicum mtrA gene locus with 5-methyltryptophan resistance. | Corynebacterium | 99,133 | 18-Aug-94 |
| glutamicum | ||||||||
| GB_BA1: CGMTRA | 587 | X75084 | C. glutamicum sequence corresponding to mtrA locus. | Corynebacterium | 99,216 | 18-Aug-94 | ||
| glutamicum | ||||||||
| GB_BA1: BLTRP | 7725 | X04960 | Brevibacterium lactofermentum tryptophan operon. | Corynebacterium | 96,800 | 10-Feb-99 | ||
| glutamicum | ||||||||
| rxa00963 | 960 | GB_EST15: AA484511 | 504 | AA484511 | nf08f07.s1 NCI_CGAP_Li1 Homo sapiens cDNA clone IMAGE: 913189 | Homo sapiens | 43,750 | 18-Aug-97 |
| similar to gb: Y00764 UBIQUINOL-CYTOCHROME C REDUCTASE | ||||||||
| 11 KD PROTEIN (HUMAN);, mRNA sequence. | ||||||||
| GB_EST20: AA894481 | 544 | AA894481 | nw76b10.s1 NCI_CGAP_Pr12 Homo sapiens cDNA clone IMAGE: 1252507 | Homo sapiens | 37,500 | 6-Apr-98 | ||
| similar to gb: Y00764 UBIQUINOL-CYTOCHROME C REDUCTASE 11 KD | ||||||||
| PROTEIN (HUMAN);, mRNA sequence. | ||||||||
| GB_EST15: AA526497 | 582 | AA526497 | ni96d07.s1 NCI_CGAP_Pr21 Homo sapiens cDNA clone IMAGE: 984685 | Homo sapiens | 38,554 | 5-Aug-97 | ||
| 3′ similar to gb: Y00764 UBIQUINOL-CYTOCHROME C REDUCTASE 11 KD | ||||||||
| PROTEIN (HUMAN);, mRNA sequence. | ||||||||
| rxa00969 | 1458 | GB_BA1: CGHOMTHR | 3685 | Y00546 | Corynebacterium glutamicum hom-thrB genes for homoserine | Corynebacterium | 99,588 | 12-Sep-93 |
| dehydrogenase and homoserine kinase. | glutamicum | |||||||
| GB_PAT: I09077 | 3685 | I09077 | Sequence 1 from Patent WO 8809819. | Unknown. | 99,246 | 02-DEC-1994 | ||
| GB_BA1: BLTHRA | 1483 | Y00476 | B. lactofermentum thr A gene. | Corynebacterium | 99,378 | 05-MAY-1993 | ||
| glutamicum | ||||||||
| rxa00971 | 341 | GB_BA1: CGHOMTHR | 3685 | Y00546 | Corynebacterium glutamicum hom-thrB genes for homoserine | Corynebacterium | 35,435 | 12-Sep-93 |
| dehydrogenase and homoserine kinase. | glutamicum | |||||||
| GB_PAT: I09077 | 3685 | I09077 | Sequence 1 from Patent WO 8809819. | Unknown. | 35,435 | 02-DEC-1994 | ||
| GB_BA1: BLTHRB | 1139 | Y00140 | Brevibacterium lactofermentum thrB gene for homoserine kinase. | Corynebacterium | 40,964 | 12-Sep-93 | ||
| glutamicum | ||||||||
| rxa00973 | 726 | GB_BA1: CGHOMTHR | 3685 | Y00546 | Corynebacterium glutamicum hom-thrB genes for homoserine | Corynebacterium | 41,797 | 12-Sep-93 |
| dehydrogenase and homoserine kinase. | glutamicum | |||||||
| GB_PAT: I09077 | 3685 | I09077 | Sequence 1 from Patent WO 8809819. | Unknown. | 41,797 | 02-DEC-1994 | ||
| GB_IN2: AC006574 | 127035 | AC006574 | Drosophila melanogaster , chromosome 2R, region 39A3-39B1, | Drosophila melanogaster | 37,355 | 16-Feb-99 | ||
| P1 clones DS02919 and DS05130, complete sequence. | ||||||||
| rxa00978 | 738 | GB_PR2: HSAC000372 | 41730 | AC000372 | Human cosmid g1980a186, complete sequence. | Homo sapiens | 34,674 | 12-MAR-1997 |
| GB_PR3: AC005503 | 40998 | AC005503 | Homo sapiens clone UWGC: g5129s003 from 7q31, complete sequence. | Homo sapiens | 34,674 | 20-Aug-98 | ||
| GB_PR2: HSAC000372 | 41730 | AC000372 | Human cosmid g1980a186, complete sequence. | Homo sapiens | 38,881 | 12-MAR-1997 | ||
| rxa00986 | 465 | GB_GSS10: AQ258013 | 761 | AQ258013 | nbxb0019H05f CUGI Rice BAC Library Oryza sativa genomic clone | Oryza sativa | 31,533 | 23-OCT-1998 |
| nbxb0019H05f, genomic survey sequence. | ||||||||
| GB_PR3: HS83L6 | 61187 | Z99130 | Human DNA sequence from PAC 83L6 on chromosome Xp11.1-11.22. | Homo sapiens | 38,395 | 23-Nov-99 | ||
| Contains ZXDA (ZFPA) zinc finger gene, ESTs and STSs, complete sequence. | ||||||||
| GB_PR3: HS598A24 | 96558 | AL031115 | Human DNA sequence from clone 598A24 on chromosome Xp11.1-11.23 | Homo sapiens | 37,333 | 23-Nov-99 | ||
| Contains zinc finger X-linked proteins ZXDA, ZXDB, ESTs | ||||||||
| and STS, complete sequence. | ||||||||
| rxa00987 | 588 | GB_HTG1: HS24A17 | 2000 | AL035452 | Homo sapiens chromosome X clone RP6-24A17, | Homo sapiens | 38,821 | 23-Nov-99 |
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: HS24A17 | 2000 | AL035452 | Homo sapiens chromosome X clone RP6-24A17, | Homo sapiens | 38,821 | 23-Nov-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_PR2: HS1156N12 | 146360 | AL009047 | Human DNA sequence from clone 1156N12 on chromosome X. | Homo sapiens | 38,821 | 23-Nov-99 | ||
| Contains an STS and GSSs, complete sequence. | ||||||||
| rxa00988 | 546 | GB_IN1: CELZC328 | 30350 | AF000194 | Caenorhabditis elegans cosmid ZC328. | Caenorhabditis elegans | 36,122 | 23-Apr-97 |
| GB_IN1: CELZC328 | 30350 | AF000194 | Caenorhabditis elegans cosmid ZC328. | Caenorhabditis elegans | 37,959 | 23-Apr-97 | ||
| rxa01005 | 969 | GB_BA1: FVBPOAD2A | 45519 | D26094 | Flavobacterium sp. plasmid pOAD2 DNA, whole sequence. | Flavobacterium sp. | 37,998 | 6-Feb-99 |
| GB_GSS1: CNS00UGV | 472 | AL090973 | Arabidopsis thaliana genome survey sequence SP6 end of BAC T6P9 | Arabidopsis thaliana | 39,024 | 28-Jun-99 | ||
| of TAMU library from strain Columbia of Arabidopsis thaliana , | ||||||||
| genomic survey sequence. | ||||||||
| GB_GSS1: CNS00S69 | 512 | AL087999 | Arabidopsis thaliana genome survey sequence SP6 end of BAC T1C4 of TAMU | Arabidopsis thaliana | 35,938 | 28-Jun-99 | ||
| library from strain Columbia of Arabidopsis thaliana , genomic survey sequence. | ||||||||
| rxa01007 | ||||||||
| rxa01008 | ||||||||
| rxa01011 | 1356 | GB_EST38: AW039107 | 598 | AW039107 | EST281080 tomato mixed elicitor, BTI Lycopersicon | Lycopersicon esculentum | 39,724 | 18-OCT-1999 |
| esculentum cDNA clone cLET12F19, mRNA sequence. | ||||||||
| GB_BA1: MTY13E12 | 43401 | Z95390 | Mycobacterium tuberculosis H37Rv complete genome; segment 147/162. | Mycobacterium | 38,618 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| GB_BA1: MBU15140 | 2136 | U15140 | Mycobacterium bovis ribosomal proteins IF-1 (infA), L36 (rpmJ), S13 (rpsM) | Mycobacterium bovis | 37,070 | 28-OCT-1996 | ||
| and S11 (rpsK) genes, complete cds, and S4 (rpsD) gene, partial cds. | ||||||||
| rxa01016 | 771 | GB_BA1: CGBPHI16 | 962 | Y12472 | C. glutamicum DNA, attachment site bacteriophage Phi-16. | Corynebacterium | 45,098 | 05-MAR-1999 |
| glutamicum | ||||||||
| GB_BA1: CGBPHI16 | 962 | Y12472 | C. glutamicum DNA, attachment site bacteriophage Phi-16. | Corynebacterium | 37,251 | 05-MAR-1999 | ||
| glutamicum | ||||||||
| rxa01017 | 732 | GB_BA1: CGBPHI16 | 962 | Y12472 | C. glutamicum DNA, attachment site bacteriophage Phi-16. | Corynebacterium | 39,245 | 05-MAR-1999 |
| glutamicum | ||||||||
| GB_BA2: AF099014 | 2500 | AF099014 | Streptomyces coelicolor strain A3(2) transposase (tnpA) and | Streptomyces coelicolor | 38,036 | 1-Jun-99 | ||
| Fe-containing superoxide dismutase I (sodF1) genes, complete cds. | ||||||||
| GB_HTG3: AC009249 | 119461 | AC009249 | Drosophila melanogaster chromosome 3 clone BACR02M06 | Drosophila melanogaster | 37,853 | 27-Aug-99 | ||
| (D1003) RPCI-98 02.M.6 map 98B-98B strain y; cn bw sp, | ||||||||
| *** SEQUENCING IN PROGRESS ***, 97 unordered pieces. | ||||||||
| rxa01021 | 622 | GB_BA2: U39718 | 8603 | U39718 | Mycoplasma genitalium section 40 of 51 of the complete genome. | Mycoplasma genitalium | 39,348 | 5-Nov-98 |
| GB_GSS3: B46221 | 457 | B46221 | HS-1063-A2-D06-MR.abi CIT Human Genomic Sperm | Homo sapiens | 39,933 | 21-OCT-1997 | ||
| Library C Homo sapiens genomic clone Plate = CT 796 Col = 12 Row = G, | ||||||||
| genomic survey sequence. | ||||||||
| GB_OV: AF035529 | 848 | AF035529 | Xenopus laevis Smad6 mRNA, partial cds. | Xenopus laevis | 37,203 | 1-Jan-98 | ||
| rxa01023 | 1101 | GB_HTG2: HSJ435K13 | 151301 | AL109941 | Homo sapiens chromosome 6 clone | Homo sapiens | 34,405 | 03-DEC-1999 |
| RP3-435K13 map q14.1-16.1, *** SEQUENCING IN PROGRESS ***, | ||||||||
| in unordered pieces. | ||||||||
| GB_HTG2: HSJ435K13 | 151301 | AL109941 | Homo sapiens chromosome 6 clone RP3-435K13 | Homo sapiens | 34,405 | 03-DEC-1999 | ||
| map q14.1-16.1, *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_BA1: RCU57682 | 86896 | U57682 | Rhodobacter capsulatus cosmids 143-147, complete sequence. | Rhodobacter capsulatus | 39,022 | 7-Feb-97 | ||
| rxa01028 | 2172 | GB_IN1: CBU55260 | 2518 | U55260 | Caenorhabditis briggsae beta tubulin (mec-7) gene, complete cds. | Caenorhabditis briggsae | 39,467 | 5-Jun-96 |
| GB_HTG1: CEY1A5 | 196643 | AL008872 | Caenorhabditis elegans chromosome III | Caenorhabditis elegans | 38,168 | 9-Nov-97 | ||
| clone Y1A5, *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG1: CEY1A5 | 196643 | AL008872 | Caenorhabditis elegans chromosome III | Caenorhabditis elegans | 38,168 | 9-Nov-97 | ||
| clone Y1A5, *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa01029 | 612 | GB_PR3: HS466P17 | 149963 | AL023806 | Human DNA sequence from clone 466P17 on chromosome 6q24. Contains a | Homo sapiens | 38,330 | 23-Nov-99 |
| putative novel gene, the 5′ part of the EPM2A (Laforin) gene, ESTs, | ||||||||
| STSs, GSSs, genomic marker D6S1703 and D6S1443, a putative | ||||||||
| CpG island and a ca repeat polymorphism, complete sequence. | ||||||||
| GB_PR3: HS466P17 | 149963 | AL023806 | Human DNA sequence from clone 466P17 on chromosome 6q24. Contains | Homo sapiens | 39,262 | 23-Nov-99 | ||
| a putative novel gene, the 5′ part of the EPM2A (Laforin) gene, ESTs. | ||||||||
| STSs, GSSs, genomic marker D6S1703 and D6S1443, a putative CpG island | ||||||||
| and a ca repeat polymorphism, complete sequence. | ||||||||
| GB_RO: D78344 | 59641 | D78344 | Mouse DNA for Ig gamma-chains, partial cds. | Mus musculus | 35,472 | 5-Feb-99 | ||
| rxa01031 | 789 | GB_PR4: AC006948 | 168558 | AC006948 | Homo sapiens chromosome 17, clone hRPK.334_M_10, complete sequence. | Homo sapiens | 44,005 | 27-Apr-99 |
| GB_PL2: AC011665 | 101845 | AC011665 | Arabidopsis thaliana chromosome I BAC T6L1 genomic sequence, complete sequence. | Arabidopsis thaliana | 38,170 | 11-Nov-99 | ||
| GB_RO: MMU19724 | 5523 | U19724 | Mus musculus MMTV integration locus, aromatase gene, 3′UTR. | Mus musculus | 35,256 | 17-Feb-96 | ||
| rxa01032 | 498 | GB_EST9: AA118349 | 576 | AA118349 | ml56b06.r1 Stratagene mouse testis (#937308) Mus musculus | Mus musculus | 43,056 | 19-Nov-96 |
| cDNA clone IMAGE: 515987 5′ similar to gb: L04852 | ||||||||
| Mouse (MOUSE);, mRNA sequence. | ||||||||
| GB_EST9: AA118349 | 576 | AA118349 | ml56b06.r1 Stratagene mouse testis (#937308) Mus musculus | Mus musculus | 42,273 | 19-Nov-96 | ||
| cDNA clone IMAGE: 515987 5′ similar to gb: L04852 | ||||||||
| Mouse (MOUSE);, mRNA sequence. | ||||||||
| rxa01033 | 459 | GB_GSS13: AQ434868 | 520 | AQ434868 | HS_5117_B1_D07_SP6E RPCI-11 Human Male BAC | Homo sapiens | 38,608 | 31-MAR-1999 |
| Library Homo sapiens genomic clone Plate = 693 | ||||||||
| Col = 13 Row = H, genomic survey sequence. | ||||||||
| GB_HTG2: HSDJ794I6 | 137124 | AL109976 | Homo sapiens chromosome 20 clone RP4-794I6, | Homo sapiens | 28,929 | 27-Nov-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG2: HSDJ794I6 | 137124 | AL109976 | Homo sapiens chromosome 20 clone RP4-794I6, | Homo sapiens | 28,929 | 27-Nov-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa01034 | 477 | GB_PL2: ATT29H11 | 87011 | AL049659 | Arabidopsis thaliana DNA chromosome 3, BAC clone T29H11. | Arabidopsis thaliana | 32,495 | 9-Jun-99 |
| GB_PL2: ATT29H11 | 87011 | AL049659 | Arabidopsis thaliana DNA chromosome 3, BAC clone T29H11. | Arabidopsis thaliana | 40,042 | 9-Jun-99 | ||
| GB_EST25: AU045739 | 436 | AU045739 | AU045739 Mouse sixteen-cell-embryo cDNA Mus musculus | Mus musculus | 35,435 | 09-DEC-1998 | ||
| cDNA clone J0940F02 3′, mRNA sequence. | ||||||||
| rxa01035 | 729 | GB_GSS1: CNS00QD8 | 526 | AL085658 | Arabidopsis thaliana genome survey sequence SP6 end of | Arabidopsis thaliana | 36,466 | 28-Jun-99 |
| BAC F11C22 of IGF library from strain Columbia of Arabidopsis | ||||||||
| thaliana , genomic survey sequence. | ||||||||
| GB_GSS13: AQ447948 | 515 | AQ447948 | mgxb0015A01r CUGI Rice Blast BAC Library | Magnaporthe grisea | 45,833 | 8-Apr-99 | ||
| Magnaporthe grisea genomic clone mgxb0015A01r, genomic survey sequence. | ||||||||
| GB_GSS1: CNS00QD8 | 526 | AL085658 | Arabidopsis thaliana genome survey sequence SP6 end | Arabidopsis thaliana | 37,500 | 28-Jun-99 | ||
| of BAC F11C22 of IGF library from strain Columbia of | ||||||||
| Arabidopsis thaliana , genomic survey sequence. | ||||||||
| rxa01036 | 576 | GB_HTG2: AC004846 | 143577 | AC004846 | Homo sapiens clone DJ0647C14, | Homo sapiens | 38,137 | 12-Jun-98 |
| *** SEQUENCING IN PROGRESS ***, 21 unordered pieces. | ||||||||
| GB_EST19: AA804532 | 427 | AA804532 | ns28c05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone | Homo sapiens | 33,582 | 18-Feb-98 | ||
| IMAGE: 1184936 3′ similar to contains element MER40 | ||||||||
| repetitive element;, mRNA sequence. | ||||||||
| GB_HTG2: AC006342 | 201618 | AC006342 | Homo sapiens clone DJ0054D12, | Homo sapiens | 38,137 | 11-Jan-99 | ||
| *** SEQUENCING IN PROGRESS ***, 3 unordered pieces. | ||||||||
| rxa01037 | 651 | GB_PR4: AC004812 | 138532 | AC004812 | Homo sapiens PAC clone 267D11 from 12, complete sequence. | Homo sapiens | 39,750 | 05-DEC-1998 |
| GB_HTG2: AC006342 | 201618 | AC006342 | Homo sapiens clone DJ0054D12, *** SEQUENCING | Homo sapiens | 41,214 | 11-Jan-99 | ||
| IN PROGRESS ***, 3 unordered pieces. | ||||||||
| GB_HTG2: AC004846 | 143577 | AC004846 | Homo sapiens clone DJ0647C14, *** SEQUENCING | Homo sapiens | 41,214 | 12-Jun-98 | ||
| IN PROGRESS ***, 21 unordered pieces. | ||||||||
| rxa01038 | ||||||||
| rxa01039 | 699 | GB_PR4: HUAC004682 | 189134 | AC004682 | Homo sapiens Chromosome 16 BAC clone CIT987SK-A-259H10, complete sequence. | Homo sapiens | 36,192 | 23-Nov-99 |
| GB_HTG2: HS500L14 | 164856 | AL023583 | Homo sapiens chromosome 6 clone RP3-500L14 | Homo sapiens | 34,632 | 30-Nov-99 | ||
| map p23-24.3, *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG2: HS500L14 | 164856 | AL023583 | Homo sapiens chromosome 6 clone RP3-500L14 | Homo sapiens | 34,632 | 30-Nov-99 | ||
| map p23-24.3, *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa01040 | 1026 | GB_EST24: AI193549 | 479 | AI193549 | qe70e06.x1 Soares_fetal_lung_NbHL19W | Homo sapiens | 40,126 | 29-OCT-1998 |
| Homo sapiens cDNA clone IMAGE: 1744354 3′, mRNA sequence. | ||||||||
| GB_PR2: HSU38545 | 3609 | U38545 | Human ARF-activated phosphatidylcholine-specific | Homo sapiens | 38,652 | 10-MAR-1997 | ||
| phospholipase D1a (hPLD1) mRNA, complete cds. | ||||||||
| GB_PR2: AC002481 | 28244 | AC002481 | Human cosmid clone LUCA12 from 3p21.3, complete sequence. | Homo sapiens | 39,643 | 21-Aug-97 | ||
| rxa01041 | 276 | GB_HTG6: AC007957 | 212658 | AC007957 | Homo sapiens , *** SEQUENCING IN PROGRESS ***, 2 ordered pieces. | Homo sapiens | 40,809 | 26-Nov-99 |
| GB_PR2: AP000552 | 157086 | AP000552 | Homo sapiens genomic DNA, chromosome 22q11.2, | Homo sapiens | 40,809 | 01-OCT-1999 | ||
| BCRL2 region, clone: KB1183D5. | ||||||||
| GB_PR3: HS57A13 | 169693 | Z83848 | Human DNA sequence from PAC 57A13 between markers | Homo sapiens | 37,647 | 23-Nov-99 | ||
| DXS6791 and DXS8038 on chromosome X contains glutamate receptor | ||||||||
| subunit GluRC, ESTs, STS and polymorphic CA repeat. | ||||||||
| rxa01042 | 1401 | GB_BA1: MTCY10G2 | 38970 | Z92539 | Mycobacterium tuberculosis H37Rv complete genome; segment 47/162. | Mycobacterium | 36,023 | 17-Jun-98 |
| tuberculosis | ||||||||
| GB_BA1: MTCY10G2 | 38970 | Z92539 | Mycobacterium tuberculosis H37Rv complete genome; segment 47/162. | Mycobacterium | 37,010 | 17-Jun-98 | ||
| tuberculosis | ||||||||
| GB_EST29: AI551042 | 538 | AI551042 | vx33d11.x1 Stratagene mouse lung 937302 Mus musculus | Mus musculus | 38,806 | 23-MAR-1999 | ||
| cDNA clone IMAGE: 1277013 3′, mRNA sequence. | ||||||||
| rxa01043 | 696 | GB_BA1: AF006658 | 2500 | AF006658 | Bacteroides fragilis beta-glucosidase gene, complete cds. | Bacteroides fragilis | 39,156 | 12-Jul-97 |
| GB_BA1: MLB1790G | 37617 | Z14314 | M. leprae genes rplL, rpoB, rpoC, end, rpsL, rpsG, efg, tuf, rpsJ, rplC for | Mycobacterium leprae | 39,970 | 11-Feb-93 | ||
| ribosomal protein L7, RNA polymerase beta subunit, RNA polymerase beta' subunit, | ||||||||
| endonuclease, ribosomal protein S7, ribosomal protein S12, elongation factor G, | ||||||||
| elongation factor Tu, ribosomal protein S10, ribosomal | ||||||||
| protein L3 and mkl gene. | ||||||||
| GB_BA1: AF006658 | 2500 | AF006658 | Bacteroides fragilis beta-glucosidase gene, complete cds. | Bacteroides fragilis | 36,472 | 12-Jul-97 | ||
| rxa01044 | 1380 | GB_HTG6: AC010998 | 144338 | AC010998 | Homo sapiens clone RP11-95I16, *** SEQUENCING | Homo sapiens | 37,630 | 08-DEC-1999 |
| IN PROGRESS ***, 17 unordered pieces. | ||||||||
| GB_HTG6: AC010998 | 144338 | AC010998 | Homo sapiens clone RP11-95I16, *** SEQUENCING | Homo sapiens | 37,864 | 08-DEC-1999 | ||
| IN PROGRESS ***, 17 unordered pieces. | ||||||||
| GB_BA2: AE000939 | 10599 | AE000939 | Methanobacterium thermoautotrophicum from bases 1698671 to 1709269 (section 145 | Methanobacterium | 34,480 | 15-Nov-97 | ||
| of 148) of the complete genome. | thermoautotrophicum | |||||||
| rxa01045 | 1947 | GB_VI: FCVF6A | 8440 | M18247 | Feline leukemia virus, subgroup A (FeLV-FAIDS), complete nucleotide sequence. | Feline leukemia virus | 37,617 | 29-MAR-1996 |
| GB_OM: CATFLVPOL | 3639 | L06140 | Felis catus endogenous FeLV proviral polyprotein | Felis catus | 41,966 | 21-Aug-95 | ||
| (protease (PRO), reverse transcriptase (RT), integrase/endonuclease (INT)) and | ||||||||
| pol pseudogene, 3′ end. | ||||||||
| GB_VI: CEAVCG | 9189 | M33677 | Caprine arthritis encephalitis virus, complete proviral genome. | Caprine arthritis- | 36,297 | 04-MAR-1996 | ||
| encephalitis virus | ||||||||
| rxa01046 | 1902 | GB_HTG3: AC008423 | 177734 | AC008423 | Homo sapiens chromosome 5 clone CIT-HSPC_298N6, | Homo sapiens | 38,720 | 3-Aug-99 |
| *** SEQUENCING IN PROGRESS ***, 56 unordered pieces. | ||||||||
| GB_HTG3: AC008423 | 177734 | AC008423 | Homo sapiens chromosome 5 clone CIT-HSPC_298N6, | Homo sapiens | 38,720 | 3-Aug-99 | ||
| *** SEQUENCING IN PROGRESS ***, 56 unordered pieces. | ||||||||
| GB_HTG3: AC008423 | 177734 | AC008423 | Homo sapiens chromosome 5 clone CIT-HSPC_298N6, | Homo sapiens | 35,882 | 3-Aug-99 | ||
| *** SEQUENCING IN PROGRESS ***, 56 unordered pieces. | ||||||||
| rxa01047 | 597 | GB_EST20: AA842685 | 510 | AA842685 | MBAFCZ9C11T3 Brugia malayi adult female cDNA | Brugia malayi | 37,965 | 02-MAR-1998 |
| (SAW96MLW-BmAF) Brugia malayi cDNA clone AFCZ9C11 5′, mRNA sequence. | ||||||||
| GB_EST20: AA842685 | 510 | AA842685 | MBAFCZ9C11T3 Brugia malayi adult female cDNA | Brugia malayi | 41,697 | 02-MAR-1998 | ||
| (SAW96MLW-BmAF) Brugia malayi cDNA clone AFCZ9C11 5′, mRNA sequence. | ||||||||
| rxa01058 | 444 | GB_GSS9: AQ160800 | 745 | AQ160800 | nbxb0006C07r CUGI Rice BAC Library Oryza sativa | Oryza sativa | 38,242 | 12-Sep-98 |
| genomic clone nbxb0006C07r, genomic survey sequence. | ||||||||
| GB_GSS3: B10162 | 1102 | B10162 | F11B10-Sp6 IGF Arabidopsis thaliana genomic | Arabidopsis thaliana | 42,263 | 14-MAY-1997 | ||
| clone F11B10, genomic survey sequence. | ||||||||
| GB_BA1: AB032799 | 9077 | AB032799 | Chromobacterium violaceum violacein biosynthetic gene cluster (vioA, | Chromobacterium | 34,475 | 02-OCT-1999 | ||
| vio B, vio C, vio D), complete cds. | violaceum | |||||||
| rxa01063 | 453 | GB_GSS4: AQ707752 | 510 | AQ707752 | HS_5560_A2_G07_T7A RPCI-11 Human Male | Homo sapiens | 36,932 | 7-Jul-99 |
| BAC Library Homo sapiens genomic clone Plate = 1136 Col = 14 | ||||||||
| Row = M, genomic survey sequence. | ||||||||
| GB_GSS4: AQ707752 | 510 | AQ707752 | HS_5560_A2_G07_T7A RPCI-11 Human Male | Homo sapiens | 35,885 | 7-Jul-99 | ||
| BAC Library Homo sapiens genomic clone Plate = 1136 Col = 14 | ||||||||
| Row = M, genomic survey sequence. | ||||||||
| rxa01066 | 849 | GB_BA2: U32709 | 10010 | U32709 | Haemophilus influenzae Rd section 24 of 163 of the complete genome. | Haemophilus influenzae Rd | 36,158 | 29-MAY-1998 |
| GB_RO: AB009615 | 1515 | AB009615 | Mus musculus mRNA for type II phosphatidylinositolphosphate | Mus musculus | 37,861 | 13-Feb-99 | ||
| kinase-alpha, complete cds. | ||||||||
| GB_RO: AB032899 | 1914 | AB032899 | Rattus norvegicus PIPK2 alpha mRNA for phosphatidylinositol | Rattus norvegicus | 38,480 | 07-OCT-1999 | ||
| 5-phosphate 4-kinase alpha, complete cds. | ||||||||
| rxa01068 | 1194 | GB_HTG4: AC006091 | 176878 | AC006091 | Drosophila melanogaster chromosome 3 clone BACR48G05 | Drosophila melanogaster | 35,539 | 27-OCT-1999 |
| (D475) RPCI-98 48.G.5 map 91F1-91F13 strain y; cn bw sp, | ||||||||
| *** SEQUENCING IN PROGRESS ***, 4 unordered pieces. | ||||||||
| GB_HTG4: AC006091 | 176878 | AC006091 | Drosophila melanogaster chromosome 3 clone BACR48G05 (D475) | Drosophila melanogaster | 35,539 | 27-OCT-1999 | ||
| RPCI-98 48.G.5 map 91F1-91F13 strain y; cn bw sp, *** SEQUENCING | ||||||||
| IN PROGRESS ***, 4 unordered pieces. | ||||||||
| GB_HTG2: AC008141 | 100729 | AC008141 | Drosophila melanogaster chromosome 3 clone BACR17F04 (D988) | Drosophila melanogaster | 34,415 | 2-Aug-99 | ||
| RPCI-98 17.F.4 map 91F-91F strain y; cn bw sp, *** SEQUENCING IN | ||||||||
| PROGRESS ***, 69 unordered pieces. | ||||||||
| rxa01069 | 837 | GB_EST15: AA531901 | 524 | AA531901 | TgESTzz32g09.r1 TgME49 invivo Bradyzoite cDNA size selected | Toxoplasma gondii | 43,005 | 22-Jul-97 |
| Toxoplasma gondii cDNA clone tgzz32g09.r1 5′, mRNA sequence. | ||||||||
| GB_EST15: AA520183 | 527 | AA520183 | TgESTzz39d01.s1 TgME49 invivo Bradyzoite cDNA size | Toxoplasma gondii | 40,664 | 16-Jul-97 | ||
| selected Toxoplasma gondii cDNA clone tgzz39d01.s1 3′, mRNA sequence. | ||||||||
| GB_HTG6: AC010846 | 187611 | AC010846 | Drosophila melanogaster chromosome X clone BACR13G13 | Drosophila melanogaster | 36,679 | 03-DEC-1999 | ||
| (D894) RPCI-98 13.G.13 map 14B-14C strain y; cn bw sp, *** SEQUENCING IN | ||||||||
| PROGRESS ***, 97 unordered pieces. | ||||||||
| rxa01071 | 2187 | GB_EST20: AA880319 | 450 | AA880319 | vx39h01.r1 Stratagene mouse lung 937302 Mus musculus | Mus musculus | 40,724 | 26-MAR-1998 |
| cDNA clone IMAGE: 1277617 5′, mRNA sequence. | ||||||||
| GB_GSS14: AQ558382 | 435 | AQ558382 | HS_2068_B1_F06_T7C CIT Approved Human Genomic Sperm | Homo sapiens | 36,882 | 29-MAY-1999 | ||
| Library D Homo sapiens genomic clone Plate = 2068 Col = 11 Row = L, | ||||||||
| genomic survey sequence. | ||||||||
| GB_GSS15: AQ600385 | 483 | AQ600385 | HS_5357_B2_C05_SP6E RPCI-11 Human Male BAC | Homo sapiens | 40,476 | 10-Jun-99 | ||
| Library Homo sapiens genomic clone Plate = 933 | ||||||||
| Col = 10 Row = F, genomic survey sequence. | ||||||||
| rxa01074 | 828 | GB_BA1: PSEHEDDH | 3060 | M74256 | Pseudomonas aeruginosa 6-phosphogluconate dehydratase | Pseudomonas aeruginosa | 39,657 | 30-Nov-93 |
| (edd) gene, and glyceraldehyde-3-phosphate dehydrogenase | ||||||||
| (gap) gene, complete cds. | ||||||||
| GB_BA1: CGL007732 | 4460 | AJ007732 | Corynebacterium glutamicum 3′ ppc gene, secG gene, amt | Corynebacterium | 39,168 | 7-Jan-99 | ||
| gene, ocd gene and 5′ soxA gene. | glutamicum | |||||||
| GB_EST9: AA066016 | 406 | AA066016 | ml52f12.r1 Stratagene mouse testis (#937308) Mus musculus | Mus musculus | 43,382 | 3-Feb-97 | ||
| cDNA clone IMAGE: 515663 5′, mRNA sequence. | ||||||||
| rxa01075 | 534 | GB_EST21: AA986543 | 445 | AA986543 | ue14f08.x1 Sugano mouse embryo mewa Mus musculus | Mus musculus | 31,236 | 28-MAY-1998 |
| cDNA clone IMAGE: 1480359 3′, mRNA sequence. | ||||||||
| GB_EST22: AI035794 | 509 | AI035794 | ue17d01.y1 Sugano mouse embryo mewa Mus musculus | Mus musculus | 42,264 | 26-Jun-98 | ||
| cDNA clone IMAGE: 1480609 5′, mRNA sequence. | ||||||||
| GB_EST22: AI006506 | 384 | AI006506 | ue14f08.y1 Sugano mouse embryo mewa Mus musculus | Mus musculus | 46,637 | 12-Jun-98 | ||
| cDNA clone IMAGE: 1480359 5′, mRNA sequence. | ||||||||
| rxa01076 | 1143 | GB_HTG2: AC007741 | 162450 | AC007741 | Homo sapiens clone NH0340F16, *** SEQUENCING IN | Homo sapiens | 38,209 | 5-Jun-99 |
| PROGRESS ***, 3 unordered pieces. | ||||||||
| GB_HTG2: AC007741 | 162450 | AC007741 | Homo sapiens clone NH0340F16, *** SEQUENCING | Homo sapiens | 38,209 | 5-Jun-99 | ||
| IN PROGRESS ***, 3 unordered pieces. | ||||||||
| GB_EST33: AV072325 | 317 | AV072325 | AV072325 Mus musculus stomach C57BL/6J adult | Mus musculus | 48,485 | 24-Jun-99 | ||
| Mus musculus cDNA clone 2200003E03, mRNA sequence. | ||||||||
| rxa01078 | 957 | GB_BA2: RCPHSYNG | 45959 | Z11165 | R. capsulatus complete photosynthesis gene cluster. | Rhodobacter capsulatus | 36,603 | 2-Sep-99 |
| GB_BA2: RCPHSYNG | 45959 | Z11165 | R. capsulatus complete photosynthesis gene cluster. | Rhodobacter capsulatus | 37,989 | 2-Sep-99 | ||
| GB_PR4: AF073931 | 7898 | AF073931 | Homo sapiens low-voltage activated calcium channel alpha 1H mRNA, complete cds. | Homo sapiens | 37,953 | 04-MAR-1999 | ||
| rxa01083 | 399 | GB_BA2: AF112535 | 4363 | AF112535 | Corynebacterium glutamicum putative glutaredoxin NrdH | Corynebacterium | 99,499 | 5-Aug-99 |
| (nrdH), Nrdl (nrdl), and ribonucleotide reductase | glutamicum | |||||||
| alpha-chain (nrdE) genes, complete cds. | ||||||||
| GB_PR3: HSH3D2 | 1789 | AF053138 | Homo sapiens histone deacetylase 3 gene, exons 11, 12, 13 and partial cds. | Homo sapiens | 33,512 | 28-MAR-1998 | ||
| GB_PR4: AF059650 | 16015 | AF059650 | Homo sapiens histone deacetylase 3 (HDAC3) gene, complete cds. | Homo sapiens | 38,814 | 03-MAR-1999 | ||
| rxa01085 | 902 | GB_EST4: H55032 | 951 | H55032 | HHU58a Sorghum bicolor cv. TX430 Sorghum bicolor cDNA | T. CRUT. bicolor | 41,111 | 27-Sep-99 |
| clone HHU58 5′ similar to transketolase, chloroplast (TKLC1), mRNA sequence. | ||||||||
| GB_HTG2: HSBA27F12 | 123489 | AL109914 | Homo sapiens chromosome 6 clone RP11-27F12 map p22.3-24, | Homo sapiens | 35,156 | 30-Nov-99 | ||
| *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| GB_HTG2: HSBA27F12 | 123489 | AL109914 | Homo sapiens chromosome 6 clone RP11-27F12 map | Homo sapiens | 35,156 | 30-Nov-99 | ||
| p22.3-24, *** SEQUENCING IN PROGRESS ***, in unordered pieces. | ||||||||
| rxa01088 | 1305 | GB_HTG5: AC010202 | 170004 | AC010202 | Homo sapiens chromosome 12q seeders clone RP11-210L7, | Homo sapiens | 37,313 | 6-Nov-99 |
| *** SEQUENCING IN PROGRESS ***, 40 unordered pieces. | ||||||||
| GB_HTG5: AC010202 | 170004 | AC010202 | Homo sapiens chromosome 12q seeders clone | Homo sapiens | 37,422 | 6-Nov-99 | ||
| RP11-210L7, *** SEQUENCING IN PROGRESS ***, 40 unordered pieces. | ||||||||
| GB_PR1: HSIGFACI | 7260 | X57025 | Human IGF-I mRNA for insulin-like growth factor I. | Homo sapiens | 38,043 | 17-Feb-92 | ||
| rxa01091 | 664 | GB_BA1: ECORELA | 4034 | J04039 | E. coli relA gene encoding ATP; GTP 3′-pyrophosphotransferase, complete cds. | Escherichia coli | 54,711 | 16-Nov-93 |
| GB_BA2: ECU29580 | 13234 | U29580 | Escherich | |||||